# WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, October 21, 2004

| Hide? | Set Name | Query | Hit Count |
|---|---|---|---|
| | *DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ* | | |
| ☐ | L12 | ephrin-B3 | 14 |
| ☐ | L11 | L10 AND angiogenesis | 19 |
| ☐ | L10 | AL-2 OR EFL-6 OR ephrin-B3 | 673 |
| ☐ | L9 | L6 AND ephrin-B3 | 0 |
| ☐ | L8 | L6 AND EFL-6 | 0 |
| ☐ | L7 | L6 AND AL-2 | 0 |
| ☐ | L6 | 514/2.CCLS. | 6340 |
| ☐ | L5 | Caras.IN. | 179 |
| ☐ | L4 | Caras-I-W.IN. | 8 |
| ☐ | L3 | Caras-I.IN. | 1 |
| ☐ | L2 | Caras-Ingrid.IN. | 2 |
| ☐ | L1 | (Caras-Ingrid-W.IN.) | 16 |

END OF SEARCH HISTORY

h e b b cg b chh e b f e ch e c ch

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 16 of 16 returned.

☐ 1. Document ID: US 20030049722 A1

**Using default format because multiple data bases are involved.**

L1: Entry 1 of 16 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049722
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049722 A1

TITLE: Novel methods of diagnosing macrophage developement related disorders, compositions, and methods of screening for macrophage developement modulators

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Murray, Richard | Cupertino | CA | US | |
| Caras, Ingrid W. | San Francisco | CA | US | |
| Hevezi, Peter | San Francisco | CA | US | |
| Wilson, Keith | Redwood City | CA | US | |

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/372, 435/7.21, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20020142444 A1

L1: Entry 2 of 16 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142444
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142444 A1

TITLE: AL-2 neurotrophic factor

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Caras, Ingrid W. | San Francisco | CA | US | |

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2

h e b b g e e e f e b ef b e

protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.



☐ 3. Document ID: US 6696557 B1

L1: Entry 3 of 16 File: USPT Feb 24, 2004

US-PAT-NO: 6696557
DOCUMENT-IDENTIFIER: US 6696557 B1

TITLE: AL-2 neurotrophic factor nucleic acid

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |

US-CL-CURRENT: 536/23.4; 435/69.7

ABSTRACT:

The present invention provides nucleic acids encoding AL-2 protein, host cells and vectors containing these nucleic acids, and methods for their use to produce AL-2 protein by recombinant DNA methods.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15



☐ 4. Document ID: US 6632634 B1

L1: Entry 4 of 16 File: USPT Oct 14, 2003

US-PAT-NO: 6632634
DOCUMENT-IDENTIFIER: US 6632634 B1

TITLE: Decay accelerating factor (DAF) and nucleic acid encoding it

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Davitz; Michael A. | Bronx | NY | | |
| Nussenzweig; Victor | New York | NY | | |
| Martin, Jr.; David W. | San Francisco | CA | | |

h e b b g e e e f e b ef b e

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/69.7, 536/23.5

ABSTRACT:

Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

22 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17



☐ 5. Document ID: US 6610296 B2

L1: Entry 5 of 16 File: USPT Aug 26, 2003

US-PAT-NO: 6610296
DOCUMENT-IDENTIFIER: US 6610296 B2

TITLE: Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Winslow; John W. | El Granada | CA | | |

US-CL-CURRENT: 424/178.1; 514/12, 514/2, 530/350, 530/399

ABSTRACT:

The present invention provides methods of enhancing cognitive function in mammals by administering intracerebrally a homo-multimeric immunoadhesin molecule that contains the extracellular domain of AL-1, also known as ephrin-A5.

4 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7



☐ 6. Document ID: US 6280732 B1

L1: Entry 6 of 16 File: USPT Aug 28, 2001

US-PAT-NO: 6280732
DOCUMENT-IDENTIFIER: US 6280732 B1

TITLE: Methods of using an AL-1 neurotrophic factor immunoadhesin

h e b b g e e e f e b ef b e

DATE-ISSUED: August 28, 2001

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Winslow; John W. | El Granada | CA | | |

US-CL-CURRENT: 424/178.1; 514/12, 514/2, 530/350, 530/399

ABSTRACT:

The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.

5 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

☐ 7. Document ID: US 5798448 A

L1: Entry 7 of 16 File: USPT Aug 25, 1998

US-PAT-NO: 5798448
DOCUMENT-IDENTIFIER: US 5798448 A

TITLE: AL-1 neurotrophic factor antibodies

DATE-ISSUED: August 25, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Winslow; John W. | El Granada | CA | | |

US-CL-CURRENT: 530/387.1; 424/130.1, 424/132.1, 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/9.34, 435/7.1, 435/7.2, 435/7.9, 436/512, 436/514, 436/517, 436/518, 436/536, 436/538, 436/547, 436/548, 530/300, 530/350, 530/387.3, 530/387.9, 530/388.1, 530/388.15, 530/388.24, 530/389.1

ABSTRACT:

The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.

9 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

h e b b g e e e f e b ef b e

☐ 8. Document ID: US 5763224 A

L1: Entry 8 of 16 File: USPT Jun 9, 1998

US-PAT-NO: 5763224
DOCUMENT-IDENTIFIER: US 5763224 A
**** See image for Certificate of Correction ****

TITLE: Decay accelerating factor (DAF) and nucleic acids encoding it

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Davitz; Michael A. | Bronx | NY | | |
| Nussenzweig; Victor | New York | NY | | |
| Martin, Jr.; David W. | San Francisco | CA | | |

US-CL-CURRENT: 435/69.6; 435/252.3, 435/320.1, 435/325, 435/455, 435/488, 435/69.7, 530/350, 530/829, 536/23.5

ABSTRACT:

This application relates to nucleic acids encoding decay accelerating factor (hereinafter abbreviated as DAF), as well as vectors and cells which comprise such nucleic acids. Additionally, nucleic acids which encode variants of DAF, such as insertion, deletion or substitution variants, are described. This application also relates to the preparation of DAF in recombinant cell culture. In particular, it is concerned with the large scale manufacture of DAF suitable for pharmaceutical or diagnostic use.

33 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17



☐ 9. Document ID: US 5759775 A

L1: Entry 9 of 16 File: USPT Jun 2, 1998

US-PAT-NO: 5759775
DOCUMENT-IDENTIFIER: US 5759775 A

TITLE: Methods for detecting nucleic acids encoding AL--1 neurotrophic factor

DATE-ISSUED: June 2, 1998

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Winslow; John W. | El Granada | CA | | |

h e b b g e e e f e b ef b e

US-CL-CURRENT: 435/6; 435/91.2, 536/23.5, 536/24.31, 536/24.33

ABSTRACT:

Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect or amplify AL-1 nucleic acid in a sample using AL-1 nucleotide sequence probes.

18 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawing Desc

---

☐ 10. Document ID: US 5374548 A

L1: Entry 10 of 16 File: USPT Dec 20, 1994

US-PAT-NO: 5374548
DOCUMENT-IDENTIFIER: US 5374548 A
**** See image for Certificate of Correction ****

TITLE: Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor

DATE-ISSUED: December 20, 1994

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |

US-CL-CURRENT: 424/450; 435/69.7, 436/829

ABSTRACT:

Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.

18 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 19

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawing Desc

---

☐ 11. Document ID: US 5264357 A

L1: Entry 11 of 16 File: USPT Nov 23, 1993

US-PAT-NO: 5264357
DOCUMENT-IDENTIFIER: US 5264357 A

h e b b g e e e f e b ef b e

TITLE: Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides

DATE-ISSUED: November 23, 1993

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Davitz; Michael A. | Riverdale | NY | | |
| Nussenzweig; Victor | New York | NY | | |
| Martin, Jr.; David W. | San Francisco | CA | | |

US-CL-CURRENT: 435/252.33; 435/252.3, 435/320.1, 435/69.7, 536/23.4

ABSTRACT:

Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

4 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14



☐ 12. Document ID: US 5109113 A

L1: Entry 12 of 16 File: USPT Apr 28, 1992

US-PAT-NO: 5109113
DOCUMENT-IDENTIFIER: US 5109113 A

TITLE: Membrane anchor fusion polypeptides

DATE-ISSUED: April 28, 1992

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |
| Davitz; Michael A. | Riverdale | NY | | |
| Nussenzweig; Victor | New York | NY | | |
| Martin, Jr.; David W. | San Francisco | CA | | |

US-CL-CURRENT: 530/350; 435/69.7, 530/359, 530/405, 530/409, 530/806, 530/807, 530/808

ABSTRACT:

Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.

h e b b g e e e f e b ef b e

10 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 13. Document ID: JP 08242882 A

L1: Entry 13 of 16 File: JPAB Sep 24, 1996

PUB-NO: JP408242882A
DOCUMENT-IDENTIFIER: JP 08242882 A
TITLE: NOVEL DAF AND ITS PRODUCTION

PUBN-DATE: September 24, 1996

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| CARAS, INGRID W | |

INT-CL (IPC): C12 P 21/02; C07 K 14/47; C12 N 5/10; C12 N 15/09

ABSTRACT:

PROBLEM TO BE SOLVED: To provide a novel decay accelerating factor(DAF) that accelerates the decaying dissociation of C2 or the like from the C3 converting enzyme in the complement cascade that has a specific amino acid sequence and dissolves the antigen cells as the target of humoral immunity reaction and is useful for treatment and diagnosis of inflammatory diseases, autoimmune diseases and the like.

SOLUTION: This novel decay accelerating factor(DAF) has an amino acid sequence including the amino acid sequence represented by the formula and comprises the mDAF not accompanied by the natural glycosylation comprises the complement cascade dissolving the antigen cells as the target of the humoral immunity reaction.



Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 14. Document ID: WO 9740153 A1

L1: Entry 14 of 16 File: EPAB Oct 30, 1997

PUB-NO: WO0009740153A1
DOCUMENT-IDENTIFIER: WO 9740153 A1
TITLE: AL-2 NEUROTROPHIC FACTOR

PUBN-DATE: October 30, 1997

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| CARAS, INGRID W | |

INT-CL (IPC): C12 N 15/12; C07 K 14/475; C12 N 15/62; A61 K 38/18; C07 K 16/22; C07 K 19/00; C12 Q 1/68; G01 N 33/50; C12 N 5/10

h e b b g e e e f e b ef b e

EUR-CL (EPC): C07K014/475

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 15. Document ID: WO 9613518 A1

L1: Entry 15 of 16 File: EPAB May 9, 1996

PUB-NO: WO009613518A1
DOCUMENT-IDENTIFIER: WO 9613518 A1
TITLE: AL-1 NEUROTROPHIC FACTOR, A LIGAND FOR AN EPH-RELATED TYROSINE KINASE RECEPTOR

PUBN-DATE: May 9, 1996

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| CARAS, INGRID W | US |
| WINSLOW, JOHN W | US |

INT-CL (IPC): C07 K 14/47; C12 N 15/12; C07 K 16/18; C07 K 19/00; C12 N 5/10; C12 Q 1/68; A61 K 38/12
EUR-CL (EPC): C07K016/22; C12N009/12, C07K014/52

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 16. Document ID: WO 8901041 A1

L1: Entry 16 of 16 File: EPAB Feb 9, 1989

PUB-NO: WO008901041A1
DOCUMENT-IDENTIFIER: WO 8901041 A1
TITLE: NUCLEIC ACID AND METHODS FOR THE SYNTHESIS OF NOVEL FUSION POLYPEPTIDES WITH A PHOSPHOLIPID ANCHOR DOMAIN

PUBN-DATE: February 9, 1989

INVENTOR-INFORMATION:

h e b b g e e e f e b ef b e

| NAME | COUNTRY |
|---|---|
| CARAS, INGRID W | US |

US-CL-CURRENT: 435/183; 435/320.1, 435/FOR.195, 530/387.3, 536/23.4
INT-CL (IPC): C12N 15/00
EUR-CL (EPC): G01N033/68; C07K014/705, C07K014/035

ABSTRACT:

CHG DATE=19990617 STATUS=O>Novel fusions of a phospholipid anchor domain and a polypeptide heterologous to the anchor domain donor polypeptide are provided for industrial use. Therapeutic administration of the fusions enables the targeting of biological activity to cell membrane surfaces.



| Terms | Documents |
|---|---|
| (Caras-Ingrid-W.IN.) | 16 |



h e b b g e e e f e b ef b e

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20040096392 A1

**Using default format because multiple data bases are involved.**

L2: Entry 1 of 2 File: PGPB May 20, 2004

PGPUB-DOCUMENT-NUMBER: 20040096392
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040096392 A1

TITLE: Antibodies against cancer antigen TMEFF2 and uses thereof

PUBLICATION-DATE: May 20, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Bhaskar, Vinay | San Francisco | CA | US | |
| de la Calle, Agustin | Planegg | CA | DE | |
| Law, Debbie | San Francisco | CA | US | |
| Caras, Ingrid | San Francisco | CA | US | |
| Ramakrishnan, Vanitha | Belmont | CA | US | |
| Murray, Richard | Cupertino | CA | US | |
| Afar, Daniel | Fremont | CA | US | |
| Powers, David | Fairfax | | US | |

US-CL-CURRENT: 424/1.11; 424/141.1, 424/178.1, 424/9.6, 530/388.8, 530/391.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: WO 3075855 A2

L2: Entry 2 of 2 File: EPAB Sep 18, 2003

PUB-NO: WO0003075855A2
DOCUMENT-IDENTIFIER: WO 3075855 A2
TITLE: ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF

PUBN-DATE: September 18, 2003

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| BHASKAR, VINAY | US |
| DE, LA CALLE AGUSTIN | DE |
| LAW, DEBBIE | US |
| CARAS, INGRID | US |
| RAMAKRISHNAN, VANITHA | US |

h e b b g e e e f e b ef b e

MURRAY, RICHARD US
AFAR, DANIEL US
POWERS, DAVID US

INT-CL (IPC): A61 K 0/
EUR-CL (EPC): C07K016/30

ABSTRACT:



Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

| Terms | Documents |
|---|---|
| Caras-Ingrid.IN. | 2 |

**Display Format:** - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e b ef b e

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20040096392 A1, WO 2003075855 A2, AU 2003252830 A1

**Using default format because multiple data bases are involved.**

L3: Entry 1 of 1 File: DWPI May 20, 2004

DERWENT-ACC-NO: 2003-756783
DERWENT-WEEK: 200434

TITLE: New antibody that competitively inhibits binding of TMEFF219 to TMEFF2, useful for treating prostate cancer, e.g. primary, metastatic, locally advanced, or androgen independent prostate cancer

INVENTOR: AFAR, D; BHASKAR, V ; CARAS, I ; DE LA CALLE, A ; LAW, D ; MURRAY, R ; POWERS, D ; RAMAKRISHNAN, V

PRIORITY-DATA: 2002US-436812P (December 27, 2002), 2002US-362837P (March 8, 2002), 2003US-0383447 (March 7, 2003)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| US 20040096392 A1 | May 20, 2004 | | 000 | A61K051/00 |
| WO 2003075855 A2 | September 18, 2003 | E | 031 | A61K000/00 |
| AU 2003252830 A1 | September 22, 2003 | | 000 | A61K000/00 |

INT-CL (IPC): A61 K 0/00; A61 K 39/395; A61 K 49/00; A61 K 51/00

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

| Terms | Documents |
|---|---|
| Caras-I.IN. | 1 |

**Display Format:** - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e b ef b e

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 6632634 B1

**Using default format because multiple data bases are involved.**

L4: Entry 1 of 8 File: DWPI Oct 14, 2003

DERWENT-ACC-NO: 2003-810556
DERWENT-WEEK: 200376
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: New nucleic acid comprising a sequence encoding a decay accelerating factor (DAF), useful for preparing a composition for treating inflammatory conditions, e.g., colitis, rheumatoid arthritis or allograft rejection

INVENTOR: CARAS, I W ; DAVITZ, M A ; MARTIN, D W ; NUSSENZWEIG, V

PRIORITY-DATA: 1993US-0017934 (February 12, 1993), 1985US-0738171 (May 24, 1985), 1986US-0859107 (May 1, 1986), 1987US-0083757 (August 6, 1987), 1991US-0811048 (December 19, 1991), 1994US-0358283 (December 19, 1994), 1998US-0014240 (January 27, 1998)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| US 6632634 B1 | October 14, 2003 | | 035 | C07H021/04 |

INT-CL (IPC): C07 H 21/04

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20030049722 A1

L4: Entry 2 of 8 File: DWPI Mar 13, 2003

DERWENT-ACC-NO: 2003-512353
DERWENT-WEEK: 200417
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Diagnosing destructive macrophage disorder (DMD) such as arthritis, aneurysms or atherosclerosis, or determining prognosis of individual with DMD, by determining expression or level of matrix metalloproteinase-19

INVENTOR: CARAS, I W ; HEVEZI, P ; MURRAY, R ; WILSON, K

PRIORITY-DATA: 2000US-0525978 (March 15, 2000), 1999US-124530P (March 15, 1999)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| US 20030049722 A1 | March 13, 2003 | | 061 | G01N033/53 |

h e b b g e e e f e b ef b e

INT-CL (IPC): C07 H 21/04; C12 N 5/08; C12 N 9/64; C12 P 21/02; G01 N 33/53; G01 N 33/567

ABSTRACTED-PUB-NO: US20030049722A
BASIC-ABSTRACT:

NOVELTY - Diagnosing (M1) destructive macrophage disorder (DMD) or determining (M2) prognosis of individual with DMD, by determining expression or level of matrix metalloproteinase (MMP)-19. (M1) involves comparing expression of gene encoding MMP-19 in a first tissue type of first individual, with expression of gene from second normal tissue from (I). (M2) involves determining level of MMP-19 in sample, where high level of MMP-19 indicates poor prognosis.

DETAILED DESCRIPTION - Diagnosing (M1) destructive macrophage disorder (DMD) or determining (M2) the prognosis of an individual with DMD, by determining the expression or level of MMP-19. (M1) involves determining expression of gene encoding or its fragment in a first tissue type of first individual (I), and comparing expression of the gene from second normal tissue from (I) or a second unaffected individual, where a difference in expression indicates that (I) has DMD. (M2) involves determining the level of MMP-19 in a sample, where a high level of MMP-19 indicates a poor prognosis.

INDEPENDENT CLAIMS are also included for the following:

(1) screening (M3) drug candidates, involves providing a cell that expresses an expression profile gene which encodes a protein encoded by any one of 5 expression profile genes which are nucleic acids differentially expressed in the development path of destructive macrophages (DMs), referred as DM sequences, and the sequence represented by accession number X92521, X62466, J04130, X62078 and X76534, or its fragment; adding a drug candidate to the cell, and determining the effect of the drug candidate on the expression of the expression profile gene;

(2) screening (M4) for a bioactive agent capable of binding to a destructive macrophage (DM) modulator protein or a bioactive agent capable of modulating the activity of a DM modulator protein, where the DM modulator protein is MMP-19 or its fragment, involves combining the DM modulator protein and a candidate bioactive agent, and determining the binding of the candidate agent to the DM modulator protein or determining the effect of the candidate agent on the bioactive of the DM modulator protein; evaluating (M5) the effect of a candidate DM drug, involves administering the drug to a patient, removing a cell sample from the patient, and determining the expression profile of the cell;

(3) a biochip comprising a nucleic acid segment encoding MMP-19, or its fragment, where the biochip comprises fewer than 1000 nucleic acid probes;

(4) an antibody (II) which specifically binds to MMP- 19, or its fragment;

(5) screening for a bioactive agent capable of interfering with the binding of a DM modulator protein or its fragment and an antibody which binds to the DM modulator protein or its fragment, involves combining DM modulator protein or its fragment, a candidate bioactive agent and an antibody which binds to DM modulator protein or its fragment, and determining the binding of DM modulator protein or its fragment and the antibody;

(6) inhibiting (M6) DMD, by administering to a cell a composition comprising (II);

(7) inhibiting (M7) DMD in a cell by administering to a cell, a composition comprising antisense molecules to MMP- 19;

(8) eliciting (M8) an immune response in an individual, by administering to the individual a composition comprising MMP-19 or its fragment, and optionally a carrier;

(9) a composition (III) capable of eliciting an immune response in an individual,

h e b b g e e e f e b ef b e

comprises nucleic acid encoding MMP-19 or its fragment and a carrier;

(10) neutralizing the effect of a MMP-19 or its fragment by contacting an agent specific for the protein;

(11) localizing (M9) a therapeutic moiety to colorectal cancer tissue by exposing the tissue to (II) conjugated to the therapeutic moiety; and

(12) treating (M10) DMD by administering to the individual having DMD (II) conjugated to a therapeutic moiety.

ACTIVITY - Antiarthritic; Antiinflammatory; Antiatherosclerotic. No biological data is given.

MECHANISM OF ACTION - MMP-19-Inhibitor . No supporting data is given.

USE - (II) is useful for treating an individual for DMD by inhibiting MMP-19. (III) is useful for eliciting an immune response in an individual. (M6) is useful for inhibiting DMD in a cell of an individual having arthritis. (M8) is useful for eliciting an immune response in an individual. (M10) is useful for treating DMD (claimed). (II) is useful for treating a DMD such as arthritis, inflammatory bowel disease, chronic obstructive pulmonary disorder and vascular disease, including atherosclerosis and aneurysms. (II) is useful for inhibiting macrophage cell division, and for inhibiting macrophage development.

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 19 of 19 returned.

☐ 1. Document ID: US 20040180823 A1

**Using default format because multiple data bases are involved.**

L11: Entry 1 of 19 File: PGPB Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040180823
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040180823 A1

TITLE: Novel agents that modulate Eph receptor activity

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Pasquale, Elena B. | San Diego | CA | US | |
| Koolpe, Mitchell | San Diego | CA | US | |
| Murai, Keith K. | Candiac | | CA | |

US-CL-CURRENT: 514/12; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040136983 A1

L11: Entry 2 of 19 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040136983
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040136983 A1

TITLE: Methods for inhibiting angiogenesis by EphB receptor antagonists

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Aguet, Michel | Lutry | | CH | |

US-CL-CURRENT: 424/143.1

ABSTRACT:

The present application describes methods of inhibiting or stimulating angiogenesis in a mammal comprising administering to the mammal an effective amount of an Eph receptor antagonist or agonist, respectively. Articles of manufacture for use in

h e b b g e e e f e b ef b e

relation to these methods are also described.



☐ 3. Document ID: US 20040132634 A1

L11: Entry 3 of 19 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132634
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132634 A1

TITLE: Compositions and methods for regulating the kinase domain of receptor tyrosine kinases

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Sicheri, Frank | Toronto | | CA | |
| Wybenga-Groot, Leanne | Etobicoke | | CA | |
| Pawson, Tony | Toronto | | CA | |

US-CL-CURRENT: 514/1; 435/194, 702/19

ABSTRACT:

The present invention relates to binding pockets of receptor tyrosine kinases (RTKs). The binding pockets may regulate the kinase domain of the receptor tyrosine kinases. In particular, the invention relates to a crystal comprising a binding pocket of a receptor tyrosine kinase that regulates the kinase domain of the receptor tyrosine kinase EphB2. The crystal may be useful for modeling and/or synthesizing mimetics of a binding pocket or ligands that associate with the binding pocket. Such mimetics or ligands may be capable of acting as modulators of receptor tyrosine kinase receptor activity, and they may be useful for treating, inhibiting, or preventing diseases modulated by such receptors. Methods are also provided for regulating the kinase domain of an RTK by changing a binding pocket of the RTK that regulates the kinase domain from an autoinhibited state to an active state or from an active state to an autoinhibited state.



☐ 4. Document ID: US 20040126793 A1

L11: Entry 4 of 19 File: PGPB Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126793
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040126793 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: July 1, 2004

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Segal, Andrew H. | Boston | MA | US | |
| Young, Elihu | Sharon | MA | US | |

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/419, 435/69.1, 530/370, 530/395, 536/23.5

ABSTRACT:

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 5. Document ID: US 20040076955 A1

L11: Entry 5 of 19 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076955
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076955 A1

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Mack, David H. | Menlo Park | CA | US | |
| Aziz, Natasha | Palo Alto | CA | US | |

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Described herein are genes whose expression are up-regulated or down-regulated in bladder cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant bladder cancer cells. Related methods and compositions that can be used for diagnosis, prognosis, or treatment of bladder cancer are disclosed. Also described herein are methods that can be used to identify modulators of bladder cancer.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 6. Document ID: US 20040002067 A1

h e b b g e e e f e b ef b e

L11: Entry 6 of 19 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002067
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002067 A1

TITLE: Breast cancer progression signatures

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Erlander, Mark G. | Encinitas | CA | US | |
| Ma, Xia-Jun | San Diego | CA | US | |
| Sgroi, Dennis C. | Winchester | MA | US | |

US-CL-CURRENT: 435/6; 435/287.2, 702/20

ABSTRACT:

Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.



7. Document ID: US 20030157712 A1

L11: Entry 7 of 19 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157712
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157712 A1

TITLE: Methods for determining cell responses through EphB receptors

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Daniel, Thomas O. | Nashville | TN | US | |
| Stein, Elke | San Francisco | CA | US | |

US-CL-CURRENT: 435/366; 435/368

ABSTRACT:

The present invention provides a method for initiating, promoting and/or directing cell attachment to a matrix or to another cell, comprising contacting an EphB receptor-expressing cell with a tetrameric EphB receptor-binding ligand, whereby binding of the tetrameric ligand promotes multimerization of the EphB receptor, thereby initiating, promoting and directing cell attachment to a matrix or to another cell. Also provided is a method for promoting angiogenesis, comprising contacting

h e b b g e e e f e b ef b e

EphB receptor-expressing cells which are associated with angiogenesis with a multimeric EphB receptor-binding ligand, whereby binding of the tetrameric ligand promotes multimerization of the EphB receptor, thereby promoting angiogenesis.



☐ 8. Document ID: US 20030154032 A1

L11: Entry 8 of 19 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030154032
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030154032 A1

TITLE: Methods and compositions for diagnosing and treating rheumatoid arthritis

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Pittman, Debra D. | Windham | NH | US | |
| Feldman, Jeffrey L. | Arlington | MA | US | |
| Shields, Kathleen M. | Harvard | MA | US | |
| Trepicchio, William L. | Andover | MA | US | |

US-CL-CURRENT: 702/20

ABSTRACT:

The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.



☐ 9. Document ID: US 20030082511 A1

L11: Entry 9 of 19 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082511
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082511 A1

TITLE: Identification of modulatory molecules using inducible promoters

PUBLICATION-DATE: May 1, 2003

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Brown, Steven J. | San Diego | CA | US | |
| Dunnington, Damien J. | San Diego | CA | US | |
| Clark, Imran | San Diego | CA | US | |

US-CL-CURRENT: 435/4; 435/6

ABSTRACT:

Methods for identifying an ion channel modulator, a target membrane receptor modulator molecule, and other modulatory molecules are disclosed, as well as cells and vectors for use in those methods. A polynucleotide encoding target is provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a result of the candidate modulatory molecule.



☐ 10. Document ID: US 20030022202 A1

L11: Entry 10 of 19 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022202 A1

TITLE: B-ephrin regulation of G-protein coupled chemoattraction, compositions, and methods of use

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Flanagan, John G. | Newton | MA | US | |
| Lu, Qiang | Brookline | MA | US | |
| Sun, Edna E. | Brookline | MA | US | |

US-CL-CURRENT: 435/6; 435/196, 435/254.2, 435/320.1, 435/368, 435/69.1, 536/23.2

ABSTRACT:

Transmembrane B ephrins and their Eph receptors signal bi-directionally. The presently claimed invention describes a cytoplasmic protein, designated PDZ-RGS3, which binds B ephrins through a PDZ domain, and has a regulator of heterotrimeric G protein signaling (RGS) domain. PDZ-RGS3 mediates signaling from the ephrin-B cytoplasmic tail. SDF-1, a chemokine with a G protein coupled receptor, or BDNF, act as chemoattractants for cerebellar granule cells, with SDF-1 action being selectively inhibited by soluble EphB receptor. The claimed invention reveals a pathway that links reverse signaling to cellular guidance, uncovers a novel mode of control for G proteins, and demonstrates a mechanism for selective regulation of responsiveness to neuronal guidance cues. Further, compositions and methods of use are provided for modulating cell migration as a function of chemokines and GPCR interaction, to aid in the treatment of disease states and medical conditions, including cancer and immune responses such as allergy and autoimmune responses. In one embodiment, a method of

h e b b g e e e f e b ef b e

altering the sensitivity of a cell to a chemokine is provided using a PDZ-RGS3 protein.



☐ 11. Document ID: US 20020147306 A1

L11: Entry 11 of 19 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147306
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147306 A1

TITLE: Peptides that modulate the interaction of B class ephrins and PDZ domains

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Lin, Danny | Scarborough | | CA | |
| Pawson, Anthony | Toronto | | CA | |
| Gish, Gerald | East York | | CA | |

US-CL-CURRENT: 530/350; 530/324

ABSTRACT:

The invention relates to complexes comprising a B class ephrin and a PDZ domain containing protein; peptides that interfere with the interaction of a B class ephrin with a PDZ domain binding site, and a PDZ domain containing protein; and, uses of the peptides and complexes. Methods for modulating the interaction of a B class ephrin and a PDZ domain containing protein, and methods for evaluating compounds for their ability to modulate the interaction are also described.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 12. Document ID: US 20020142444 A1

L11: Entry 12 of 19 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020142444
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020142444 A1

TITLE: AL-2 neurotrophic factor

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Caras, Ingrid W. | San Francisco | CA | US | |

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1, 536/23.2

h e b b g e e e f e b ef b e

ABSTRACT:

The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.



☐ 13. Document ID: US 20020052308 A1

L11: Entry 13 of 19 File: PGPB May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052308
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020052308 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Rosen, Craig A. | Laytonsville | MD | US | |
| Ruben, Steven M. | Olney | MD | US | |

US-CL-CURRENT: 514/1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350, 536/23.1

ABSTRACT:

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.



☐ 14. Document ID: US 6727063 B1

L11: Entry 14 of 19 File: USPT Apr 27, 2004

US-PAT-NO: 6727063
DOCUMENT-IDENTIFIER: US 6727063 B1

h e b b g e e e f e b ef b e

TITLE: Single nucleotide polymorphisms in genes

DATE-ISSUED: April 27, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Lander; Eric S. | Cambridge | MA | | |
| Cargill; Michele | Gaithersburg | MD | | |
| Ireland; James S. | Gaithersburg | MD | | |
| Bolk; Stacey | West Roxbury | MA | | |
| Daley; George Q. | Weston | MA | | |
| McCarthy; Jeanette J. | San Diego | CA | | |

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

ABSTRACT:

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

4 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8



15. Document ID: US 6696557 B1

L11: Entry 15 of 19 File: USPT Feb 24, 2004

US-PAT-NO: 6696557
DOCUMENT-IDENTIFIER: US 6696557 B1

TITLE: AL-2 neurotrophic factor nucleic acid

DATE-ISSUED: February 24, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Caras; Ingrid W. | San Francisco | CA | | |

US-CL-CURRENT: 536/23.4; 435/69.7

ABSTRACT:

The present invention provides nucleic acids encoding AL-2 protein, host cells and vectors containing these nucleic acids, and methods for their use to produce AL-2

h e b b g e e e f e b ef b e

protein by recombinant DNA methods.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15



☐ 16. Document ID: US 6555321 B1

L11: Entry 16 of 19 File: USPT Apr 29, 2003

US-PAT-NO: 6555321
DOCUMENT-IDENTIFIER: US 6555321 B1

TITLE: Methods for determining cell responses through EphB receptors

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Daniel; Thomas O. | Nashville | TN | | |
| Stein; Elke | San Francisco | CA | | |

US-CL-CURRENT: 435/7.1; 435/334, 435/7.2, 435/7.21, 435/7.8

ABSTRACT:

The present invention provides methods for screening an EphB receptor or an EphB receptor-binding ligand for the ability to promote a selected biological activity when in multimeric form. The invention also provides methods for initiating, promoting, directing, or inhibiting biological activities that involve EphB receptors and/or EphB receptor-binding ligands. The invention further provides compositions that can be used in the foregoing methods.

8 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7



☐ 17. Document ID: US 6514497 B1

L11: Entry 17 of 19 File: USPT Feb 4, 2003

US-PAT-NO: 6514497
DOCUMENT-IDENTIFIER: US 6514497 B1

TITLE: Inhibition of LERK-2-mediated cell adhesion

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| h e b b g e e e f | e b | ef | b e | |

| | | |
|---|---|---|
| Briskin; Michael J. | Lexington | MA |
| Zou; Lily | Cambridge | MA |

US-CL-CURRENT: 424/143.1; 424/130.1, 424/137.1, 424/141.1, 424/152.1, 424/172.1, 530/387.1, 530/387.5, 530/388.1, 530/388.22

ABSTRACT:

Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.

8 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8



☐ 18. Document ID: WO 9740153 A1

L11: Entry 18 of 19 File: EPAB Oct 30, 1997

PUB-NO: WO009740153A1
DOCUMENT-IDENTIFIER: WO 9740153 A1
TITLE: AL-2 NEUROTROPHIC FACTOR

PUBN-DATE: October 30, 1997

INVENTOR-INFORMATION:

| NAME | COUNTRY |
|---|---|
| CARAS, INGRID W | |

INT-CL (IPC): C12 N 15/12; C07 K 14/475; C12 N 15/62; A61 K 38/18; C07 K 16/22; C07 K 19/00; C12 Q 1/68; G01 N 33/50; C12 N 5/10
EUR-CL (EPC): C07K014/475

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention provides nucleic acids encoding AL-2 protein, as well as AL-2 protein produced by recombinant DNA methods. Such AL-2 protein and nucleic acid are useful in preparing antibodies and antagonists and in diagnosing and treating various neuronal disorders and disorders or conditions associated with angiogenesis.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 19. Document ID: US 6696557 B1, WO 9740153 A1, AU 9726723 A, EP 904368 A1, AU 719273 B, JP 2000509978 W, US 20020142444 A1

L11: Entry 19 of 19 File: DWPI Feb 24, 2004

DERWENT-ACC-NO: 1997-535837

h e b b g e e e f e b ef b e

DERWENT-WEEK: 200415


TITLE: Human AL-2 neurotrophic factor and related DNA - used to develop products for, e.g. treating neurologic disorders, angiogenesis disorders, tumours or rheumatoid arthritis or for wound healing

INVENTOR: CARAS, I W

PRIORITY-DATA: 1996US-0635130 (April 19, 1996), 2001US-0021121 (December 6, 2001)

PATENT-FAMILY:

| PUB-NO | PUB-DATE | LANGUAGE | PAGES | MAIN-IPC |
|---|---|---|---|---|
| US 6696557 B1 | February 24, 2004 | | 000 | C07H021/04 |
| WO 9740153 A1 | October 30, 1997 | E | 086 | C12N015/12 |
| AU 9726723 A | November 12, 1997 | | 000 | C12N015/12 |
| EP 904368 A1 | March 31, 1999 | E | 000 | C12N015/12 |
| AU 719273 B | May 4, 2000 | | 000 | C12N015/12 |
| JP 2000509978 W | August 8, 2000 | | 130 | C12N015/09 |
| US 20020142444 A1 | October 3, 2002 | | 000 | C12N009/64 |

INT-CL (IPC): A61 K 38/18; C07 H 21/04; C07 K 14/475; C07 K 14/52; C07 K 16/22; C07 K 16/24; C07 K 19/00; C12 N 5/06; C12 N 5/10; C12 N 9/64; C12 N 15/09; C12 N 15/12; C12 N 15/62; C12 P 21/02; C12 P 21/08; C12 Q 1/68; G01 N 33/50

ABSTRACTED-PUB-NO: US20020142444A
BASIC-ABSTRACT:

A novel isolated nucleic acid (I) which encodes a polypeptide having an amino acid sequence that is at least 75% identical to 455 or 340 amino acid sequence for mature AL-2 (given in the specification). Also claimed are: (1) an expression vector comprising (I) operably linked to a promoter; (2) a host cell transformed with an expression vector as in (1); (3) an isolated polypeptide as above; and (4) an antibody that specifically binds to a polypeptide as above.

USE - AL-2 is a novel Eph-related tyrosine kinase receptor ligand. AL-2 can be administered to patients in whom the nervous system has been damaged by trauma, surgery, stroke, ischaemia, infection, metabolic disease, nutritional deficiency, malignancy, or toxic agents, to promote the survival or growth of neurons. They can be used to treat motoneuron disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease), Bell's palsy, and various conditions involving spinal muscular atrophy, or paralysis. AL-2 can be used to treat human neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, demyelinating diseases such as multiple sclerosis, Huntingtons chorea, Down's syndrome, nerve deafness, Menier's disease, and other disorders of the cerebellum. AL-2 can be used as cognitive enhancer, to enhance learning particularly in dementias or trauma, since they can promote axonal outgrowth and synaptic plasticity, particularly of hippocampal neurons that express AL-2 binding Eph-family receptors and cortical neurons that express AL-2. AL-2 can also be used for wound healing, i.e. accelerating neovascularisation of, e.g. burns and ulcers. AL-2 antagonists can be used for modulating angiogenesis. They can also be used for the treatment of tumours, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS), diabetic retinopathy, neovascular glaucoma, psoriasis and rheumatoid arthritis. The products can also be used for detection and diagnosis.
ABSTRACTED-PUB-NO:

WO 9740153A EQUIVALENT-ABSTRACTS:

A novel isolated nucleic acid (I) which encodes a polypeptide having an amino acid sequence that is at least 75% identical to 455 or 340 amino acid sequence for mature

h e b b g e e e f e b ef b e

AL-2 (given in the specification). Also claimed are: (1) an expression vector comprising (I) operably linked to a promoter; (2) a host cell transformed with an expression vector as in (1); (3) an isolated polypeptide as above; and (4) an antibody that specifically binds to a polypeptide as above.

USE - AL-2 is a novel Eph-related tyrosine kinase receptor ligand. AL-2 can be administered to patients in whom the nervous system has been damaged by trauma, surgery, stroke, ischaemia, infection, metabolic disease, nutritional deficiency, malignancy, or toxic agents, to promote the survival or growth of neurons. They can be used to treat motoneuron disorders such as amyotrophic lateral sclerosis (Lou Gehrig's disease), Bell's palsy, and various conditions involving spinal muscular atrophy, or paralysis. AL-2 can be used to treat human neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, demyelinating diseases such as multiple sclerosis, Huntingtons chorea, Down's syndrome, nerve deafness, Menier's disease, and other disorders of the cerebellum. AL-2 can be used as cognitive enhancer, to enhance learning particularly in dementias or trauma, since they can promote axonal outgrowth and synaptic plasticity, particularly of hippocampal neurons that express AL-2 binding Eph-family receptors and cortical neurons that express AL-2. AL-2 can also be used for wound healing, i.e. accelerating neovascularisation of, e.g. burns and ulcers. AL-2 antagonists can be used for modulating angiogenesis. They can also be used for the treatment of tumours, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS), diabetic retinopathy, neovascular glaucoma, psoriasis and rheumatoid arthritis. The products can also be used for detection and diagnosis.



| Terms | Documents |
|---|---|
| L10 AND angiogenesis | 19 |



h e b b g e e e f e b ef b e

# Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

**Search Results** - Record(s) 1 through 14 of 14 returned.

☐ 1. Document ID: US 20040180823 A1

**Using default format because multiple data bases are involved.**

L12: Entry 1 of 14 File: PGPB Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040180823
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040180823 A1

TITLE: Novel agents that modulate Eph receptor activity

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Pasquale, Elena B. | San Diego | CA | US | |
| Koolpe, Mitchell | San Diego | CA | US | |
| Murai, Keith K. | Candiac | | CA | |

US-CL-CURRENT: 514/12; 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040136983 A1

L12: Entry 2 of 14 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040136983
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040136983 A1

TITLE: Methods for inhibiting angiogenesis by EphB receptor antagonists

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Aguet, Michel | Lutry | | CH | |

US-CL-CURRENT: 424/143.1

ABSTRACT:

The present application describes methods of inhibiting or stimulating angiogenesis in a mammal comprising administering to the mammal an effective amount of an Eph receptor antagonist or agonist, respectively. Articles of manufacture for use in

h e b b g e e e f e b ef b e

relation to these methods are also described.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 3. Document ID: US 20040132634 A1

L12: Entry 3 of 14 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132634
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132634 A1

TITLE: Compositions and methods for regulating the kinase domain of receptor tyrosine kinases

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Sicheri, Frank | Toronto | | CA | |
| Wybenga-Groot, Leanne | Etobicoke | | CA | |
| Pawson, Tony | Toronto | | CA | |

US-CL-CURRENT: 514/1; 435/194, 702/19

ABSTRACT:

The present invention relates to binding pockets of receptor tyrosine kinases (RTKs). The binding pockets may regulate the kinase domain of the receptor tyrosine kinases. In particular, the invention relates to a crystal comprising a binding pocket of a receptor tyrosine kinase that regulates the kinase domain of the receptor tyrosine kinase EphB2. The crystal may be useful for modeling and/or synthesizing mimetics of a binding pocket or ligands that associate with the binding pocket. Such mimetics or ligands may be capable of acting as modulators of receptor tyrosine kinase receptor activity, and they may be useful for treating, inhibiting, or preventing diseases modulated by such receptors. Methods are also provided for regulating the kinase domain of an RTK by changing a binding pocket of the RTK that regulates the kinase domain from an autoinhibited state to an active state or from an active state to an autoinhibited state.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 4. Document ID: US 20040126793 A1

L12: Entry 4 of 14 File: PGPB Jul 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040126793
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040126793 A1

TITLE: Lectin compositions and methods for modulating an immune response to an antigen

PUBLICATION-DATE: July 1, 2004

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Segal, Andrew H. | Boston | MA | US | |
| Young, Elihu | Sharon | MA | US | |

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/419, 435/69.1, 530/370, 530/395, 536/23.5

ABSTRACT:

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide. The present invention further relates to a method of modulating an immune response in an animal using such compositions.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 5. Document ID: US 20040076955 A1

L12: Entry 5 of 14 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040076955
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040076955 A1

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Mack, David H. | Menlo Park | CA | US | |
| Aziz, Natasha | Palo Alto | CA | US | |

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Described herein are genes whose expression are up-regulated or down-regulated in bladder cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant bladder cancer cells. Related methods and compositions that can be used for diagnosis, prognosis, or treatment of bladder cancer are disclosed. Also described herein are methods that can be used to identify modulators of bladder cancer.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 6. Document ID: US 20040002067 A1

h e b b g e e e f e b ef b e

L12: Entry 6 of 14 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002067
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002067 A1

TITLE: Breast cancer progression signatures

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Erlander, Mark G. | Encinitas | CA | US | |
| Ma, Xia-Jun | San Diego | CA | US | |
| Sgroi, Dennis C. | Winchester | MA | US | |

US-CL-CURRENT: 435/6; 435/287.2, 702/20

ABSTRACT:

Methods and compositions for the identification of breast cancer progression signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages of breast cancer.



☐ 7. Document ID: US 20030157712 A1

L12: Entry 7 of 14 File: PGPB Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030157712
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030157712 A1

TITLE: Methods for determining cell responses through EphB receptors

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Daniel, Thomas O. | Nashville | TN | US | |
| Stein, Elke | San Francisco | CA | US | |

US-CL-CURRENT: 435/366; 435/368

ABSTRACT:

The present invention provides a method for initiating, promoting and/or directing cell attachment to a matrix or to another cell, comprising contacting an EphB receptor-expressing cell with a tetrameric EphB receptor-binding ligand, whereby binding of the tetrameric ligand promotes multimerization of the EphB receptor, thereby initiating, promoting and directing cell attachment to a matrix or to another cell. Also provided is a method for promoting angiogenesis, comprising contacting

h e b b g e e e f e b ef b e

EphB receptor-expressing cells which are associated with angiogenesis with a multimeric EphB receptor-binding ligand, whereby binding of the tetrameric ligand promotes multimerization of the EphB receptor, thereby promoting angiogenesis.



☐ 8. Document ID: US 20030154032 A1

L12: Entry 8 of 14 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030154032
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030154032 A1

TITLE: Methods and compositions for diagnosing and treating rheumatoid arthritis

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Pittman, Debra D. | Windham | NH | US | |
| Feldman, Jeffrey L. | Arlington | MA | US | |
| Shields, Kathleen M. | Harvard | MA | US | |
| Trepicchio, William L. | Andover | MA | US | |

US-CL-CURRENT: 702/20

ABSTRACT:

The invention provides methods and compositions for diagnostic assays for detecting R.A. and therapeutic methods and compositions for treating R.A. The invention also provides methods for designing, identifying, and optimizing therapeutics for R.A. Diagnostic compositions of the invention include compositions comprising detection agents for detecting one or more genes that have been shown to be up- or down-regulated in cells of R.A. relative to normal counterpart cells. Exemplary detection agents include nucleic acid probes, which can be in solution or attached to a solid surface, e.g., in the form of a microarray. The invention also provides computer-readable media comprising values of levels of expression of one or more genes that are up- or down-regulated in R.A.



☐ 9. Document ID: US 20030082511 A1

L12: Entry 9 of 14 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082511
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082511 A1

TITLE: Identification of modulatory molecules using inducible promoters

PUBLICATION-DATE: May 1, 2003

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Brown, Steven J. | San Diego | CA | US | |
| Dunnington, Damien J. | San Diego | CA | US | |
| Clark, Imran | San Diego | CA | US | |

US-CL-CURRENT: 435/4; 435/6

ABSTRACT:

Methods for identifying an ion channel modulator, a target membrane receptor modulator molecule, and other modulatory molecules are disclosed, as well as cells and vectors for use in those methods. A polynucleotide encoding target is provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a result of the candidate modulatory molecule.



10. Document ID: US 20030022202 A1

L12: Entry 10 of 14 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022202 A1

TITLE: B-ephrin regulation of G-protein coupled chemoattraction, compositions, and methods of use

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Flanagan, John G. | Newton | MA | US | |
| Lu, Qiang | Brookline | MA | US | |
| Sun, Edna E. | Brookline | MA | US | |

US-CL-CURRENT: 435/6; 435/196, 435/254.2, 435/320.1, 435/368, 435/69.1, 536/23.2

ABSTRACT:

Transmembrane B ephrins and their Eph receptors signal bi-directionally. The presently claimed invention describes a cytoplasmic protein, designated PDZ-RGS3, which binds B ephrins through a PDZ domain, and has a regulator of heterotrimeric G protein signaling (RGS) domain. PDZ-RGS3 mediates signaling from the ephrin-B cytoplasmic tail. SDF-1, a chemokine with a G protein coupled receptor, or BDNF, act as chemoattractants for cerebellar granule cells, with SDF-1 action being selectively inhibited by soluble EphB receptor. The claimed invention reveals a pathway that links reverse signaling to cellular guidance, uncovers a novel mode of control for G proteins, and demonstrates a mechanism for selective regulation of responsiveness to neuronal guidance cues. Further, compositions and methods of use are provided for modulating cell migration as a function of chemokines and GPCR interaction, to aid in the treatment of disease states and medical conditions, including cancer and immune responses such as allergy and autoimmune responses. In one embodiment, a method of

h e b b g e e e f e b ef b e

altering the sensitivity of a cell to a chemokine is provided using a PDZ-RGS3 protein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 11. Document ID: US 20020052308 A1

L12: Entry 11 of 14 File: PGPB May 2, 2002

PGPUB-DOCUMENT-NUMBER: 20020052308
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020052308 A1

TITLE: Nucleic acids, proteins and antibodies

PUBLICATION-DATE: May 2, 2002

INVENTOR-INFORMATION:

| NAME | CITY | STATE | COUNTRY | RULE-47 |
|---|---|---|---|---|
| Rosen, Craig A. | Laytonsville | MD | US | |
| Ruben, Steven M. | Olney | MD | US | |

US-CL-CURRENT: 514/1; 435/183, 435/320.1, 435/325, 435/6, 435/69.1, 435/7.1, 530/350, 536/23.1

ABSTRACT:

This invention relates to newly identified tissue specific cancer associated polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "cancer antigens," and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such tissue specific cancer antigens for detection, prevention and treatment of tissue specific disorders, particularly the presense of cancer. This invention relates to the cancer antigens as well as vectors, host cells, antibodies directed to cancer antigens and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing tissue specific disorders, including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of cancer antigens of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and/or function of the polypeptides of the present invention.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 12. Document ID: US 6727063 B1

L12: Entry 12 of 14 File: USPT Apr 27, 2004

US-PAT-NO: 6727063
DOCUMENT-IDENTIFIER: US 6727063 B1

TITLE: Single nucleotide polymorphisms in genes

DATE-ISSUED: April 27, 2004

h e b b g e e e f e b ef b e

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Lander; Eric S. | Cambridge | MA | | |
| Cargill; Michele | Gaithersburg | MD | | |
| Ireland; James S. | Gaithersburg | MD | | |
| Bolk; Stacey | West Roxbury | MA | | |
| Daley; George Q. | Weston | MA | | |
| McCarthy; Jeanette J. | San Diego | CA | | |

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

ABSTRACT:

The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

4 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8



13. Document ID: US 6555321 B1

L12: Entry 13 of 14 File: USPT Apr 29, 2003

US-PAT-NO: 6555321
DOCUMENT-IDENTIFIER: US 6555321 B1

TITLE: Methods for determining cell responses through EphB receptors

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Daniel; Thomas O. | Nashville | TN | | |
| Stein; Elke | San Francisco | CA | | |

US-CL-CURRENT: 435/7.1; 435/334, 435/7.2, 435/7.21, 435/7.8

ABSTRACT:

The present invention provides methods for screening an EphB receptor or an EphB receptor-binding ligand for the ability to promote a selected biological activity when in multimeric form. The invention also provides methods for initiating, promoting, directing, or inhibiting biological activities that involve EphB receptors and/or EphB receptor-binding ligands. The invention further provides compositions that can be used in the foregoing methods.

h e b b g e e e f e b ef b e

8 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 14. Document ID: US 6514497 B1

L12: Entry 14 of 14 File: USPT Feb 4, 2003

US-PAT-NO: 6514497
DOCUMENT-IDENTIFIER: US 6514497 B1

TITLE: Inhibition of LERK-2-mediated cell adhesion

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

| NAME | CITY | STATE | ZIP CODE | COUNTRY |
|---|---|---|---|---|
| Briskin; Michael J. | Lexington | MA | | |
| Zou; Lily | Cambridge | MA | | |

US-CL-CURRENT: 424/143.1; 424/130.1, 424/137.1, 424/141.1, 424/152.1, 424/172.1, 530/387.1, 530/387.5, 530/388.1, 530/388.22

ABSTRACT:

Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.

8 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

| Terms | Documents |
|---|---|
| ephrin-B3 | 14 |

Display Format: - Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e b ef b e

Display Summary Show: 20 Sort Send to Text

Items 1 - 5 of 5

One p

1: Pascall JC, Brown KD. Related Articles, Li

Intramembrane cleavage of ephrinB3 by the human rhomboid family protease RHBDL2.
Biochem Biophys Res Commun. 2004 Apr 23;317(1):244-52.
PMID: 15047175 [PubMed - indexed for MEDLINE]

2: Yu G, Luo H, Wu Y, Wu J. Related Articles, Li

Mouse ephrinB3 augments T-cell signaling and responses to T-cell receptor ligation.
J Biol Chem. 2003 Nov 21;278(47):47209-16. Epub 2003 Sep 17.
PMID: 13679370 [PubMed - indexed for MEDLINE]

3: Kiehn O, Butt SJ. Related Articles, Li

Physiological, anatomical and genetic identification of CPG neurons in the developing mammalian spinal cord.
Prog Neurobiol. 2003 Jul;70(4):347-61. Review.
PMID: 12963092 [PubMed - indexed for MEDLINE]

4: Kullander K, Butt SJ, Lebret JM, Lundfald L, Restrepo CE, Rydstrom A, Klein R, Kiehn O. Related Articles, Li

Role of EphA4 and EphrinB3 in local neuronal circuits that control walking.
Science. 2003 Mar 21;299(5614):1889-92.
PMID: 12649481 [PubMed - indexed for MEDLINE]

5: Coonan JR, Greferath U, Messenger J, Hartley L, Murphy M, Boyd AW, Dottori M, Galea MP, Bartlett PF. Related Articles, Li

Development and reorganization of corticospinal projections in EphA4 deficie mice.
J Comp Neurol. 2001 Jul 23;436(2):248-62.
PMID: 11438928 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text



h cb h g e e e fcg

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 41 of 41

One p

1: Wieland I, Jakubiczka S, Muschke P, Cohen M, Thiele H, Gerlach KL, Adams RH, Wieacker P. Related Articles, Li

Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome.
Am J Hum Genet. 2004 Jun;74(6):1209-15. Epub 2004 Apr 29.
PMID: 15124102 [PubMed - indexed for MEDLINE]

2: Bembenek ME, Schmidt S, Li P, Morawiak J, Prack A, Jain S, Roy R, Parsons T, Chee L. Related Articles, Li

Characterization of the kinase domain of the ephrin-B3 receptor tyrosine kina using a scintillation proximity assay.
Assay Drug Dev Technol. 2003 Aug;1(4):555-63.
PMID: 15090252 [PubMed - indexed for MEDLINE]

3: Pascall JC, Brown KD. Related Articles, Li

Intramembrane cleavage of ephrinB3 by the human rhomboid family protease RHBDL2.
Biochem Biophys Res Commun. 2004 Apr 23;317(1):244-52.
PMID: 15047175 [PubMed - indexed for MEDLINE]

4: Chen ZY, Sun C, Reuhl K, Bergemann A, Henkemeyer M, Zhou R. Related Articles, Li

Abnormal hippocampal axon bundling in EphB receptor mutant mice.
J Neurosci. 2004 Mar 10;24(10):2366-74.
PMID: 15014111 [PubMed - indexed for MEDLINE]

5: Grunwald IC, Korte M, Adelmann G, Plueck A, Kullander K, Adams RH, Frotscher M, Bonhoeffer T, Klein R. Related Articles, Li

Hippocampal plasticity requires postsynaptic ephrinBs.
Nat Neurosci. 2004 Jan;7(1):33-40. Epub 2003 Dec 14.
PMID: 14699416 [PubMed - indexed for MEDLINE]

6: Yu G, Luo H, Wu Y, Wu J. Related Articles, Li

Mouse ephrinB3 augments T-cell signaling and responses to T-cell receptor ligation.
J Biol Chem. 2003 Nov 21;278(47):47209-16. Epub 2003 Sep 17.
PMID: 13679370 [PubMed - indexed for MEDLINE]

7: Egawa M, Yoshioka S, Higuchi T, Sato Y, Tatsumi K, Fujiwara H, Fujii S. Related Articles, Li

Ephrin B1 is expressed on human luteinizing granulosa cells in corpora lutea the early luteal phase: the possible involvement of the B class Eph-ephrin system during corpus luteum formation.
J Clin Endocrinol Metab. 2003 Sep;88(9):4384-92.
PMID: 12970314 [PubMed - indexed for MEDLINE]

8: Kiehn O, Butt SJ. Related Articles, Li

Physiological, anatomical and genetic identification of CPG neurons in the developing mammalian spinal cord.
Prog Neurobiol. 2003 Jul;70(4):347-61. Review.
PMID: 12963092 [PubMed - indexed for MEDLINE]

h cb hg e e e fcg e ch b e

☐ **9:** de Saint-Vis B, Bouchet C, Gautier G, Valladeau J, Caux C, Garrone P. Related Articles, Li

Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin.
Blood. 2003 Dec 15;102(13):4431-40. Epub 2003 Aug 07.
PMID: 12907451 [PubMed - indexed for MEDLINE]

☐ **10:** Tabakoff B, Bhave SV, Hoffman PL. Related Articles, Li

Selective breeding, quantitative trait locus analysis, and gene arrays identify candidate genes for complex drug-related behaviors.
J Neurosci. 2003 Jun 1;23(11):4491-8.
PMID: 12805289 [PubMed - indexed for MEDLINE]

☐ **11:** Brors D, Bodmer D, Pak K, Aletsee C, Schafers M, Dazert S, Ryan AF. Related Articles, Li

EphA4 provides repulsive signals to developing cochlear ganglion neurites mediated through ephrin-B2 and -B3.
J Comp Neurol. 2003 Jul 14;462(1):90-100.
PMID: 12761826 [PubMed - indexed for MEDLINE]

☐ **12:** Kubis N, Catala M. Related Articles, Li

[Development and maturation of the pyramidal tract]
Neurochirurgie. 2003 May;49(2-3 Pt 2):145-53. Review. French.
PMID: 12746689 [PubMed - indexed for MEDLINE]

☐ **13:** Sanchez-Carbayo M, Belbin TJ, Scotlandi K, Prystowsky M, Baldini N, Childs G, Cordon-Cardo C. Related Articles, Li

Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
Lab Invest. 2003 Apr;83(4):507-17.
PMID: 12695554 [PubMed - indexed for MEDLINE]

☐ **14:** Howard MA, Rodenas-Ruano A, Henkemeyer M, Martin GK, Lonsbury-Martin BL, Liebl DJ Related Articles, Li

Eph receptor deficiencies lead to altered cochlear function.
Hear Res. 2003 Apr;178(1-2):118-30.
PMID: 12684184 [PubMed - indexed for MEDLINE]

☐ **15:** Pickles JO. Related Articles, Li

Expression of Ephs and ephrins in developing mouse inner ear.
Hear Res. 2003 Apr;178(1-2):44-51.
PMID: 12684176 [PubMed - indexed for MEDLINE]

☐ **16:** Kullander K, Butt SJ, Lebret JM, Lundfald L, Restrepo CE, Rydstrom A, Klein R, Kiehn O. Related Articles, Li

Role of EphA4 and EphrinB3 in local neuronal circuits that control walking.
Science. 2003 Mar 21;299(5614):1889-92.
PMID: 12649481 [PubMed - indexed for MEDLINE]

☐ **17:** Bianchi LM, Dinsio K, Davoli K, Gale NW. Related Articles, Li

Lac z Histochemistry and immunohistochemistry reveal ephrin-B ligand expression in the inner ear.
J Histochem Cytochem. 2002 Dec;50(12):1641-5.
PMID: 12486086 [PubMed - indexed for MEDLINE]

☐ **18:** Takemoto M, Fukuda T, Sonoda R, Murakami F, Tanaka H, Yamamoto N. Related Articles, Li

Ephrin-B3-EphA4 interactions regulate the growth of specific thalamocortic axon populations in vitro.
Eur J Neurosci. 2002 Sep;16(6):1168-72.

h cb h g e e e fcg e ch b e

PMID: 12383247 [PubMed - indexed for MEDLINE]

19: Varelias A, Koblar SA, Cowled PA, Carter CD, Clayer M. Related Articles, Li

Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.
Cancer. 2002 Aug 15;95(4):862-9.
PMID: 12209731 [PubMed - indexed for MEDLINE]

20: Hindges R, McLaughlin T, Genoud N, Henkemeyer M, O'Leary DD. Related Articles, Li

EphB forward signaling controls directional branch extension and arborizatic required for dorsal-ventral retinotopic mapping.
Neuron. 2002 Aug 1;35(3):475-87.
PMID: 12165470 [PubMed - indexed for MEDLINE]

21: Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM. Related Articles, Li

Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Cancer. 2002 Feb 15;94(4):934-9.
PMID: 11920461 [PubMed - indexed for MEDLINE]

22: Grunwald IC, Korte M, Wolfer D, Wilkinson GA, Unsicker K, Lipp HP, Bonhoeffer T, Klein R. Related Articles, Li

Kinase-independent requirement of EphB2 receptors in hippocampal synapti plasticity.
Neuron. 2001 Dec 20;32(6):1027-40.
PMID: 11754835 [PubMed - indexed for MEDLINE]

23: Coonan JR, Greferath U, Messenger J, Hartley L, Murphy M, Boyd AW, Dottori M, Galea MP, Bartlett PF. Related Articles, Li

Development and reorganization of corticospinal projections in EphA4 deficient mice.
J Comp Neurol. 2001 Jul 23;436(2):248-62.
PMID: 11438928 [PubMed - indexed for MEDLINE]

24: Stuckmann I, Weigmann A, Shevchenko A, Mann M, Huttner WB. Related Articles, Li

Ephrin B1 is expressed on neuroepithelial cells in correlation with neocortica neurogenesis.
J Neurosci. 2001 Apr 15;21(8):2726-37.
PMID: 11306625 [PubMed - indexed for MEDLINE]

25: Kullander K, Croll SD, Zimmer M, Pan L, McClain J, Hughes V, Zabski S, DeChiara TM, Klein R, Yancopoulos GD, Gale NW. Related Articles, Li

Ephrin-B3 is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control.
Genes Dev. 2001 Apr 1;15(7):877-88.
PMID: 11297511 [PubMed - indexed for MEDLINE]

26: Rutherford A. Related Articles, Li

Looking into mirror movement disorder.
Trends Mol Med. 2001 Mar;7(3):101. No abstract available.
PMID: 11286777 [PubMed - indexed for MEDLINE]

27: Yokoyama N, Romero MI, Cowan CA, Galvan P, Helmbacher F, Charnay P, Parada LF, Henkemeyer M. Related Articles, Li

Forward signaling mediated by ephrin-B3 prevents contralateral corticospina axons from recrossing the spinal cord midline.
Neuron. 2001 Jan;29(1):85-97.
PMID: 11182083 [PubMed - indexed for MEDLINE]

28: Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL. Related Articles, Li

h cb h g e e e fcg e ch b e

Cheung NK, Brodeur GM, Evans AE, Ikegaki N.

Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.
Med Pediatr Oncol. 2000 Dec;35(6):656-8.
PMID: 11107140 [PubMed - indexed for MEDLINE]

29: Tang XX, Zhao H, Robinson ME, Cohen B, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N. Related Articles, Li

Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10936-41.
PMID: 10984508 [PubMed - indexed for MEDLINE]

30: L'Allemain G. Related Articles, Li

[Involvement of ephrins and their receptors in oncogenesis]
Bull Cancer. 2000 Jul;87(7-8):529-30. French.
PMID: 10969208 [PubMed - indexed for MEDLINE]

31: Helbling PM, Saulnier DM, Robinson V, Christiansen JH, Wilkinson DG, Brandli AW. Related Articles, Li

Comparative analysis of embryonic gene expression defines potential interaction sites for Xenopus EphB4 receptors with ephrin-B ligands.
Dev Dyn. 1999 Dec;216(4-5):361-73.
PMID: 10633856 [PubMed - indexed for MEDLINE]

32: Helbling PM, Saulnier DM, Brandli AW. Related Articles, Li

The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis.
Development. 2000 Jan;127(2):269-78.
PMID: 10603345 [PubMed - indexed for MEDLINE]

33: van Heumen WR, Claxton C, Pickles JO. Related Articles, Li

Expression of EphA4 in developing inner ears of the mouse and guinea pig.
Hear Res. 2000 Jan;139(1-2):42-50.
PMID: 10601711 [PubMed - indexed for MEDLINE]

34: Tang XX, Evans AE, Zhao H, Cnaan A, London W, Cohn SL, Brodeur GM, Ikegaki N. Related Articles, Li

High-level expression of EPHB6, EFNB2, and EFNB3 is associated with lov tumor stage and high TrkA expression in human neuroblastomas.
Clin Cancer Res. 1999 Jun;5(6):1491-6.
PMID: 10389937 [PubMed - indexed for MEDLINE]

35: Miranda JD, White LA, Marcillo AE, Willson CA, Jagid J, Whittemore SR. Related Articles, Li

Induction of Eph B3 after spinal cord injury.
Exp Neurol. 1999 Mar;156(1):218-22.
PMID: 10192794 [PubMed - indexed for MEDLINE]

36: O'Leary DD, Wilkinson DG. Related Articles, Li

Eph receptors and ephrins in neural development.
Curr Opin Neurobiol. 1999 Feb;9(1):65-73. Review.
PMID: 10072375 [PubMed - indexed for MEDLINE]

37: Tang XX, Brodeur GM, Campling BG, Ikegaki N. Related Articles, Li

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinase and their ephrin-B ligands in human small cell lung carcinoma.
Clin Cancer Res. 1999 Feb;5(2):455-60.
PMID: 10037197 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

**38:** Lin D, Gish GD, Songyang Z, Pawson T. Related Articles, Li

The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif.
J Biol Chem. 1999 Feb 5;274(6):3726-33.
PMID: 9920925 [PubMed - indexed for MEDLINE]

**39:** Flanagan JG, Vanderhaeghen P. Related Articles, Li

The ephrins and Eph receptors in neural development.
Annu Rev Neurosci. 1998;21:309-45. Review.
PMID: 9530499 [PubMed - indexed for MEDLINE]

**40:** Bergemann AD, Zhang L, Chiang MK, Brambilla R, Klein R, Flanagan JG. Related Articles, Li

Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube.
Oncogene. 1998 Jan 29;16(4):471-80.
PMID: 9484836 [PubMed - indexed for MEDLINE]

**41:** Tang XX, Pleasure DE, Ikegaki N. Related Articles, Li

cDNA cloning, chromosomal localization, and expression pattern of EPLG8, new member of the EPLG gene family encoding ligands of EPH-related protein-tyrosine kinase receptors.
Genomics. 1997 Apr 1;41(1):17-24.
PMID: 9126477 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text



h cb h g e e e fcg e ch b e

1: Development. 2000 Jan;127(2):269-78.



# The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis.

**Helbling PM, Saulnier DM, Brandli AW.**

Institute of Cell Biology, Swiss Federal Institute of Technology, ETH-Honggerberg, CH-8093 Zurich, Switzerland.

The cues and signaling systems that guide the formation of embryonic blood vessels in tissues and organs are poorly understood. Members of the Eph famil of receptor tyrosine kinases and their cell membrane-anchored ligands, the ephrins, have been assigned important roles in the control of cell migration dui embryogenesis, particularly in axon guidance and neural crest migration. Here investigated the role of EphB receptors and their ligands during embryonic blo vessel development in Xenopus laevis. In a survey of tadpole-stage Xenopus embryos for EphB receptor expression, we detected expression of EphB4 receptors in the posterior cardinal veins and their derivatives, the intersomitic veins. Vascular expression of other EphB receptors, including EphB1, EphB2 EphB3, could however not be observed, suggesting that EphB4 is the principal EphB receptor of the early embryonic vasculature of Xenopus. Furthermore, w found that ephrin-B ligands are expressed complementary to EphB4 in the somites adjacent to the migratory pathways taken by intersomitic veins during angiogenic growth. We performed RNA injection experiments to study the function of EphB4 and its ligands in intersomitic vein development. Disruptio EphB4 signaling by dominant negative EphB4 receptors or misexpression of ephrin-B ligands in Xenopus embryos resulted in intersomitic veins growing abnormally into the adjacent somitic tissue. Our findings demonstrate that Eph and B-class ephrins act as regulators of angiogenesis possibly by mediating repulsive guidance cues to migrating endothelial cells.

PMID: 10603345 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

Display Abstract Show: 20 Sort Send to Text

1: Science. 2003 Mar 21;299(5614):1889-92.



# Role of EphA4 and EphrinB3 in local neuronal circuits that contr walking.

**Kullander K, Butt SJ, Lebret JM, Lundfald L, Restrepo CE, Rydstrom A Klein R, Kiehn O.**

Department of Medical Biochemistry, Gothenburg University, Medicinaregata A, 405 30 Gothenburg, Sweden. klas.kullander@medkem.gu.se

Local circuits in the spinal cord that generate locomotion are termed central pattern generators (CPGs). These provide coordinated bilateral control over th normal limb alternation that underlies walking. The molecules that organize th mammalian CPG are unknown. Isolated spinal cords from mice lacking either EphA4 receptor or its ligand ephrinB3 have lost left-right limb alternation and instead exhibit synchrony. We identified EphA4-positive neurons as an excitat component of the locomotor CPG. Our study shows that dramatic locomotor changes can occur as a consequence of local genetic rewiring and identifies ge required for the development of normal locomotor behavior.

PMID: 12649481 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text



h cb hg e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for ephrin AND angiogenesis Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

Items 1 - 79 of 79

One p

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Umeda N, Ozaki H, Hayashi H, Oshima K. Related Articles, Li

Expression of ephrinB2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases.
Am J Ophthalmol. 2004 Aug;138(2):270-9.
PMID: 15289137 [PubMed - indexed for MEDLINE]

2: Freiss G, Bompard G, Vignon F. Related Articles, Li

[PTPL1, a proapoptotic protein tyrosine phosphatase in breast cancers]
Bull Cancer. 2004 Apr;91(4):325-32. Review. French.
PMID: 15242314 [PubMed - indexed for MEDLINE]

3: Cowan CA, Yokoyama N, Saxena A, Chumley MJ, Silvany RE, Baker LA, Srivastava D, Henkemeyer M. Related Articles, Li

Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valv formation but not early vascular development.
Dev Biol. 2004 Jul 15;271(2):263-71.
PMID: 15223333 [PubMed - indexed for MEDLINE]

4: Goldman-Wohl D, Greenfield C, Haimov-Kochman R, Ariel I, Anteby EY, Hochner-Celnikier D, Farhat M, Yagel S. Related Articles, Li

Eph and ephrin expression in normal placental development and preeclampsia
Placenta. 2004 Aug;25(7):623-30.
PMID: 15193868 [PubMed - in process]

5: Yin Y, Yamashita Y, Noda H, Okafuji T, Go MJ, Tanaka H. Related Articles, Li

EphA receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis.
Neurosci Res. 2004 Mar;48(3):285-96.
PMID: 15154674 [PubMed - indexed for MEDLINE]

6: Martiny-Baron G, Korff T, Schaffner F, Esser N, Eggstein S, Marme D, Augustin HG. Related Articles, Li

Inhibition of tumor growth and angiogenesis by soluble EphB4.
Neoplasia. 2004 May-Jun;6(3):248-57.
PMID: 15153337 [PubMed - in process]

7: Fox BP, Kandpal RP. Related Articles, Li

Invasiveness of breast carcinoma cells and transcript profile: Eph receptors an ephrin ligands as molecular markers of potential diagnostic and prognostic application.
Biochem Biophys Res Commun. 2004 Jun 11;318(4):882-92.
PMID: 15147954 [PubMed - indexed for MEDLINE]

8: Liu W, Jung YD, Ahmad SA, McCarty MF, Stoeltzing O, Reinmuth N, Fan F, Ellis LM. Related Articles, Li

Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer.
Br J Cancer. 2004 Apr 19;90(8):1620-6.
PMID: 15083195 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

9: Morikawa Y, Cserjesi P. Related Articles, Li

Extra-embryonic vasculature development is regulated by the transcription factor HAND1.
Development. 2004 May;131(9):2195-204. Epub 2004 Apr 08.
PMID: 15073150 [PubMed - indexed for MEDLINE]

10: Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Related Articles, Li

Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8. Epub 2004 Apr 05.
PMID: 15067119 [PubMed - indexed for MEDLINE]

11: Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. Related Articles, Li

EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPas activation.
J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49. Epub 2004 Mar 30.
PMID: 15054110 [PubMed - in process]

12: Davy A, Aubin J, Soriano P. Related Articles, Li

Ephrin-B1 forward and reverse signaling are required during mouse development.
Genes Dev. 2004 Mar 1;18(5):572-83.
PMID: 15037550 [PubMed - indexed for MEDLINE]

13: Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE. Related Articles, Li

Endostatin's antiangiogenic signaling network.
Mol Cell. 2004 Mar 12;13(5):649-63.
PMID: 15023336 [PubMed - indexed for MEDLINE]

14: Patan S. Related Articles, Li

Vasculogenesis and angiogenesis.
Cancer Treat Res. 2004;117:3-32. Review.
PMID: 15015550 [PubMed - indexed for MEDLINE]

15: Zisch AH, Zeisberger SM, Ehrbar M, Djonov V, Weber CC, Ziemiecki A, Pasquale EB, Hubbell JA. Related Articles, Li

Engineered fibrin matrices for functional display of cell membrane-bound growth factor-like activities: study of angiogenic signaling by ephrin-B2.
Biomaterials. 2004 Jul;25(16):3245-57.
PMID: 14980419 [PubMed - indexed for MEDLINE]

16: Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ. Related Articles, Li

Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.
Mol Cancer Res. 2004 Jan;2(1):36-42.
PMID: 14757844 [PubMed - indexed for MEDLINE]

17: Bicknell R, Harris AL. Related Articles, Li

Novel angiogenic signaling pathways and vascular targets.
Annu Rev Pharmacol Toxicol. 2004;44:219-38. Review.
PMID: 14744245 [PubMed - indexed for MEDLINE]

18: Sturz A, Bader B, Thierauch KH, Glienke J. Related Articles, Li

EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.

h cb hg e e e fcg e ch b e

Biochem Biophys Res Commun. 2004 Jan 2;313(1):80-8.
PMID: 14672701 [PubMed - indexed for MEDLINE]

☐ **19:** Sawai Y, Tamura S, Fukui K, Ito N, Imanaka K, Saeki A, Sakuda S, Kiso S, Matsuzawa Y. Related Articles, Li

Expression of ephrin-B1 in hepatocellular carcinoma: possible involvement i neovascularization.
J Hepatol. 2003 Dec;39(6):991-6.
PMID: 14642617 [PubMed - indexed for MEDLINE]

☐ **20:** Shibuya M. Related Articles, Li

VEGF-receptor inhibitors for anti-angiogenesis.
Nippon Yakurigaku Zasshi. 2003 Dec;122(6):498-503. Review.
PMID: 14639004 [PubMed - indexed for MEDLINE]

☐ **21:** Bogenrieder T, Herlyn M. Related Articles, Li

Axis of evil: molecular mechanisms of cancer metastasis.
Oncogene. 2003 Sep 29;22(42):6524-36. Review.
PMID: 14528277 [PubMed - indexed for MEDLINE]

☐ **22:** Maekawa H, Oike Y, Kanda S, Ito Y, Yamada Y, Kurihara H, Nagai R, Suda T. Related Articles, Li

Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature.
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2008-14. Epub 2003 Sep 18.
PMID: 14500293 [PubMed - indexed for MEDLINE]

☐ **23:** Egawa M, Yoshioka S, Higuchi T, Sato Y, Tatsumi K, Fujiwara H, Fujii S. Related Articles, Li

Ephrin B1 is expressed on human luteinizing granulosa cells in corpora lutea the early luteal phase: the possible involvement of the B class Eph-ephrin system during corpus luteum formation.
J Clin Endocrinol Metab. 2003 Sep;88(9):4384-92.
PMID: 12970314 [PubMed - indexed for MEDLINE]

☐ **24:** Baker RK, Antin PB. Related Articles, Li

Ephs and ephrins during early stages of chick embryogenesis.
Dev Dyn. 2003 Sep;228(1):128-42.
PMID: 12950087 [PubMed - indexed for MEDLINE]

☐ **25:** Augustin HG, Reiss Y. Related Articles, Li

EphB receptors and ephrinB ligands: regulators of vascular assembly and homeostasis.
Cell Tissue Res. 2003 Oct;314(1):25-31. Epub 2003 Aug 02. Review.
PMID: 12905065 [PubMed - indexed for MEDLINE]

☐ **26:** Sullivan DC, Bicknell R. Related Articles, Li

New molecular pathways in angiogenesis.
Br J Cancer. 2003 Jul 21;89(2):228-31. Review.
PMID: 12865906 [PubMed - indexed for MEDLINE]

☐ **27:** Favre CJ, Mancuso M, Maas K, McLean JW, Baluk P, McDonald DM. Related Articles, Li

Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung.
Am J Physiol Heart Circ Physiol. 2003 Nov;285(5):H1917-38. Epub 2003 Jul 03.
PMID: 12842817 [PubMed - indexed for MEDLINE]

☐ **28:** Myshkin E, Wang B. Related Articles, Li

h cb h g e e e fcg e ch b e

Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach.
J Chem Inf Comput Sci. 2003 May-Jun;43(3):1004-10.
PMID: 12767159 [PubMed - indexed for MEDLINE]

**29:** Fuller T, Korff T, Kilian A, Dandekar G, Augustin HG. Related Articles, Li

Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.
J Cell Sci. 2003 Jun 15;116(Pt 12):2461-70. Epub 2003 May 06.
PMID: 12734395 [PubMed - indexed for MEDLINE]

**30:** Deroanne C, Vouret-Craviari V, Wang B, Pouyssegur J. Related Articles, Li

EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreadi via the Rac/PAK pathway.
J Cell Sci. 2003 Apr 1;116(Pt 7):1367-76.
PMID: 12615978 [PubMed - indexed for MEDLINE]

**31:** Marme D. Related Articles, Li

VEGFs, angiopoietins, Ephrins and their receptors: putative targets for tumo therapy?
Ann Hematol. 2002;81 Suppl 2:S66. No abstract available.
PMID: 12611080 [PubMed - indexed for MEDLINE]

**32:** Augustin HG. Related Articles, Li

[Angiogenesis research--quo vadis?]
Ophthalmologe. 2003 Feb;100(2):104-10. Review. German.
PMID: 12589453 [PubMed - indexed for MEDLINE]

**33:** Kaban K, Herbst RS. Related Articles, Li

Angiogenesis as a target for cancer therapy.
Hematol Oncol Clin North Am. 2002 Oct;16(5):1125-71. Review.
PMID: 12512387 [PubMed - indexed for MEDLINE]

**34:** Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J. Related Articles, Li

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Mol Cancer Res. 2002 Nov;1(1):2-11.
PMID: 12496364 [PubMed - indexed for MEDLINE]

**35:** Nagashima K, Endo A, Ogita H, Kawana A, Yamagishi A, Kitabatake A, Matsuda M, Mochizuki N. Related Articles, Li

Adaptor protein Crk is required for ephrin-B1-induced membrane ruffling an focal complex assembly of human aortic endothelial cells.
Mol Biol Cell. 2002 Dec;13(12):4231-42.
PMID: 12475948 [PubMed - indexed for MEDLINE]

**36:** Meyer S, Hafner C, Vogt T. Related Articles, Li

[Role of receptor tyrosine kinase in the angiogenesis]
Hautarzt. 2002 Sep;53(9):629-42. Review. German. No abstract available.
PMID: 12432901 [PubMed - indexed for MEDLINE]

**37:** Bogenrieder T, Herlyn M. Related Articles, Li

Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.
Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15. Review.
PMID: 12398996 [PubMed - indexed for MEDLINE]

**38:** Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE. Related Articles, Li

h cb h g e e e fcg e ch b e

Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J.

Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
Oncogene. 2002 Oct 10;21(46):7011-26.
PMID: 12370823 [PubMed - indexed for MEDLINE]

**39:** Koolpe M, Dail M, Pasquale EB. Related Articles, Li

An ephrin mimetic peptide that selectively targets the EphA2 receptor.
J Biol Chem. 2002 Dec 6;277(49):46974-9. Epub 2002 Sep 25.
PMID: 12351647 [PubMed - indexed for MEDLINE]

**40:** Papoutsi M, Othman-Hassan K, Christ B, Patel K, Wilting J. Related Articles, Li

Development of an arterial tree in C6 gliomas but not in A375 melanomas.
Histochem Cell Biol. 2002 Sep;118(3):241-9. Epub 2002 Jul 13.
PMID: 12271360 [PubMed - indexed for MEDLINE]

**41:** Nakamoto M, Bergemann AD. Related Articles, Li

Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenes
Microsc Res Tech. 2002 Oct 1;59(1):58-67. Review.
PMID: 12242697 [PubMed - indexed for MEDLINE]

**42:** Marvin KW, Keelan JA, Eykholt RL, Sato TA, Mitchell MD. Related Articles, Li

Expression of angiogenic and neurotrophic factors in the human amnion and choriodecidua.
Am J Obstet Gynecol. 2002 Sep;187(3):728-34.
PMID: 12237655 [PubMed - indexed for MEDLINE]

**43:** Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH, Granger HJ. Related Articles, Li

Eph B4 receptor signaling mediates endothelial cell migration and proliferati via the phosphatidylinositol 3-kinase pathway.
J Biol Chem. 2002 Nov 15;277(46):43830-5. Epub 2002 Sep 13.
PMID: 12235151 [PubMed - indexed for MEDLINE]

**44:** Deregowski V, Delhalle S, Benoit V, Bours V, Merville MP. Related Articles, Li

Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells.
Biochem Pharmacol. 2002 Sep;64(5-6):873-81.
PMID: 12213581 [PubMed - indexed for MEDLINE]

**45:** Oike Y, Ito Y, Hamada K, Zhang XQ, Miyata K, Arai F, Inada T, Araki K, Nakagata N, Takeya M, Kisanuki YY, Yanagisawa M, Gale NW, Suda T. Related Articles, Li

Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells.
Blood. 2002 Aug 15;100(4):1326-33.
PMID: 12149214 [PubMed - indexed for MEDLINE]

**46:** Huynh-Do U, Vindis C, Liu H, Cerretti DP, McGrew JT, Enriquez M, Chen J, Daniel TO. Related Articles, Li

Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis.
J Cell Sci. 2002 Aug 1;115(Pt 15):3073-81.
PMID: 12118063 [PubMed - indexed for MEDLINE]

**47:** Palmer A, Zimmer M, Erdmann KS, Eulenburg V, Porthin A, Heumann R, Deutsch U, Klein R. Related Articles, Li

EphrinB phosphorylation and reverse signaling: regulation by Src kinases an PTP-BL phosphatase.
Mol Cell. 2002 Apr;9(4):725-37.
PMID: 11983165 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

**48:** Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM. Related Articles, Li

Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Cancer. 2002 Feb 15;94(4):934-9.
PMID: 11920461 [PubMed - indexed for MEDLINE]

**49:** Gerety SS, Anderson DJ. Related Articles, Li

Cardiovascular ephrinB2 function is essential for embryonic angiogenesis.
Development. 2002 Mar;129(6):1397-410.
PMID: 11880349 [PubMed - indexed for MEDLINE]

**50:** Cheng N, Brantley DM, Chen J. Related Articles, Li

The ephrins and Eph receptors in angiogenesis.
Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85. Review.
PMID: 11750881 [PubMed - indexed for MEDLINE]

**51:** Toth J, Cutforth T, Gelinas AD, Bethoney KA, Bard J, Harrison CJ. Related Articles, Li

Crystal structure of an ephrin ectodomain.
Dev Cell. 2001 Jul;1(1):83-92.
PMID: 11703926 [PubMed - indexed for MEDLINE]

**52:** Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M. Related Articles, Li

Angiogenesis factors.
Intern Med. 2001 Jul;40(7):565-72. Review.
PMID: 11506294 [PubMed - indexed for MEDLINE]

**53:** Zhang XQ, Takakura N, Oike Y, Inada T, Gale NW, Yancopoulos GD, Suda T. Related Articles, Li

Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2(+) endothelial cells.
Blood. 2001 Aug 15;98(4):1028-37.
PMID: 11493448 [PubMed - indexed for MEDLINE]

**54:** Bovenkamp DE, Greer PA. Related Articles, Li

Degenerate PCR-based cloning method for Eph receptors and analysis of the expression in the developing murine central nervous system and vasculature.
DNA Cell Biol. 2001 Apr;20(4):203-13.
PMID: 11403717 [PubMed - indexed for MEDLINE]

**55:** Adams RH, Klein R. Related Articles, Li

Eph receptors and ephrin ligands. essential mediators of vascular developme
Trends Cardiovasc Med. 2000 Jul;10(5):183-8. Review.
PMID: 11282292 [PubMed - indexed for MEDLINE]

**56:** Cheng N, Chen J. Related Articles, Li

Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism.
J Biol Chem. 2001 Apr 27;276(17):13771-7. Epub 2001 Feb 02.
PMID: 11278471 [PubMed - indexed for MEDLINE]

**57:** Klein R. Related Articles, Li

Excitatory Eph receptors and adhesive ephrin ligands.
Curr Opin Cell Biol. 2001 Apr;13(2):196-203. Review.
PMID: 11248553 [PubMed - indexed for MEDLINE]

**58:** Patan S. Related Articles, Li

h cb h g e e e fcg e ch b e

Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling.
J Neurooncol. 2000 Oct-Nov;50(1-2):1-15. Review.
PMID: 11245270 [PubMed - indexed for MEDLINE]

**59:** Adams RH, Diella F, Hennig S, Helmbacher F, Deutsch U, Klein R. Related Articles, Li

The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration.
Cell. 2001 Jan 12;104(1):57-69.
PMID: 11163240 [PubMed - indexed for MEDLINE]

**60:** Gale NW, Baluk P, Pan L, Kwan M, Holash J, DeChiara TM, McDonald DM, Yancopoulos GD. Related Articles, Li

Ephrin-B2 selectively marks arterial vessels and neovascularization sites in t adult, with expression in both endothelial and smooth-muscle cells.
Dev Biol. 2001 Feb 15;230(2):151-60.
PMID: 11161569 [PubMed - indexed for MEDLINE]

**61:** Shin D, Garcia-Cardena G, Hayashi S, Gerety S, Asahara T, Stavrakis G, Isner J, Folkman J, Gimbrone MA Jr, Anderson DJ. Related Articles, Li

Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization.
Dev Biol. 2001 Feb 15;230(2):139-50.
PMID: 11161568 [PubMed - indexed for MEDLINE]

**62:** Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. Related Articles, Li

The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Oncogene. 2000 Dec 7;19(52):6043-52.
PMID: 11146556 [PubMed - indexed for MEDLINE]

**63:** Umess LD, Sorensen LK, Li DY. Related Articles, Li

Arteriovenous malformations in mice lacking activin receptor-like kinase-1.
Nat Genet. 2000 Nov;26(3):328-31.
PMID: 11062473 [PubMed - indexed for MEDLINE]

**64:** L'Allemain G. Related Articles, Li

[Involvement of ephrins and their receptors in oncogenesis]
Bull Cancer. 2000 Jul;87(7-8):529-30. French.
PMID: 10969208 [PubMed - indexed for MEDLINE]

**65:** Yuan K, Jin YT, Lin MT. Related Articles, Li

Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis.
J Periodontal Res. 2000 Jun;35(3):165-71.
PMID: 10929871 [PubMed - indexed for MEDLINE]

**66:** Myers C, Charboneau A, Boudreau N. Related Articles, Li

Homeobox B3 promotes capillary morphogenesis and angiogenesis.
J Cell Biol. 2000 Jan 24;148(2):343-51.
PMID: 10648567 [PubMed - indexed for MEDLINE]

**67:** Helbling PM, Saulnier DM, Brandli AW. Related Articles, Li

The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis.
Development. 2000 Jan;127(2):269-78.

h cb h g e e e fcg e ch b e

PMID: 10603345 [PubMed - indexed for MEDLINE]

68: Ilan N, Madri JA. Related Articles, Li

New paradigms of signaling in the vasculature: ephrins and metalloproteases
Curr Opin Biotechnol. 1999 Dec;10(6):536-40. Review.
PMID: 10600686 [PubMed - indexed for MEDLINE]

69: Gerety SS, Wang HU, Chen ZF, Anderson DJ. Related Articles, Li

Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development.
Mol Cell. 1999 Sep;4(3):403-14.
PMID: 10518221 [PubMed - indexed for MEDLINE]

70: Choi S, Jeong J, Kim T, Park S. Related Articles, Li

Characterization of ephrin-A1 and ephrin-A4 as ligands for the EphA8 recep protein tyrosine kinase.
Mol Cells. 1999 Aug 31;9(4):440-5.
PMID: 10515610 [PubMed - indexed for MEDLINE]

71: Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R. Related Articles, Li

Roles of ephrinB ligands and EphB receptors in cardiovascular development demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.
Genes Dev. 1999 Feb 1;13(3):295-306.
PMID: 9990854 [PubMed - indexed for MEDLINE]

72: Chiarugi V, Magnelli L, Gallo O. Related Articles, Li

Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review).
Int J Mol Med. 1998 Dec;2(6):715-9. Review.
PMID: 9850741 [PubMed - indexed for MEDLINE]

73: McBride JL, Ruiz JC. Related Articles, Li

Ephrin-A1 is expressed at sites of vascular development in the mouse.
Mech Dev. 1998 Oct;77(2):201-4.
PMID: 9831653 [PubMed - indexed for MEDLINE]

74: Wang HU, Chen ZF, Anderson DJ. Related Articles, Li

Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.
Cell. 1998 May 29;93(5):741-53.
PMID: 9630219 [PubMed - indexed for MEDLINE]

75: Stein E, Lane AA, Cerretti DP, Schoecklmann HO, Schroff AD, Van Etten RL, Daniel TO. Related Articles, Li

Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses.
Genes Dev. 1998 Mar 1;12(5):667-78.
PMID: 9499402 [PubMed - indexed for MEDLINE]

76: Stein E, Huynh-Do U, Lane AA, Cerretti DP, Daniel TO. Related Articles, Li

Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c Jun kinase.
J Biol Chem. 1998 Jan 16;273(3):1303-8.
PMID: 9430661 [PubMed - indexed for MEDLINE]

77: Stein E, Cerretti DP, Daniel TO. Related Articles, Li

Ligand activation of ELK receptor tyrosine kinase promotes its association

h cb h g e e e fcg e ch b e

with Grb10 and Grb2 in vascular endothelial cells.
J Biol Chem. 1996 Sep 20;271(38):23588-93.
PMID: 8798570 [PubMed - indexed for MEDLINE]

78: Takahashi H, Ikeda T. Related Articles, Li

Molecular cloning and expression of rat and mouse B61 gene: implications c organogenesis.
Oncogene. 1995 Sep 7;11(5):879-83.
PMID: 7675446 [PubMed - indexed for MEDLINE]

79: Pandey A, Shao H, Marks RM, Polverini PJ, Dixit VM. Related Articles, Li

Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis.
Science. 1995 Apr 28;268(5210):567-9.
PMID: 7536959 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg e ch b e

1: Genes Dev. 1999 Feb 1;13(3):295-306.



# Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.

**Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R.**

European Molecular Biology Laboratory, D-69117 Heidelberg, Germany.

Eph receptor tyrosine kinases and their cell-surface-bound ligands, the ephrins regulate axon guidance and bundling in the developing brain, control cell migration and adhesion, and help patterning the embryo. Here we report that tv ephrinB ligands and three EphB receptors are expressed in and regulate the formation of the vascular network. Mice lacking ephrinB2 and a proportion of double mutants deficient in EphB2 and EphB3 receptor signaling die in utero before embryonic day 11.5 (E11.5) because of defects in the remodeling of the embryonic vascular system. Our phenotypic analysis suggests complex interactions and multiple functions of Eph receptors and ephrins in the embryo vasculature. Interaction between ephrinB2 on arteries and its EphB receptors o veins suggests a role in defining boundaries between arterial and venous doma Expression of ephrinB1 by arterial and venous endothelial cells and EphB3 by veins and some arteries indicates that endothelial cell-to-cell interactions betw ephrins and Eph receptors are not restricted to the border between arteries and veins. Furthermore, expression of ephrinB2 and EphB2 in mesenchyme adjace to vessels and vascular defects in ephB2/ephB3 double mutants indicate a requirement for ephrin-Eph signaling between endothelial cells and surroundir mesenchymal cells. Finally, ephrinB ligands induce capillary sprouting in vitr with a similar efficiency as angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF), demonstrating a stimulatory role of ephrins in the remodeling of the developing vascular system.

PMID: 9990854 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

1: Genes Dev. 1999 Feb 1;13(3):295-306.



# Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.

**Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R.**

European Molecular Biology Laboratory, D-69117 Heidelberg, Germany.

Eph receptor tyrosine kinases and their cell-surface-bound ligands, the ephrins regulate axon guidance and bundling in the developing brain, control cell migration and adhesion, and help patterning the embryo. Here we report that tv ephrinB ligands and three EphB receptors are expressed in and regulate the formation of the vascular network. Mice lacking ephrinB2 and a proportion of double mutants deficient in EphB2 and EphB3 receptor signaling die in utero before embryonic day 11.5 (E11.5) because of defects in the remodeling of the embryonic vascular system. Our phenotypic analysis suggests complex interactions and multiple functions of Eph receptors and ephrins in the embryo vasculature. Interaction between ephrinB2 on arteries and its EphB receptors o veins suggests a role in defining boundaries between arterial and venous doma Expression of ephrinB1 by arterial and venous endothelial cells and EphB3 by veins and some arteries indicates that endothelial cell-to-cell interactions betw ephrins and Eph receptors are not restricted to the border between arteries and veins. Furthermore, expression of ephrinB2 and EphB2 in mesenchyme adjace to vessels and vascular defects in ephB2/ephB3 double mutants indicate a requirement for ephrin-Eph signaling between endothelial cells and surroundir mesenchymal cells. Finally, ephrinB ligands induce capillary sprouting in vitr with a similar efficiency as angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF), demonstrating a stimulatory role of ephrins in the remodeling of the developing vascular system.

PMID: 9990854 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

1: Curr Opin Biotechnol. 1999 Dec;10(6):536-40.

Related Articles, L

FREE SCIENCE
FULL-TEXT ARTICLE

# New paradigms of signaling in the vasculature: ephrins and metalloproteases.

**Ilan N, Madri JA.**

Department of Pathology, Yale University School of Medicine, New Haven, C 06510, USA.

As our understanding of the control of vasculogenesis and angiogenesis contin to grow, we will be confronted with an increasing number of interacting and intersecting receptor-mediated signaling pathways. If we are to be successful i developing new and novel effective therapeutic reagents that can function as stimulators or inhibitors of these critically important processes, we will have t develop a sophisticated, full understanding of the complex interactions associa with ephrin-based and metalloprotease-based signaling pathways.

Publication Types:

- Review
- Review, Tutorial

PMID: 10600686 [PubMed - indexed for MEDLINE]



h cb hg e e e fcg c e e e b b e b c

1: J Neurooncol. 2000 Oct-Nov;50(1-2):1-15. Related Articles, L

# Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling.

**Patan S.**

Division of Cardiology, Albert Einstein College of Medicine, Yeshiva Univers Bronx, New York 10461, USA. spatan@aecom.yu.du

Two distinct mechanisms, vasculogenesis and angiogenesis implement the formation of the vascular network in the embryo. Vasculogenesis gives rise to heart and the first primitive vascular plexus inside the embryo and in its surrounding membranes, as the yolk sac circulation. Angiogenesis is responsib for the remodeling and expansion of this network. While vasculogenesis refers in situ differentiation and growth of blood vessels from mesodermal derived hemangioblasts, angiogenesis comprises two different mechanisms: endothelia sprouting and intussusceptive microvascular growth (IMG). The sprouting process is based on endothelial cell migration, proliferation and tube formatior IMG divides existing vessel lumens by formation and insertion of tissue folds columns of interstitial tissue into the vessel lumen. The latter are termed interstitial or inter-vascular tissue structures (ITSs) and tissue pillars or posts. Intussusception also includes the establishment of new vessels by in situ loop formation in the wall of large veins. The molecular regulation of these distinct mechanisms is discussed in respect to the most important positive regulators, vascular endothelial growth factor (VEGF) and its receptors flk-1 (KDR) and f 1, the Angiopoietin/tie system and the ephrin-B/EpH-B system. The cellular mechanisms and the molecular regulation of angiogenesis in the pathological state are summarized and the differences of physiological and pathological angiogenesis elaborated.

Publication Types:

- Review
- Review, Academic

PMID: 11245270 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

1: Trends Cardiovasc Med. 2000 Jul;10(5):183-8.



## Eph receptors and ephrin ligands. essential mediators of vascular development.

**Adams RH, Klein R.**

Developmental Biology Program, Heidelberg, Germany.

The molecular and cellular mechanisms governing vascular development are s poorly understood. Prominent among the intercellular signals that control the initial establishment of the vascular network (termed vasculogenesis) and the subsequent remodeling process (called angiogenesis) are soluble ligands that signal through receptor tyrosine kinases (RTKs). Recent reports have added ce bound ephrin ligands and their cognate Eph RTKs to the list of key players in vascular development.

Publication Types:

- Review
- Review, Tutorial

PMID: 11282292 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text



h cb hg e e e fcg c e e e b b e b c

## Angiogenesis factors.

**Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M**

Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka.

Angiogenesis is a recent highlight in the medical field; the developmental proc and pathological conditions for various diseases can be understood from the nc aspect of "angiogenesis". Many angiogenesis-related factors are involved in th development of vessels during embryogenesis (vasculogenesis), as well as the induction of new vessels in response to physiological or pathological stimuli. I particular, the appearance of hemangioblasts, precursor cells for vascular endothelial cells and blood cells, and blood islands are expected to play a "prelude" role in tubulogenesis. Gene knock out mice of vascular endothelial growth factor (VEGF)/VEGF receptor, ephrin-B2, and angiopoietin-1 results i failure of normal vessels production. Dormant factors derived from proteolytic cleavage of various physiological substrates are expected to balance a homeostasis of "angiogenic states" in the host. Furthermore, angiogenesis und various pathological conditions of malignant tumors, ocular diseases, psoriasis rheumatoid arthritis, atherosclerosis and other diseases is associated with comp angiogenesis networks, suggesting pleiotropic mechanisms for angiogenesis.

Publication Types:
- Review
- Review, Tutorial

PMID: 11506294 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

1: Intern Med. 2001 Jul;40(7):565-72.



## Angiogenesis factors.

**Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M**

Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka.

Angiogenesis is a recent highlight in the medical field; the developmental proc and pathological conditions for various diseases can be understood from the nc aspect of "angiogenesis". Many angiogenesis-related factors are involved in th development of vessels during embryogenesis (vasculogenesis), as well as the induction of new vessels in response to physiological or pathological stimuli. I particular, the appearance of hemangioblasts, precursor cells for vascular endothelial cells and blood cells, and blood islands are expected to play a "prelude" role in tubulogenesis. Gene knock out mice of vascular endothelial growth factor (VEGF)/VEGF receptor, ephrin-B2, and angiopoietin-1 results i failure of normal vessels production. Dormant factors derived from proteolytic cleavage of various physiological substrates are expected to balance a homeostasis of "angiogenic states" in the host. Furthermore, angiogenesis und various pathological conditions of malignant tumors, ocular diseases, psoriasis rheumatoid arthritis, atherosclerosis and other diseases is associated with comp angiogenesis networks, suggesting pleiotropic mechanisms for angiogenesis.

Publication Types:
- Review
- Review, Tutorial

PMID: 11506294 [PubMed - indexed for MEDLINE]



h cb hg e e e fcg c e e e b b e b c

1: Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85.



## The ephrins and Eph receptors in angiogenesis.

**Cheng N, Brantley DM, Chen J.**

Department of Cancer Biology, Vanderbilt University School of Medicine, A-4323 MCN, 1161 21st Avenue South, Nashville, TN 37232, USA.

Eph receptors are a unique family of receptor tyrosine kinases that play critical roles in embryonic patterning, neuronal targeting, vascular development and a neovascularization. Engagement of Eph receptors by ephrin ligands mediates critical steps of angiogenesis, including juxtacrine cell-cell contacts, cell adhes to extracellular matrix, and cell migration. Recent evidence from in vitro angiogenesis assays and analysis of mice deficient for one or more members o the Eph family establishes the role of Eph signaling in sprouting angiogenesis blood vessel remodeling during vascular development. Furthermore, elevated expression of Eph receptors and ephrin ligands is associated with tumors and associated tumor vasculature, suggesting that Eph receptors and their ephrin ligands also play critical roles in tumor angiogenesis and tumor growth. This review will focus on the relevance of Eph receptor signaling in embryonic and adult neovascularization, and possible contributions to tumor growth and metastasis.

Publication Types:
- Review
- Review, Tutorial

PMID: 11750881 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

1: Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85.

SCIENCE DIRECT FULL TEXT ARTICLE

Related Articles, L

# The ephrins and Eph receptors in angiogenesis.

**Cheng N, Brantley DM, Chen J.**

Department of Cancer Biology, Vanderbilt University School of Medicine, A-4323 MCN, 1161 21st Avenue South, Nashville, TN 37232, USA.

Eph receptors are a unique family of receptor tyrosine kinases that play critical roles in embryonic patterning, neuronal targeting, vascular development and a neovascularization. Engagement of Eph receptors by ephrin ligands mediates critical steps of angiogenesis, including juxtacrine cell-cell contacts, cell adhes to extracellular matrix, and cell migration. Recent evidence from in vitro angiogenesis assays and analysis of mice deficient for one or more members o the Eph family establishes the role of Eph signaling in sprouting angiogenesis blood vessel remodeling during vascular development. Furthermore, elevated expression of Eph receptors and ephrin ligands is associated with tumors and associated tumor vasculature, suggesting that Eph receptors and their ephrin ligands also play critical roles in tumor angiogenesis and tumor growth. This review will focus on the relevance of Eph receptor signaling in embryonic and adult neovascularization, and possible contributions to tumor growth and metastasis.

Publication Types:
- Review
- Review, Tutorial

PMID: 11750881 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text



h cb h g e e e fcg c e e e b b e b c

1: Ophthalmologe. 2003 Feb;100(2):104-10.



# [Angiogenesis research--quo vadis?]

[Article in German]

**Augustin HG.**

Abt. fur Vasklare Biologie und Angiogeneseforshcung, Klinik fur Tumorbiolo Freiburg. augustin@angiogenese.de

The field of angiogenesis research has seen an explosion of knowledge within last 10 years. More than 3500 angiogenesis-related papers are presently being published per year compared to the less than 200 annual papers published in th early 1990s.Paralleling the progress in the field of basic angiogenesis research, translational research has led to the identification of more than 100 angiomanipulatory compounds. Presently, more than 40 substances are in vari phases of clinical trials. The prospect of these exciting developments is presen dampened by the negative outcome of some advanced clinical trials. Thus, following euphoria and disillusion, the field is presently experiencing that translational clinical research requires endurance to eventually accomplish the successful implementation of angiomanipulatory therapies in the clinical settin The present article provides an overview of the field of angiogenesis research a summarizes ongoing efforts aimed at developing angiomanipulatory therapies.

Publication Types:
- Review
- Review, Tutorial

PMID: 12589453 [PubMed - indexed for MEDLINE]



h cb h g e e e fcg c e e e b b e b c

Items 1 - 7 of 7

One p

1: Gilbert WM, Nesbitt TS, Danielsen B. Related Articles, Li

The cost of prematurity: quantification by gestational age and birth weight.
Obstet Gynecol. 2003 Sep;102(3):488-92.
PMID: 12962929 [PubMed - indexed for MEDLINE]

2: Kravitz RL, Leigh JP, Samuels SJ, Schembri M, Gilbert WM. Related Articles, Li

Tracking career satisfaction and perceptions of quality among US obstetrician and gynecologists.
Obstet Gynecol. 2003 Sep;102(3):463-70.
PMID: 12962925 [PubMed - indexed for MEDLINE]

3: Gilbert WM, Danielsen B. Related Articles, Li

Pregnancy outcomes associated with intrauterine growth restriction.
Am J Obstet Gynecol. 2003 Jun;188(6):1596-9; discussion 1599-601.
PMID: 12824998 [PubMed - indexed for MEDLINE]

4: Hueston WJ, Gilbert GE, Davis L, Sturgill V. Related Articles, Li

Delayed prenatal care and the risk of low birth weight delivery.
J Community Health. 2003 Jun;28(3):199-208.
PMID: 12713070 [PubMed - indexed for MEDLINE]

5: Gilbert WM, Newman PS, Eby-Wilkens E, Brace RA. Related Articles, Li

Technetium Tc 99m rapidly crosses the ovine placenta and intramembranous pathway.
Am J Obstet Gynecol. 1996 Dec;175(6):1557-62.
PMID: 8987941 [PubMed - indexed for MEDLINE]

6: McVea K, Crabtree BF, Medder JD, Susman JL, Lukas L, McIlvain HE, Davis CM, Gilbert CS, Hawver M. Related Articles, Li

An ounce of prevention? Evaluation of the 'Put Prevention into Practice' program.
J Fam Pract. 1996 Oct;43(4):361-9.
PMID: 8874371 [PubMed - indexed for MEDLINE]

7: Gale NW, Flenniken A, Compton DC, Jenkins N, Copeland NG, Gilbert DJ, Davis S, Wilkinson DG, Yancopoulos GD. Related Articles, Li

Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segment
Oncogene. 1996 Sep 19;13(6):1343-52.
PMID: 8808709 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text



h cb h g e e e fcg e ch b e

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 5 of 5 One p

1: Gale NW, Flenniken A, Compton DC, Jenkins N, Copeland NG, Gilbert DJ, Davis S, Wilkinson DG, Yancopoulos GD. Related Articles, Li

Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segment
Oncogene. 1996 Sep 19;13(6):1343-52.
PMID: 8808709 [PubMed - indexed for MEDLINE]

2: Cerretti DP, Copeland NG, Gilbert DJ, Jenkins NA, Kuefer MU, Valentine V, Shapiro DN, Cui X, Morris SW. Related Articles, Li

The gene encoding LERK-7 (EPLG7, Epl7), a ligand for the Eph-related receptor tyrosine kinases, maps to human chromosome 5 at band q21 and to mouse chromosome 17.
Genomics. 1996 Jul 15;35(2):376-9.
PMID: 8661153 [PubMed - indexed for MEDLINE]

3: Cerretti DP, Lyman SD, Kozlosky CJ, Copeland NG, Gilbert DJ, Jenkins NA, Valentine V, Kirstein MN, Shapiro DN, Morris SW. Related Articles, Li

The genes encoding the eph-related receptor tyrosine kinase ligands LERK-1 (EPLG1, Epl1), LERK-3 (EPLG3, Epl3), and LERK-4 (EPLG4, Epl4) are clustered on human chromosome 1 and mouse chromosome 3.
Genomics. 1996 Apr 15;33(2):277-82.
PMID: 8660976 [PubMed - indexed for MEDLINE]

4: Cerretti DP, Vanden Bos T, Nelson N, Kozlosky CJ, Reddy P, Maraskovsky E, Park LS, Lyman SD, Copeland NG, Gilbert DJ. Related Articles, Li

Isolation of LERK-5: a ligand of the eph-related receptor tyrosine kinases.
Mol Immunol. 1995 Nov;32(16):1197-205.
PMID: 8559144 [PubMed - indexed for MEDLINE]

5: Ellis J, Liu Q, Breitman M, Jenkins NA, Gilbert DJ, Copeland NG, Tempest HV, Warren S, Muir E, Schilling H. Related Articles, Li

Embryo brain kinase: a novel gene of the eph/elk receptor tyrosine kinase family.
Mech Dev. 1995 Aug;52(2-3):319-41.
PMID: 8541219 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text



h cb h g e e e fcg e ch b e

1: Oncogene. 1996 Sep 19;13(6):1343-52. Related Articles, L

# Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roo plate and hindbrain segments.

**Gale NW, Flenniken A, Compton DC, Jenkins N, Copeland NG, Gilbert D Davis S, Wilkinson DG, Yancopoulos GD.**

Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591, USA.

The Eph family of receptor tyrosine kinases has 13 distinct members and seve ligands for these receptors have been described to date. These receptors and th ligands have been implicated in regulating neuronal axon guidance and in patterning of the developing nervous system and may also serve a patterning a compartmentalization role outside of the nervous system as well. The ligands a all membrane-attached, and this attachment appears to be crucial for their norn function; five of the known ligands are linked to the membrane via a glycosyl phosphotidylinositol (GPI) linkage, while two of the ligands are transmembran proteins. Despite the large number of Eph family receptors and ligands, they c be divided into just two major subclasses based on their binding specificities. the GPI-anchored ligands bind and activate one subclass of the Eph receptors (that represented by Eck) while the two transmembrane ligands bind and activ the other major subclass of receptors (represented by Elk). Here we report the identification and characterization of the third, and most divergent, member of transmembrane group of Eph ligands, which we term Elk-L3 (Elk-related rece ligand number 3). Elk-L3 is notable for its remarkably restricted and prominen expression in the floor plate and roof plate of the developing neural tube and it rhombomere-specific expression in the developing hindbrain. The Elk-L3 gen has been localized to mouse chromosome 11 and human chromosome 17.

PMID: 8808709 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text



h cb h g e e e fcg c e e e b b e b c

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Bergemann AND 1998 Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 10 of 10 One p

1: Muller E, van Leen MW, Bergemann R. Related Articles, Li

Economic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers.
Pharmacoeconomics. 2001;19(12):1209-16.
PMID: 11772156 [PubMed - indexed for MEDLINE]

2: Horstkotte D, Bergemann R, Oelert H, Schulte HD, Laas J, Zerkowski HR. Related Articles, Li

[Increased acceptance of the International Normalized Ratio (INR) as a monitoring parameter of oral anticoagulation therapy in Germany. GELIA Stu Group]
Z Kardiol. 1998 Oct;87(10):837-43. German.
PMID: 9857460 [PubMed - indexed for MEDLINE]

3: Eggert H, Bergemann K, Saumweber H. Related Articles, Li

Molecular screening for P-element insertions in a large genomic region of Drosophila melanogaster using polymerase chain reaction mediated by the vectorette.
Genetics. 1998 Jul;149(3):1427-34.
PMID: 9649531 [PubMed - indexed for MEDLINE]

4: Horstkotte D, Piper C, Wiemer M, Arendt G, Steinmetz H, Bergemann R, Schulte HD, Schultheiss HP. Related Articles, Li

[Emergency heart valve replacement after acute cerebral embolism during flo endocarditis]
Med Klin (Munich). 1998 May 15;93(5):284-93. German.
PMID: 9630812 [PubMed - indexed for MEDLINE]

5: Bergemann AD, Zhang L, Chiang MK, Brambilla R, Klein R, Flanagan JG. Related Articles, Li

Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube.
Oncogene. 1998 Jan 29;16(4):471-80.
PMID: 9484836 [PubMed - indexed for MEDLINE]

6: NEUWEILER W, ARNOLD M, BERGEMANN E, DELNON J, RICHTER RH. Related Articles, Li

[On 2 cases of pseudohermaphroditism]
Arch Gynakol. 1963;198:400-4. German. No abstract available.
PMID: 13938188 [PubMed - OLDMEDLINE for Pre1966]

7: BERGEMANN E. Related Articles, Li

[The frequency of sex chromatin deviations from the normal and a familial investigation of triplo-X]
Helv Med Acta. 1962 Dec;29:420-2. German. No abstract available.
PMID: 13970651 [PubMed - OLDMEDLINE for Pre1966]

8: BERGEMANN E. Related Articles, Li

[When is sex diagnosis by sex chromatin determination or by chromosome culture to be used?]
Schweiz Med Wochenschr. 1962 Oct 13;92:1253-9. German. No abstract available.
PMID: 13970652 [PubMed - OLDMEDLINE for Pre1966]

**9:** BERGEMANN E. Related Articles, Li

[Familial manifestation of the triple-X karyotype. Preliminary report]
J Genet Hum. 1961 Dec;10:370-1. French. No abstract available.
PMID: 13867632 [PubMed - OLDMEDLINE for Pre1966]

**10:** HERRMANN U, BERGEMANN E, ARNOLD M. Related Articles, Li

[On the use of ethinyl-nortestosterone acetate]
Gynaecologia. 1959 Nov;148:334-40. German. No abstract available.
PMID: 14401378 [PubMed - OLDMEDLINE for Pre1966]



h cb hg e e e fcg e ch b e

1: Oncogene. 1998 Jan 29;16(4):471-80.



nature publishing group

# Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube.

**Bergemann AD, Zhang L, Chiang MK, Brambilla R, Klein R, Flanagan J**

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.

The ephrins are a family of ligands that bind to Eph family receptor tyrosine kinases, and have been implicated in axon guidance and other patterning processes during vertebrate development. We describe here the identification a characterization of murine ephrin-B3. The cDNA encodes a 340 amino acid transmembrane molecule, most closely related to the two other known transmembrane ligands, ephrin-B1 and ephrin-B2. In addition to homology in their extracellular receptor binding domains, these transmembrane ligands sha striking homology between their cytoplasmic domains, with 31 of the last 34 amino acids of ephrin-B3 being identical to ephrin-B2, suggesting functional interactions of the cytoplasmic tail. While most Eph family ligands are promiscuous in their interactions with Eph receptors, binding studies with the receptors known to bind other transmembrane ligands only revealed a high affinity interaction of ephrin-B3 with EphB3, with a dissociation constant of approximately 1 nM. In situ hybridization of mouse embryos showed ephrin-B is expressed prominently at the dorsal and ventral midline of the neural tube, particularly in the floor plate, a structure with key functions in patterning the nervous system. The isolation of this ligand may help to elucidate the molecul basis of patterning activities at the neural tube midline.

PMID: 9484836 [PubMed - indexed for MEDLINE]



h cb hg e e e fcg c e e e b b e b c

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:59:45 ON 21 OCT 2004

=> file BIOSCIENCe
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'ANABSTR' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:00:31 ON 21 OCT 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 12:00:31 ON 21 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'CAPLUS' ENTERED AT 12:00:31 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:00:31 ON 21 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
```

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DRUGB' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'FOMAD' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'HEALSAFE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'MEDLINE' ENTERED AT 12:00:31 ON 21 OCT 2004

FILE 'NIOSHTIC' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:00:31 ON 21 OCT 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 12:00:31 ON 21 OCT 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:00:31 ON 21 OCT 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:00:31 ON 21 OCT 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:00:31 ON 21 OCT 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:00:31 ON 21 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:00:31 ON 21 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 12:00:31 ON 21 OCT 2004

```
FILE 'WPIFV' ENTERED AT 12:00:31 ON 21 OCT 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s ephrin
  50 FILES SEARCHED...
L1          7200 EPHRIN

=> S L1 AND angiogenesis
  46 FILES SEARCHED...
L2          1340 L1 AND ANGIOGENESIS

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  46% COMPLETE FOR L2
PROCESSING IS APPROXIMATELY  98% COMPLETE FOR L2
PROCESSING COMPLETED FOR L2
L3           715 DUP REM L2 (625 DUPLICATES REMOVED)

=> S L3 AND ephrin-B3
  24 FILES SEARCHED...
  51 FILES SEARCHED...
L4            28 L3 AND EPHRIN-B3

=> S ephrin-B3
  61 FILES SEARCHED...
L5           301 EPHRIN-B3

=> D L4 1-28

L4   ANSWER 1 OF 28  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   2004:134279  BIOSIS
DN   PREV200400132342
TI     ***Ephrin***  -B1 promotes neovascularization and invasion in
     hepatocellular carcinoma.
AU   Sawai, Yoshiyuki [Reprint Author]; Tamura, Shinji [Reprint Author]; Fukui,
     Koji [Reprint Author]; Ito, Nobuyuki; Imanaka, Kazuho [Reprint Author];
     Saeki, Ayuko [Reprint Author]; Sakuda, Shigeru [Reprint Author]; Kiso,
     Shinichi [Reprint Author]; Matsuzawa, Yuji [Reprint Author]
CS   Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
SO   Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp. 760A-761A. print.
     Meeting Info.: 54th Annual Meeting of the American Association for the
     Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American
     Association for the Study of Liver Diseases.
     ISSN: 0270-9139 (ISSN print).
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 10 Mar 2004
     Last Updated on STN: 10 Mar 2004

L4   ANSWER 2 OF 28  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   2004:120204  BIOSIS
DN   PREV200400122589
TI   Expression of   ***ephrin***  -B1 in hepatocellular carcinoma: Possible
     involvement in neovascularization.
AU   Sawai, Yoshiyuki; Tamura, Shinji [Reprint Author]; Fukui, Koji; Ito,
     Nobuyuki; Imanaka, Kazuho; Saeki, Ayuko; Sakuda, Shigeru; Kiso, Shinichi;
     Matsuzawa, Yuji
CS   Department of Internal Medicine and Molecular Science, Graduate School of
     Medicine, Medical School, Osaka University, 2-2 Yamadaoka, Suita, Osaka,
     565-0871, Japan
     tamuras@imed2.med.osaka-u.ac.jp
SO   Journal of Hepatology, (December 2003) Vol. 39, No. 6, pp. 991-996. print.
     ISSN: 0168-8278 (ISSN print).
DT   Article
LA   English
ED   Entered STN: 3 Mar 2004
```

L4 ANSWER 3 OF 28 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:543156 BIOSIS
DN PREV200300538665
TI EPHRINA1 SIGNALING INHIBITS VEGF - INDUCED ERK1/2 PHOSPHORYLATION AND RETINAL ENDOTHELIAL CELL PROLIFERATION.
AU Ojima, T. [Reprint Author]; Takagi, H. [Reprint Author]; Suzuma, K. [Reprint Author]; Oh, H. [Reprint Author]; Suzuma, I. [Reprint Author]; Ohashi, H. [Reprint Author]; Watanabe, D. [Reprint Author]; Suganami, E. [Reprint Author]; Honda, Y. [Reprint Author]
CS Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
SO ARVO Annual Meeting Abstract Search and Program Planner, (2003) Vol. 2003, pp. Abstract No. 2881. cd-rom.
Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA. May 04-08, 2003. Association for Research in Vision and Ophthalmology.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 19 Nov 2003
Last Updated on STN: 19 Nov 2003

L4 ANSWER 4 OF 28 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:542402 BIOSIS
DN PREV200300543738
TI ***Ephrin*** B1 is expressed on human luteinizing granulosa cells in corpora lutea of the early luteal phase: The possible involvement of the B class Eph- ***ephrin*** system during corpus luteum formation.
AU Egawa, Miho; Yoshioka, Shinya; Higuchi, Toshihiro; Sato, Yukiyasu; Tatsumi, Keiji; Fujiwara, Hiroshi [Reprint Author]; Fujii, Shingo
CS Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan
fuji@kuhp.kyoto-u.ac.jp
SO Journal of Clinical Endocrinology & Metabolism, (September 2003) Vol. 88, No. 9, pp. 4384-4392. print.
ISSN: 0021-972X (ISSN print).
DT Article
LA English
ED Entered STN: 19 Nov 2003
Last Updated on STN: 19 Nov 2003

L4 ANSWER 5 OF 28 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:214449 BIOSIS
DN PREV200200214449
TI Coexpression of ***ephrin*** -Bs and their receptors in colon carcinoma.
AU Liu, Wenbiao; Ahmad, Syed A.; Jung, Young D.; Reinmuth, Niels; Fan, Fan; Bucana, Corazon D.; Ellis, Lee M. [Reprint author]
CS Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 444, Houston, TX, 77030-4009, USA
lellis@mdanderson.org
SO Cancer, (February 15, 2002) Vol. 94, No. 4, pp. 934-939. print.
CODEN: CANCAR. ISSN: 0008-543X.
DT Article
LA English
ED Entered STN: 27 Mar 2002
Last Updated on STN: 27 Mar 2002

L4 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:355085 CAPLUS
DN 140:369944
TI Human tissue-specific housekeeping genes identified by expression profiling
IN Aburatani, Hiroyuki; Yamamoto, Shogo
PA NGK Insulators, Ltd., Japan
SO PCT Int. Appl., 372 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

PI WO 2004035785 A1 20040429 WO 2002-JP10753 20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI WO 2002-JP10753 20021016
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:42302 CAPLUS
DN 138:105633
TI Tie-Fc and ***Ephrin*** -Fc fusion proteins for screening therapeutic capable of modulating growth, migration and proliferation of endothelial cells and treating cancers
IN Alitalo, Kari; Kubo, Hajime
PA Licentia Ltd., Finland
SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2003004529 | A2 | 20030116 | WO 2002-IB2524 | 20020702 |
| WO 2003004529 | A3 | 20040610 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-302960P P 20010702

L4 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:24291 CAPLUS
DN 132:178235
TI Comparative analysis of embryonic gene expression defines potential interaction sites for Xenopus EphB4 receptors with ***ephrin*** -B ligands
AU Helbling, Paul M.; Saulnier, Didier M. E.; Robinson, Vicky; Christiansen, Jeff H.; Wilkinson, David G.; Brandli, Andre W.
CS Institute of Cell Biology, Swiss Federal Institute of Technology, Zurich, CH-8093, Switz.
SO Developmental Dynamics (1999), 216(4/5), 361-373
CODEN: DEDYEI; ISSN: 1058-8388
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 28 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABU07846 Protein DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an ***Ephrin*** ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an ***Ephrin*** in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent

OS 2003-210341 [20]
CR N-PSDB: ABX12547
DESC Mouse ***ephrin*** - ***B3*** ligand.

L4 ANSWER 10 OF 28 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABU07845 Protein DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an ***Ephrin*** ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an ***Ephrin*** in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR N-PSDB: ABX12546
DESC Human ***ephrin*** - ***B3*** ligand.

L4 ANSWER 11 OF 28 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABX12547 cDNA DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an ***Ephrin*** ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an ***Ephrin*** in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR P-PSDB: ABU07846
DESC cDNA encoding mouse ***ephrin*** - ***B3*** ligand.

L4 ANSWER 12 OF 28 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABX12546 cDNA DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an ***Ephrin*** ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an ***Ephrin*** in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR P-PSDB: ABU07845
DESC cDNA encoding human ***ephrin*** - ***B3*** ligand.

L4 ANSWER 13 OF 28 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004407732 EMBASE
TI ***Ephrins*** and their receptors: Binding versus biology.
AU Blits-Huizinga C.T.; Nelersa C.M.; Malhotra A.; Liebl D.J.
CS D.J. Liebl, Miami Project to Cure Paralysis, Univ. of Miami School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, United States. dliebl@miami.edu
SO IUBMB Life, (2004) 56/5 (257-265).
Refs: 49
ISSN: 1521-6543 CODEN: IULIF8
CY United States
DT Journal; General Review
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 14 OF 28 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.

AN 2004190550 EMBASE
TI Eph- ***ephrin*** promiscuity is now crystal clear.
AU Pasquale E.B.
CS E.B. Pasquale, Burnham Institute, San Diego, CA 92037, United States. elenap@burnham.org
SO Nature Neuroscience, (2004) 7/5 (417-418).
Refs: 15
ISSN: 1097-6256 CODEN: NANEFN
CY United States
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 15 OF 28 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:164868 FEDRIP
NR CRISP 5R01CA85519-03
TI Functions of EPH Receptors and ***Ephrins*** in Neuroblastoma
SF Principal Investigator: IKEGAKI, NAOHIKO; IKEGAKI@EMAIL.CHOP.EDU, CHILDREN'S HOSPITAL OF PHILADELP, 3516 CIVIC CENTER BLVD
CSP CHILDREN'S HOSPITAL OF PHILADELPHIA, PHILADELPHIA, PENNSYLVANIA
CSS Supported By: NATIONAL CANCER INSTITUTE
DB 2007 (/01/01)
FYR 2003
DE 2006 (/30/06)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L4 ANSWER 16 OF 28 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:929677 SCISEARCH
GA The Genuine Article (R) Number: 379PM
TI Prognostic significance of EPHB6, EFNB2 and EFNB3 expressions in neuroblastoma
AU Tang X X; Zhao H Q; Robinson M E; Cnaan A; London W; Cohn S L; Cheung N K V; Brodeur G M; Evans A E; Ikegaki N (Reprint)
CS CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, ARC SUITE 902, 3516 CIVIC CTR BLVD, PHILADELPHIA, PA 19104 (Reprint); CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104; CHILDRENS HOSP PHILADELPHIA, DIV BIOSTAT & EPIDEMIOL, PHILADELPHIA, PA 19104; UNIV FLORIDA, PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL; NORTHWESTERN UNIV, DEPT PEDIAT, CHICAGO, IL 60611; CHILDRENS MEM HOSP, CHICAGO, IL; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021
CYA USA
SO MEDICAL AND PEDIATRIC ONCOLOGY, (DEC 2000) Vol. 35, No. 6, pp. 656-658. Publisher: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012.
ISSN: 0098-1532.
DT Article; Journal
FS CLIN
LA English
REC Reference Count: 21
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

L4 ANSWER 17 OF 28 USPATFULL on STN
AN 2004:233749 USPATFULL
TI Novel agents that modulate Eph receptor activity
IN Pasquale, Elena B., San Diego, CA, UNITED STATES
Koolpe, Mitchell, San Diego, CA, UNITED STATES
Murai, Keith K., Candiac, CANADA
PI US 2004180823 A1 20040916
AI US 2003-652407 A1 20030829 (10)
PRAI US 2002-413242P 20020924 (60)
DT Utility
FS APPLICATION
LN.CNT 3175
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-17
ICS: C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4  ANSWER 18 OF 28  USPATFULL on STN
AN  2004:196424  USPATFULL
TI  Lectin compositions and methods for modulating an immune response to an antigen
IN  Segal, Andrew H., Boston, MA, UNITED STATES
    Young, Elihu, Sharon, MA, UNITED STATES
PA  Genitrix, LLC (U.S. corporation)
PI  US 2004151728  A1  20040805
AI  US 2003-666834  A1  20030919 (10)
RLI  Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI  US 2002-404823P  20020820 (60)
    US 2003-487407P  20030715 (60)
DT  Utility
FS  APPLICATION
LN.CNT 39129
INCL  INCLM: 424/184.100
    INCLS: 424/199.100; 424/200.100; 530/395.000
NCL  NCLM:  424/184.100
    NCLS:  424/199.100; 424/200.100; 530/395.000
IC  [7]
    ICM: A61K039-00
    ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4  ANSWER 19 OF 28  USPATFULL on STN
AN  2004:172470  USPATFULL
TI  Compositions and methods for regulating the kinase domain of receptor tyrosine kinases
IN  Sicheri, Frank, Toronto, CANADA
    Wybenga-Groot, Leanne, Etobicoke, CANADA
    Pawson, Tony, Toronto, CANADA
PI  US 2004132634  A1  20040708
AI  US 2004-470840  A1  20040217 (10)
    WO 2002-CA114  20020131
PRAI  US 2001-60265510  20010131
DT  Utility
FS  APPLICATION
LN.CNT 7170
INCL  INCLM: 514/001.000
    INCLS: 435/194.000; 702/019.000
NCL  NCLM:  514/001.000
    NCLS:  435/194.000; 702/019.000
IC  [7]
    ICM: A61K031-00
    ICS: G06F019-00; G01N033-48; G01N033-50; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4  ANSWER 20 OF 28  USPATFULL on STN
AN  2004:165307  USPATFULL
TI  Lectin compositions and methods for modulating an immune response to an antigen
IN  Segal, Andrew H., Boston, MA, UNITED STATES
    Young, Elihu, Sharon, MA, UNITED STATES
PA  Genitrix, LLC (U.S. corporation)
PI  US 2004126793  A1  20040701
AI  US 2003-666885  A1  20030919 (10)
RLI  Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI  US 2002-404823P  20020820 (60)
    US 2003-487407P  20030715 (60)
DT  Utility
FS  APPLICATION
LN.CNT 28979
INCL  INCLM: 435/006.000
    INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
NCL  NCLM:  435/006.000
    NCLS:  435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
IC  [7]
    ICM: C12Q001-68
    ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4  ANSWER 21 OF 28  USPATFULL on STN
AN  2004:164872  USPATFULL

antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39007
INCL INCLM: 424/085.100
INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 28 USPATFULL on STN
AN 2004:101093 USPATFULL
TI Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Aziz, Natasha, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA, UNITED STATES, 94080-7019 (U.S. corporation)
PI US 2004076955 A1 20040422
AI US 2002-188832 A1 20020702 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-343705P 20011108 (60)
US 2001-310099P 20010803 (60)
US 2001-302814P 20010703 (60)
DT Utility
FS APPLICATION
LN.CNT 27357
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 28 USPATFULL on STN
AN 2004:2047 USPATFULL
TI Breast cancer progression signatures
IN Erlander, Mark G., Encinitas, CA, UNITED STATES
Ma, Xia-Jun, San Diego, CA, UNITED STATES
Sgroi, Dennis C., Winchester, MA, UNITED STATES
PI US 2004002067 A1 20040101
AI US 2001-28018 A1 20011221 (10)
DT Utility
FS APPLICATION
LN.CNT 5596
INCL INCLM: 435/006.000
INCLS: 435/287.200; 702/020.000
NCL NCLM: 435/006.000
NCLS: 435/287.200; 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 28 USPATFULL on STN
AN 2003:220740 USPATFULL
TI Methods and compositions for diagnosing and treating rheumatoid arthritis
IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES

PI US 2003154032 A1 20030814
AI US 2001-23451 A1 20011217 (10)
PRAI US 2000-255861P 20001215 (60)
DT Utility
FS APPLICATION
LN.CNT 25385
INCL INCLM: 702/020.000
NCL NCLM: 702/020.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 28 USPATFULL on STN
AN 2003:120026 USPATFULL
TI Identification of modulatory molecules using inducible promoters
IN Brown, Steven J., San Diego, CA, UNITED STATES
Dunnington, Damien J., San Diego, CA, UNITED STATES
Clark, Imran, San Diego, CA, UNITED STATES
PI US 2003082511 A1 20030501
AI US 2001-965201 A1 20010925 (9)
DT Utility
FS APPLICATION
LN.CNT 5526
INCL INCLM: 435/004.000
INCLS: 435/006.000
NCL NCLM: 435/004.000
NCLS: 435/006.000
IC [7]
ICM: C12Q001-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 28 USPATFULL on STN
AN 2003:30255 USPATFULL
TI B- ***ephrin*** regulation of G-protein coupled chemoattraction, compositions, and methods of use
IN Flanagan, John G., Newton, MA, UNITED STATES
Lu, Qiang, Brookline, MA, UNITED STATES
Sun, Edna E., Brookline, MA, UNITED STATES
PI US 2003022202 A1 20030130
AI US 2002-113794 A1 20020401 (10)
PRAI US 2001-280260P 20010330 (60)
DT Utility
FS APPLICATION
LN.CNT 1905
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/254.200; 435/368.000; 435/196.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/254.200; 435/368.000; 435/196.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N001-18; C12N009-16; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 28 USPATFULL on STN
AN 2002:266423 USPATFULL
TI Peptides that modulate the interaction of B class ***ephrins*** and PDZ domains
IN Lin, Danny, Scarborough, CANADA
Pawson, Anthony, Toronto, CANADA
Gish, Gerald, East York, CANADA
PI US 2002147306 A1 20021010
AI US 2001-862179 A1 20010521 (9)
PRAI WO 1999-CA1101 19991119
US 1998-109158P 19981120 (60)
DT Utility
FS APPLICATION
LN.CNT 2332
INCL INCLM: 530/350.000
INCLS: 530/324.000
NCL NCLM: 530/350.000
NCLS: 530/324.000

```
       ICM: C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 28 OF 28  USPATFULL on STN
AN     2002:99407  USPATFULL
TI     Nucleic acids, proteins and antibodies
IN     Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Ruben, Steven M., Olney, MD, UNITED STATES
PI     US 2002052308      A1   20020502
AI     US 2001-925301     A1   20010810 (9)
RLI    Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN
PRAI   US 1999-124270P     19990312 (60)
DT     Utility
FS     APPLICATION
LN.CNT 30577
INCL   INCLM: 514/001.000
       INCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
              530/350.000; 435/320.100; 435/325.000
NCL    NCLM:  514/001.000
       NCLS:  435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100;
              530/350.000; 435/320.100; 435/325.000
IC     [7]
       ICM: A61K031-00
       ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435;
       C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> S ephrin-B3 OR ephrinB3
  51 FILES SEARCHED...
L6          335 EPHRIN-B3 OR EPHRINB3

=> DUP REM L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7           159 DUP REM L6 (176 DUPLICATES REMOVED)

=> D L7 1-159

L7   ANSWER 1 OF 159  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:355085  CAPLUS
DN   140:369944
TI   Human tissue-specific housekeeping genes identified by expression
     profiling
IN   Aburatani, Hiroyuki; Yamamoto, Shogo
PA   NGK Insulators, Ltd., Japan
SO   PCT Int. Appl., 372 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.           KIND   DATE         APPLICATION NO.          DATE
     ---------------      ----   --------     -------------------      --------
PI   WO 2004035785         A1    20040429     WO 2002-JP10753          20021016
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
PRAI WO 2002-JP10753          20021016
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7   ANSWER 2 OF 159  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:204003  CAPLUS
DN   140:248255
TI   Synovial sarcoma up-regulated gene FZD10 (Frizzled homolog 10) and other
```

IN Nakamurā, Yusuke; Katāgiri, Toyomasa
PA Oncotherapy Science, Inc., Japan; Japan as Represented by President of the University of Tokyo
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004020668 | A2 | 20040311 | WO 2003-JP10591 | 20030821 |
| WO 2004020668 | A3 | 20040617 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | |
|---|---|---|---|
| PRAI US 2002-407506P | P | 20020830 | |
| US 2003-486195P | P | 20030711 | |

L7 ANSWER 3 OF 159 USPATFULL on STN
AN 2004:233749 USPATFULL
TI Novel agents that modulate Eph receptor activity
IN Pasquale, Elena B., San Diego, CA, UNITED STATES
Koolpe, Mitchell, San Diego, CA, UNITED STATES
Murai, Keith K., Candiac, CANADA
PI US 2004180823 A1 20040916
AI US 2003-652407 A1 20030829 (10)
PRAI US 2002-413242P 20020924 (60)
DT Utility
FS APPLICATION
LN.CNT 3175
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-17
ICS: C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 159 USPATFULL on STN
AN 2004:233299 USPATFULL
TI Genetic diagnosis of alcoholism subtypes
IN Tabakoff, Boris, Denver, CO, UNITED STATES
Martinez, Larry, Colorado Springs, CO, UNITED STATES
Hoffman, Paula, Denver, CO, UNITED STATES
PA THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate, Boulder, CA (U.S. corporation)
PI US 2004180370 A1 20040916
AI US 2004-766590 A1 20040127 (10)
PRAI US 2003-443072P 20030127 (60)
DT Utility
FS APPLICATION
LN.CNT 3517
INCL INCLM: 435/006.000
INCLS: 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 159 USPATFULL on STN
AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES

PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39129
INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000
NCL NCLM: 424/184.100
NCLS: 424/199.100; 424/200.100; 530/395.000
IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 159 USPATFULL on STN
AN 2004:177819 USPATFULL
TI Methods for inhibiting angiogenesis by EphB receptor antagonists
IN Aguet, Michel, Lutry, SWITZERLAND
PI US 2004136983 A1 20040715
AI US 2004-770543 A1 20040202 (10)
RLI Division of Ser. No. US 1999-442898, filed on 18 Nov 1999, ABANDONED
PRAI US 1998-109275P 19981120 (60)
DT Utility
FS APPLICATION
LN.CNT 1952
INCL INCLM: 424/143.100
NCL NCLM: 424/143.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 159 USPATFULL on STN
AN 2004:172470 USPATFULL
TI Compositions and methods for regulating the kinase domain of receptor tyrosine kinases
IN Sicheri, Frank, Toronto, CANADA
Wybenga-Groot, Leanne, Etobicoke, CANADA
Pawson, Tony, Toronto, CANADA
PI US 2004132634 A1 20040708
AI US 2004-470840 A1 20040217 (10)
WO 2002-CA114 20020131
PRAI US 2001-60265510 20010131
DT Utility
FS APPLICATION
LN.CNT 7170
INCL INCLM: 514/001.000
INCLS: 435/194.000; 702/019.000
NCL NCLM: 514/001.000
NCLS: 435/194.000; 702/019.000
IC [7]
ICM: A61K031-00
ICS: G06F019-00; G01N033-48; G01N033-50; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 159 USPATFULL on STN
AN 2004:165307 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126793 A1 20040701
AI US 2003-666885 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 28979
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;

NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000; 530/395.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 159 USPATFULL on STN
AN 2004:164872 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 39007
INCL INCLM: 424/085.100
INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 159 USPATFULL on STN
AN 2004:133338 USPATFULL
TI Targets for therapeutic intervention identified in the mitochondrial proteome
IN Ghosh, Soumitra S., San Diego, CA, UNITED STATES
Fahy, Eoin D., San Diego, CA, UNITED STATES
Zhang, Bing, Spring, TX, UNITED STATES
Gibson, Bradford W., Berkeley, CA, UNITED STATES
Taylor, Steven W., San Diego, CA, UNITED STATES
Glenn, Gary M., Encinitas, CA, UNITED STATES
Warnock, Dale E., San Diego, CA, UNITED STATES
Gaucher, Sara P., Castro Valley, CA, UNITED STATES
PA MitoKor Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
The Buck Institute for Age Research, Novato, CA, UNITED STATES, 94948-0638 (U.S. corporation)
PI US 2004101874 A1 20040527
AI US 2003-408765 A1 20030404 (10)
PRAI US 2002-412418P 20020920 (60)
US 2002-389987P 20020617 (60)
US 2002-372843P 20020412 (60)
DT Utility
FS APPLICATION
LN.CNT 5998
INCL INCLM: 435/006.000
INCLS: 435/317.100
NCL NCLM: 435/006.000
NCLS: 435/317.100
IC [7]
ICM: C12Q001-68
ICS: C12N001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 159 USPATFULL on STN
AN 2004:101093 USPATFULL
TI Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Aziz, Natasha, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA, UNITED STATES, 94080-7019 (U.S. corporation)
PI US 2004076955 A1 20040422
AI US 2002-188832 A1 20020702 (10)
PRAI US 2002-372246P 20020412 (60)

US 2001-343705P 20011108 (60)
US 2001-310099P 20010803 (60)
US 2001-302814P 20010703 (60)
DT Utility
FS APPLICATION
LN.CNT 27357
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 159 USPATFULL on STN
AN 2004:76614 USPATFULL
TI Use of novel stem cell markers for isolation of intestinal stem cells, and use of the intestinal stem cells thus obtained for the preparation of a therapeutical composition
IN Clevers, Johannes Carolus, Huis Ter Heide, NETHERLANDS
Gomez, Eduard Batlle, Utrecht, NETHERLANDS
Van De Wetering, Marcus Lambertus, Houten, NETHERLANDS
Suils, Elena Sancho, Utrecht, NETHERLANDS
PA Kylix B.V., Driebergen, NETHERLANDS, NL-3971 JD (non-U.S. corporation)
PI US 2004058392 A1 20040325
AI US 2002-246786 A1 20020917 (10)
PRAI EP 2002-78917 20020917
DT Utility
FS APPLICATION
LN.CNT 646
INCL INCLM: 435/007.200
INCLS: 435/366.000
NCL NCLM: 435/007.200
NCLS: 435/366.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 159 USPATFULL on STN
AN 2004:2047 USPATFULL
TI Breast cancer progression signatures
IN Erlander, Mark G., Encinitas, CA, UNITED STATES
Ma, Xia-Jun, San Diego, CA, UNITED STATES
Sgroi, Dennis C., Winchester, MA, UNITED STATES
PI US 2004002067 A1 20040101
AI US 2001-28018 A1 20011221 (10)
DT Utility
FS APPLICATION
LN.CNT 5596
INCL INCLM: 435/006.000
INCLS: 435/287.200; 702/020.000
NCL NCLM: 435/006.000
NCLS: 435/287.200; 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 159 USPATFULL on STN
AN 2004:103677 USPATFULL
TI Single nucleotide polymorphisms in genes
IN Lander, Eric S., Cambridge, MA, United States
Cargill, Michele, Gaithersburg, MD, United States
Ireland, James S., Gaithersburg, MD, United States
Bolk, Stacey, West Roxbury, MA, United States
Daley, George Q., Weston, MA, United States
McCarthy, Jeanette J., San Diego, CA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Whitehead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)
PI US 6727063 B1 20040427
AI US 2000-657472 20000907 (9)

US 2000-225724P 20000816 (60)
US 1999-153357P 19990910 (60)
DT Utility
FS GRANTED
LN.CNT 14015
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34
EXF 435/6; 435/91.1; 435/91.2; 536/23.1; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004382596 EMBASE
TI Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.
AU Tang X.X.; Robinson M.E.; Riceberg J.S.; Kim D.Y.; Kung B.; Titus T.B.; Hayashi S.; Flake A.W.; Carpentieri D.; Ikegaki N.
CS N. Ikegaki, Division of Hematology/Oncology, Department of Pediatrics, Emory University School of Medicine, 2040 Ridgewood Drive NE, Atlanta, GA 30322, United States. nao_ikegaki@oz.ped.emory.edu
SO Clinical Cancer Research, (1 Sep 2004) 10/17 (5837-5844).
Refs: 16
ISSN: 1078-0432 CODEN: CCREF4
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
016 Cancer
037 Drug Literature Index
LA English
SL English

L7 ANSWER 16 OF 159 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:521594 SCISEARCH
GA The Genuine Article (R) Number: 823ZZ
TI Rescuing transient corticospinal terminations and promoting growth with corticospinal stimulation in kittens
AU Salimi I; Martin J H (Reprint)
CS Columbia Univ, Ctr Neurobiol & Behav, New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA (Reprint); Columbia Univ, Ctr Neurobiol & Behav, New York State Psychiat Inst, New York, NY 10032 USA
CYA USA
SO JOURNAL OF NEUROSCIENCE, (26 MAY 2004) Vol. 24, No. 21, pp. 4952-4961. Publisher: SOC NEUROSCIENCE, 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA.
ISSN: 0270-6474.
DT Article; Journal
LA English
REC Reference Count: 40
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

L7 ANSWER 17 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004413235 EMBASE
TI Identification of tissue-restricted transcripts in human islets.
AU Maffei A.; Liu Z.; Witkowski P.; Moschella F.; Del Pozzo G.; Liu E.; Herold K.; Winchester R.J.; Hardy M.A.; Harris P.E.
CS Dr. P.E. Harris, Department of Medicine BB 20-06, Columbia University, College of Physicians and Surgeons, 650 West 168th Street, New York, NY 10032, Italy. peh1@columbia.edu
SO Endocrinology, (2004) 145/10 (4513-4521).
Refs: 64
ISSN: 0013-7227 CODEN: ENDOAO
CY United States
DT Journal; Article
FS 003 Endocrinology
022 Human Genetics
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 18 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 1
AN 2004:192651 BIOSIS
DN PREV200400180545
TI Abnormal hippocampal axon bundling in EphB receptor mutant mice.
AU Chen, Zhi-Yong; Sun, Chunhua; Reuhl, Kenneth; Bergemann, Andrew; Henkemeyer, Mark; Zhou, Renping [Reprint Author]
CS Department of Chemical Biology, College of Pharmacy, Rutgers University, Piscataway, NJ, 08854, USA
rzhou@rci.rutgers.edu
SO Journal of Neuroscience, (March 10 2004) Vol. 24, No. 10, pp. 2366-2374. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 7 Apr 2004
Last Updated on STN: 7 Apr 2004

L7 ANSWER 19 OF 159 MEDLINE on STN
AN 2004233594 MEDLINE
DN PubMed ID: 15124102
TI Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome.
AU Wieland Ilse; Jakubiczka Sibylle; Muschke Petra; Cohen Monika; Thiele Hannelore; Gerlach Klaus L; Adams Ralf H; Wieacker Peter
CS Institut fur Humangenetik, Otto-von-Guericke-Universitat Magdeburg, 39120 Magdeburg, Germany.
SO American journal of human genetics, (2004 Jun) 74 (6) 1209-15.
Journal code: 0370475. ISSN: 0002-9297.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-XM038809
EM 200407
ED Entered STN: 20040511
Last Updated on STN: 20040707
Entered Medline: 20040706

L7 ANSWER 20 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:316085 BIOSIS
DN PREV200400316690
TI Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application.
AU Fox, Brian P.; Kandpal, Raj P. [Reprint Author]
CS Dept Biol Sci, Fordham Univ, Bronx, NY, 10458, USA
kandpal@fordham.edu
SO Biochemical and Biophysical Research Communications, (June 11 2004) Vol. 318, No. 4, pp. 882-892. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 15 Jul 2004
Last Updated on STN: 15 Jul 2004

L7 ANSWER 21 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004385354 EMBASE
TI Ephrin signaling in axon guidance.
AU Huot J.
CS Canada. Jacques.Huot@phc.ulaval.ca
SO Progress in Neuro-Psychopharmacology and Biological Psychiatry, (2004) 28/5 (813-818).
Refs: 24
ISSN: 0278-5846 CODEN: PNPPD7
PUI S 0278-5846(04)00082-X
CY United States
DT Journal; General Review
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 22 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN

DN 140:301431
TI Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers
AU Hafner, Christian; Schmitz, Gerd; Meyer, Stefanie; Bataille, Frauke; Hau, Peter; Langmann, Thomas; Dietmaier, Wolfgang; Landthaler, Michael; Vogt, Thomas
CS Department of Dermatology, University of Regensburg, Regensburg, Germany
SO Clinical Chemistry (Washington, DC, United States) (2004), 50(3), 490-499 CODEN: CLCHAU; ISSN: 0009-9147
PB American Association for Clinical Chemistry
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004190550 EMBASE
TI Eph-ephrin promiscuity is now crystal clear.
AU Pasquale E.B.
CS E.B. Pasquale, Burnham Institute, San Diego, CA 92037, United States. elenap@burnham.org
SO Nature Neuroscience, (2004) 7/5 (417-418).
Refs: 15
ISSN: 1097-6256 CODEN: NANEFN
CY United States
DT Journal; (Short Survey)
FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 24 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004407732 EMBASE
TI Ephrins and their receptors: Binding versus biology.
AU Blits-Huizinga C.T.; Nelersa C.M.; Malhotra A.; Liebl D.J.
CS D.J. Liebl, Miami Project to Cure Paralysis, Univ. of Miami School of Medicine, 1095 NW 14th Terrace, Miami, FL 33136, United States. dliebl@miami.edu
SO IUBMB Life, (2004) 56/5 (257-265).
Refs: 49
ISSN: 1521-6543 CODEN: IULIF8
CY United States
DT Journal; General Review
FS 008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 25 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 2
AN 2004:321300 BIOSIS
DN PREV200400319321
TI Intramembrane cleavage of ***ephrinB3*** by the human rhomboid family protease, RHBDL2.
AU Pascall, John C.; Brown, Kenneth D. [Reprint Author]
CS Signalling Programme, Babraham Inst, Babraham Hall, Cambridge, CB2 4AT, England ken.brown@bbsrc.ac.uk
SO Biochemical and Biophysical Research Communications, (April 23 2004) Vol. 317, No. 1, pp. 244-252. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 21 Jul 2004
Last Updated on STN: 21 Jul 2004

L7 ANSWER 26 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2004065640 EMBASE
TI Ganglion cell axon pathfinding in the retina and optic nerve.
AU Oster S.F.; Deiner M.; Birgbauer E.; Sretavan D.W.
CS D.W. Sretavan, Depts. of Ophthalmol. and Physiology, Programs Neurosci.

Francisco, CA 94143, United States. dws@itsa.ucsf.edu
SO Seminars in Cell and Developmental Biology, (2004) 15/1 (125-136).
Refs: 82
ISSN: 1084-9521 CODEN: SCDBFX
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
012 Ophthalmology
021 Developmental Biology and Teratology
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 27 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2003509599 EMBASE
TI EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.
AU Sturz A.; Bader B.; Thierauch K.-H.; Glienke J.
CS J. Glienke, Research Laboratories of Schering AG, Berlin, Germany. jens.glienke@schering.de
SO Biochemical and Biophysical Research Communications, (2 Jan 2004) 313/1 (80-88).
Refs: 21
ISSN: 0006-291X CODEN: BBRCA
CY United States
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 28 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
AN 2003:1012729 CAPLUS
DN 140:196856
TI Hippocampal plasticity requires postsynaptic ephrinBs
AU Grunwald, Ilona C.; Korte, Martin; Adelmann, Giselind; Plueck, Anne; Kullander, Klas; Adams, Ralf H.; Frotscher, Michael; Bonhoeffer, Tobias; Klein, Ruediger
CS Department of Molecular Neurobiology, Max-Planck Institute of Neurobiology, Munich-Martinsried, 82152, Germany
SO Nature Neuroscience (2004), 7(1), 33-40
CODEN: NANEFN; ISSN: 1097-6256
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 29 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:292476 BIOSIS
DN PREV200400291958
TI Genes that Influence Acute Ethanol Tolerance.
AU Hudson, Holly R [Reprint Author]; Bhave, Sanjiv V; Tabakoff, Boris; Hoffman, Paula L
CS Pharmacology, University of Colorado Health Sciences Center, 4200 E. Ninth Ave., Box C-236, Denver, CO, 80262, USA holly.hudson@uchsc.edu
SO FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 161.12. http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB.
ISSN: 0892-6638 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 23 Jun 2004
Last Updated on STN: 23 Jun 2004

L7 ANSWER 30 OF 159 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2004:48564 DISSABS Order Number: AAI3118187
TI Ephrins and Eph receptors participate in spinal cord development and injury responses in the adult
AU Bundesen, Liza Q. [Ph.D.]; Kromer, Lawrence F. [advisor]; Bregman, Barbara

CS Georgetown University Medical Center (0544)
SO Dissertation Abstracts International, (2003) Vol. 64, No. 12B, p. 5947. Order No.: AAI3118187. 296 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 20040902
Last Updated on STN: 20040902

L7 ANSWER 31 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
AN 2003:42302 CAPLUS
DN 138:105633
TI Tie-Fc and Ephrin-Fc fusion proteins for screening therapeutic capable of modulating growth, migration and proliferation of endothelial cells and treating cancers
IN Alitalo, Kari; Kubo, Hajime
PA Licentia Ltd., Finland
SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2003004529 | A2 | 20030116 | WO 2002-IB2524 | 20020702 |
| WO 2003004529 | A3 | 20040610 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-302960P P 20010702

L7 ANSWER 32 OF 159 USPATFULL on STN
AN 2003:250468 USPATFULL
TI Compositions and methods for diagnosing and treating mental disorders
IN Akil, Huda, Ann Arbor, MI, UNITED STATES
Bunney, William E., Laguna Beach, CA, UNITED STATES
Burke, Sharon, Ann Arbor, MI, UNITED STATES
Choudary, Prabhakara V., Davis, CA, UNITED STATES
Cox, David R., Belmont, CA, UNITED STATES
Evans, Simon, Milan, MI, UNITED STATES
Jones, Edward G., Winters, CA, UNITED STATES
Li, Jun, Palo Alto, CA, UNITED STATES
Lopez, Juan F., Ann Arbor, MI, UNITED STATES
Myers, Richard M., Stanford, CA, UNITED STATES
Thompson, Robert, Ann Arbor, MI, UNITED STATES
Vawter, Marquis P., Laguna Niguel, CA, UNITED STATES
Watson, Stanley J., Ann Arbor, MI, UNITED STATES
PI US 2003175253 A1 20030918
AI US 2002-293582 A1 20021112 (10)
PRAI US 2001-339252P 20011109 (60)
DT Utility
FS APPLICATION
LN.CNT 5118
INCL INCLM: 424/093.210
INCLS: 435/006.000
NCL NCLM: 424/093.210
NCLS: 435/006.000
IC [7]
ICM: C12Q001-68
ICS: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 33 OF 159 USPATFULL on STN
AN 2003:225900 USPATFULL
TI Methods for determining cell responses through EphB receptors
IN Daniel, Thomas O., Nashville, TN, UNITED STATES
Stein, Elke, San Francisco, CA, UNITED STATES

AI US 2003-420029 A1 20030417 (10)
RLI Division of Ser. No. US 2000-485653, filed on 14 Feb 2000, GRANTED, Pat. No. US 6555321 A 371 of International Ser. No. WO 1998-US17157, filed on 19 Aug 1998, PENDING
PRAI US 1997-56164P 19970819 (60)
DT Utility
FS APPLICATION
LN.CNT 2651
INCL INCLM: 435/366.000
INCLS: 435/368.000
NCL NCLM: 435/366.000
NCLS: 435/368.000
IC [7]
ICM: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 34 OF 159 USPATFULL on STN
AN 2003:220740 USPATFULL
TI Methods and compositions for diagnosing and treating rheumatoid arthritis
IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES
PI US 2003154032 A1 20030814
AI US 2001-23451 A1 20011217 (10)
PRAI US 2000-255861P 20001215 (60)
DT Utility
FS APPLICATION
LN.CNT 25385
INCL INCLM: 702/020.000
NCL NCLM: 702/020.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 35 OF 159 USPATFULL on STN
AN 2003:120026 USPATFULL
TI Identification of modulatory molecules using inducible promoters
IN Brown, Steven J., San Diego, CA, UNITED STATES
Dunnington, Damien J., San Diego, CA, UNITED STATES
Clark, Imran, San Diego, CA, UNITED STATES
PI US 2003082511 A1 20030501
AI US 2001-965201 A1 20010925 (9)
DT Utility
FS APPLICATION
LN.CNT 5526
INCL INCLM: 435/004.000
INCLS: 435/006.000
NCL NCLM: 435/004.000
NCLS: 435/006.000
IC [7]
ICM: C12Q001-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 36 OF 159 USPATFULL on STN
AN 2003:30255 USPATFULL
TI B-ephrin regulation of G-protein coupled chemoattraction, compositions, and methods of use
IN Flanagan, John G., Newton, MA, UNITED STATES
Lu, Qiang, Brookline, MA, UNITED STATES
Sun, Edna E., Brookline, MA, UNITED STATES
PI US 2003022202 A1 20030130
AI US 2002-113794 A1 20020401 (10)
PRAI US 2001-280260P 20010330 (60)
DT Utility
FS APPLICATION
LN.CNT 1905
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/254.200; 435/368.000; 435/196.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/254.200; 435/368.000; 435/196.000;

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N001-18; C12N009-16; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 37 OF 159 USPATFULL on STN
AN 2003:115716 USPATFULL
TI Methods for determining cell responses through EphB receptors
IN Daniel, Thomas O., Nashville, TN, United States
Stein, Elke, San Francisco, CA, United States
PA Vanderbilt University, Nashville, TN, United States (U.S. corporation)
PI US 6555321 B1 20030429
WO 9908696 19990225
AI US 2000-485653 20000214 (9)
WO 1998-US17157 19980819
PRAI US 1997-56164P 19970819 (60)
DT Utility
FS GRANTED
LN.CNT 2362
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/007.210; 435/007.800; 435/334.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.210; 435/007.800; 435/334.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N005-06
EXF 435/7.1; 435/7.21; 435/7.8; 435/7.2; 435/334
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 38 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 5
AN 2004:64011 BIOSIS
DN PREV200400065498
TI Mouse ***ephrinB3*** augments T-cell signaling and responses to T-cell receptor ligation.
AU Yu, Guang; Luo, Hongyu; Wu, Yulian; Wu, Jiangping [Reprint Author]
CS Laboratory of Immunology, Research Centre, Notre Dame Hospital, CHUM, 1560 Sherbrooke St. East, Pavilion DeSeve, Room Y-5616, Montreal, PQ, H2L 4M1, Canada
jianping.wu@umontreal.ca
SO Journal of Biological Chemistry, (November 21 2003) Vol. 278, No. 47, pp. 47209-47216. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 28 Jan 2004
Last Updated on STN: 28 Jan 2004

L7 ANSWER 39 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 6
AN 2003:314321 BIOSIS
DN PREV200300314321
TI Selective breeding, quantitative trait locus analysis, and gene arrays identify candidate genes for complex drug-related behaviors.
AU Tabakoff, Boris [Reprint Author]; Bhave, Sanjiv V.; Hoffman, Paula L.
CS Department of Pharmacology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C-236, Denver, CO, 80262, USA
boris.tabakoff@uchsc.edu
SO Journal of Neuroscience, (June 1 2003) Vol. 23, No. 11, pp. 4491-4498. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 9 Jul 2003
Last Updated on STN: 9 Jul 2003

L7 ANSWER 40 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 7
AN 2004:30990 BIOSIS
DN PREV200400023575
TI Human dendritic cells express neuronal Eph receptor tyrosine kinases: Role of EphA2 in regulating adhesion to fibronectin.
AU de Saint-Vis, Blandine [Reprint Author]; Bouchet, Caroline; Gautier, Gregory; Valladeau, Jenny; Caux, Christophe; Garrone, Pierre
CS Laboratory for Immunological Research, Schering-Plough, 27 Chemin des

blandine.de.saint.vis@spcorp.com
SO Blood, (December 15 2003) Vol. 102, No. 13, pp. 4431-4440. print.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Article
LA English
ED Entered STN: 31 Dec 2003
Last Updated on STN: 31 Dec 2003

L7 ANSWER 41 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 8
AN 2003:542402 BIOSIS
DN PREV200300543738
TI Ephrin B1 is expressed on human luteinizing granulosa cells in corpora lutea of the early luteal phase: The possible involvement of the B class Eph-ephrin system during corpus luteum formation.
AU Egawa, Miho; Yoshioka, Shinya; Higuchi, Toshihiro; Sato, Yukiyasu; Tatsumi, Keiji; Fujiwara, Hiroshi [Reprint Author]; Fujii, Shingo
CS Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8507, Japan
fuji@kuhp.kyoto-u.ac.jp
SO Journal of Clinical Endocrinology & Metabolism, (September 2003) Vol. 88, No. 9, pp. 4384-4392. print.
ISSN: 0021-972X (ISSN print).
DT Article
LA English
ED Entered STN: 19 Nov 2003
Last Updated on STN: 19 Nov 2003

L7 ANSWER 42 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 9
AN 2003:185723 BIOSIS
DN PREV200300185723
TI Role of EphA4 and ***ephrinB3*** in local neuronal circuits that control walking.
AU Kullander, Klas [Reprint Author]; Butt, Simon J. B.; Lebret, James M.; Lundfald, Line; Restrepo, Carlos E.; Rydstrom, Anna; Klein, Ruediger; Kiehn, Ole
CS Department of Medical Biochemistry, Gothenburg University, Medicinaregatan 9 A, 405 30, Gothenburg, Sweden
klas.kullander@medkem.gu.se; ole.kiehn@neuro.ki.se
SO Science (Washington D C), (21 March 2003) Vol. 299, No. 5614, pp. 1889-1892. print.
ISSN: 0036-8075 (ISSN print).
DT Article
LA English
ED Entered STN: 16 Apr 2003
Last Updated on STN: 16 Apr 2003

L7 ANSWER 43 OF 159 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2003:37215108 BIOTECHNO
TI Analysis of EphB receptors and their ligands in the developing retinocollicular system of the wallaby reveals dynamic patterns of expression in the retina
AU Vidovic M.; Marotte L.R.
CS Dr. L.R. Marotte, Developmental Biology Group, Res. School of Biological Sciences, Australian National University, Canberra, ACT 0200, Australia. E-mail: marotte@rsbs.anu.edu.au
SO European Journal of Neuroscience, (2003), 18/6 (1549-1558), 54 reference(s)
CODEN: EJONEI ISSN: 0953-816X
DT Journal; Article
CY United Kingdom
LA English
SL English

L7 ANSWER 44 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:60539 BIOSIS
DN PREV200400048109
TI Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus.
AU Henkemeyer, Mark; Itkis, Olga S.; Ngo, Michelle; Hickmott, Peter W.; Ethell, Iryna M. [Reprint Author]
CS Division of Biomedical Sciences, University of California Riverside,

iryna.ethell@ucr.edu
SO Journal of Cell Biology, (December 22 2003) Vol. 163, No. 6, pp. 1313-1326. print.
CODEN: JCLBA3. ISSN: 0021-9525.
DT Article
LA English
ED Entered STN: 21 Jan 2004
Last Updated on STN: 21 Jan 2004

L7 ANSWER 45 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 11
AN 2004:120204 BIOSIS
DN PREV200400122589
TI Expression of ephrin-B1 in hepatocellular carcinoma: Possible involvement in neovascularization.
AU Sawai, Yoshiyuki; Tamura, Shinji [Reprint Author]; Fukui, Koji; Ito, Nobuyuki; Imanaka, Kazuho; Saeki, Ayuko; Sakuda, Shigeru; Kiso, Shinichi; Matsuzawa, Yuji
CS Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Medical School, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
tamuras@imed2.med.osaka-u.ac.jp
SO Journal of Hepatology, (December 2003) Vol. 39, No. 6, pp. 991-996. print.
ISSN: 0168-8278 (ISSN print).
DT Article
LA English
ED Entered STN: 3 Mar 2004
Last Updated on STN: 3 Mar 2004

L7 ANSWER 46 OF 159 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:809695 SCISEARCH
GA The Genuine Article (R) Number: 721BA
TI Generating X: Formation of the optic chiasm
AU Rasband K; Hardy M; Chien C B (Reprint)
CS Univ Utah, Med Ctr, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA (Reprint)
CYA USA
SO NEURON, (11 SEP 2003) Vol. 39, No. 6, pp. 885-888.
Publisher: CELL PRESS, 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA.
ISSN: 0896-6273.
DT General Review; Journal
LA English
REC Reference Count: 20
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*

L7 ANSWER 47 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:134279 BIOSIS
DN PREV200400132342
TI Ephrin-B1 promotes neovascularization and invasion in hepatocellular carcinoma.
AU Sawai, Yoshiyuki [Reprint Author]; Tamura, Shinji [Reprint Author]; Fukui, Koji [Reprint Author]; Ito, Nobuyuki; Imanaka, Kazuho [Reprint Author]; Saeki, Ayuko [Reprint Author]; Sakuda, Shigeru [Reprint Author]; Kiso, Shinichi [Reprint Author]; Matsuzawa, Yuji [Reprint Author]
CS Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
SO Hepatology, (October 2003) Vol. 38, No. 4 Suppl. 1, pp. 760A-761A. print.
Meeting Info.: 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA. October 24-28, 2003. American Association for the Study of Liver Diseases.
ISSN: 0270-9139 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 10 Mar 2004
Last Updated on STN: 10 Mar 2004

L7 ANSWER 48 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 12
AN 2003:710074 CAPLUS
DN 140:334464
TI Characterization of the kinase domain of the ***ephrin*** - ***B3*** receptor tyrosine kinase using a scintillation proximity assay
AU Bembenek, Michael E.; Schmidt, Stephen; Li, Ping; Morawiak, Jennifer; Prack, Andrea; Jain, Sadhana; Roy, Rebecca; Parsons, Thomas; Chee, Linda

SO Assay and Drug Development Technologies (2003), 1(4), 555-563
CODEN: ADDTAR; ISSN: 1540-658X
PB Mary Ann Liebert, Inc.
DT Journal
LA English
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 13
AN 2003:227583 BIOSIS
DN PREV200300227583
TI Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: Regulation of cell adhesion, apoptosis, and tumor suppression-related genes.
AU Sanchez-Carbayo, Marta [Reprint Author]; Belbin, Thomas J.; Scotlandi, Katia; Prystowsky, Michael; Baldini, Nicola; Childs, Geoffrey; Cordon-Cardo, Carlos
CS Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA
cordon-c@mskcc.org
SO Laboratory Investigation, (April 2003) Vol. 83, No. 4, pp. 507-517. print.
CODEN: LAINAW. ISSN: 0023-6837.
DT Article
LA English
ED Entered STN: 14 May 2003
Last Updated on STN: 30 Jun 2003

L7 ANSWER 50 OF 159 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN DUPLICATE
AN 2003:37101136 BIOTECHNO
TI Physiological, anatomical and genetic identification of CPG neurons in the developing mammalian spinal cord
AU Kiehn O.; Butt S.J.B.
CS O. Kiehn, Mammalian Locomotor Laboratory, Department of Neuroscience, Karolinska Institutet, Retzius vag 8, 171 77 Stockholm, Sweden.
E-mail: ole.kiehn@neuro.ki.se
SO Progress in Neurobiology, (2003), 70/4 (347-361), 164 reference(s)
CODEN: PGNBA5 ISSN: 0301-0082
DT Journal; General Review
CY United Kingdom
LA English
SL English

L7 ANSWER 51 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:1002152 CAPLUS
DN 141:81777
TI The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines
AU Farivar, Robert Saeid; Gardner-Thorpe, James; Ito, Hiromichi; Arshad, Hassan; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.
CS Department of Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
SO Journal of Surgical Research (2003), 115(2), 219-225
CODEN: JSGRA2; ISSN: 0022-4804
PB Elsevier Science
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 52 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN DUPLICATE 15
AN 2003184749 EMBASE
TI [Development and maturation of the pyramidal tract].
DEVELOPPEMENT ET MATURATION DU FAISCEAU PYRAMIDAL.
AU Kubis N.; Catala M.
CS M. Catala, Lab. d'Histologie et Embryologie, UMR CNRS 7000, Faculte Medecine Pitie-Salpetriere, 105, boulevard de l'Hopital, 75631 Paris Cedex 13, France. catala@ext.jussieu.fr
SO Neurochirurgie, (2003) 49/2-3 II (145-153).
Refs: 36
ISSN: 0028-3770 CODEN: NUREB
CY France
DT Journal; Conference Article

008 Neurology and Neurosurgery
021 Developmental Biology and Teratology
LA French
SL English; French

L7 ANSWER 53 OF 159 MEDLINE on STN
AN 2003166745 MEDLINE
DN PubMed ID: 12684184
TI Eph receptor deficiencies lead to altered cochlear function.
AU Howard MacKenzie A; Rodenas-Ruano Alma; Henkemeyer Mark; Martin Glen K; Lonsbury-Martin Brenda L; Liebl Daniel J
CS Neuroscience Program, University of Miami School of Medicine, Miami, FL 33101-6960, USA.
NC DC00613 (NIDCD)
DC03114 (NIDCD)
SO Hearing research, (2003 Apr) 178 (1-2) 118-30.
Journal code: 7900445. ISSN: 0378-5955.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200312
ED Entered STN: 20030410
Last Updated on STN: 20031217
Entered Medline: 20031211

L7 ANSWER 54 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 16
AN 2003:394402 BIOSIS
DN PREV200300394402
TI EphA4 provides repulsive signals to developing cochlear ganglion neurites mediated through Ephrin-B2 and -B3.
AU Brors, Dominik; Bodmer, Daniel; Pak, Kwang; Aletsee, Christoph; Schafers, Maria; Dazert, Stefan; Ryan, Allen F. [Reprint Author]
CS UCSD School of Medicine, 9500 Gilman Drive, No. 0666, La Jolla, CA, 92093, USA
afryan@ucsd.edu
SO Journal of Comparative Neurology, (May 26 2003) Vol. 462, No. 1, pp. 90-100. print.
ISSN: 0021-9967 (ISSN print).
DT Article
LA English
ED Entered STN: 27 Aug 2003
Last Updated on STN: 27 Aug 2003

L7 ANSWER 55 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 17
AN 2003:273411 BIOSIS
DN PREV200300273411
TI Expression of Ephs and ephrins in developing mouse inner ear.
AU Pickles, James O. [Reprint Author]
CS Vision Touch and Hearing Research Centre, School of Biomedical Sciences, University of Queensland, Brisbane, QLD, 4072, Australia
j.pickles@vthrc.uq.edu.au
SO Hearing Research, (April 2003) Vol. 178, No. 1-2, pp. 44-51. print.
ISSN: 0378-5955 (ISSN print).
DT Article
LA English
ED Entered STN: 11 Jun 2003
Last Updated on STN: 11 Jun 2003

L7 ANSWER 56 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:73228 BIOSIS
DN PREV200300073228
TI mRNA expression of ephrins and Eph receptor tyrosine kinases in the neonatal and adult mouse central nervous system.
AU Liebl, Daniel J. [Reprint Author]; Morris, Carol J.; Henkemeyer, Mark; Parada, Luis F.
CS Miami Project to Cure Paralysis, University of Miami School of Medicine, 1095 NW 14th Terrace, Miami, FL, 33136, USA
dliebl@miami.edu
SO Journal of Neuroscience Research, (January 1 2003) Vol. 71, No. 1, pp. 7-22. print.
ISSN: 0360-4012 (ISSN print).

LA English
ED Entered STN: 29 Jan 2003
Last Updated on STN: 29 Jan 2003

L7 ANSWER 57 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:554900 BIOSIS
DN PREV200300552158
TI SLIT AND EPHB AXON GUIDANCE MOLECULES IN OPTIC NERVE INJURY.
AU Liu, X. [Reprint Author]; Ishimaru, T. [Reprint Author]; Sretavan, D. [Reprint Author]
CS Ophthalmology and Physiology, University of California San Francisco, San Francisco, CA, USA
SO ARVO Annual Meeting Abstract Search and Program Planner, (2003) Vol. 2003, pp. Abstract No. 5221. cd-rom.
Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA. May 04-08, 2003. Association for Research in Vision and Ophthalmology.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003

L7 ANSWER 58 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:543156 BIOSIS
DN PREV200300538665
TI EPHRINA1 SIGNALING INHIBITS VEGF - INDUCED ERK1/2 PHOSPHORYLATION AND RETINAL ENDOTHELIAL CELL PROLIFERATION.
AU Ojima, T. [Reprint Author]; Takagi, H. [Reprint Author]; Suzuma, K. [Reprint Author]; Oh, H. [Reprint Author]; Suzuma, I. [Reprint Author]; Ohashi, H. [Reprint Author]; Watanabe, D. [Reprint Author]; Suganami, E. [Reprint Author]; Honda, Y. [Reprint Author]
CS Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
SO ARVO Annual Meeting Abstract Search and Program Planner, (2003) Vol. 2003, pp. Abstract No. 2881. cd-rom.
Meeting Info.: Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL, USA. May 04-08, 2003. Association for Research in Vision and Ophthalmology.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 19 Nov 2003
Last Updated on STN: 19 Nov 2003

L7 ANSWER 59 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:580658 BIOSIS
DN PREV200300571287
TI INTRA-VILLOUS ADENOMAS IN THE DUODENUM OF PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP): IMPLICATIONS FOR THE ORIGINS OF ADENOMAS AND FOR THE RELEVANCE OF MOUSE MODELS FOR INTESTINAL NEOPLASIA.
AU Novelli, Marco [Reprint Author]; Preston, Sean L. [Reprint Author]; Kyriakides, Evangelos [Reprint Author]; Oukrif, Dahmane [Reprint Author]; Tomlinson, Ian [Reprint Author]; Poulson, Richard [Reprint Author]; Wright, Nicholas A. [Reprint Author]
CS London, UK
SO Digestive Disease Week Abstracts and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. S990. e-file.
Meeting Info.: Digestive Disease 2003. FL, Orlando, USA. May 17-22, 2003. American Association for the Study of Liver Diseases; American Gastroenterological Association; American Society for Gastrointestinal Endoscopy; Society for Surgery of the Alimentary Tract.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 10 Dec 2003
Last Updated on STN: 10 Dec 2003

L7 ANSWER 60 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

DN PREV200400198485
TI Role of ephrins and Eph receptors in adult neurogenesis.
AU Ricard, J. [Reprint Author]; Salinas, J. A. [Reprint Author]; Liebl, D. J. [Reprint Author]
CS Miami Project to Cure Paralysis, Univ. of Miami, Miami, FL, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 356.11. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Apr 2004
Last Updated on STN: 14 Apr 2004

L7 ANSWER 61 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:160067 BIOSIS
DN PREV200400160217
TI Corpus callosum axon guidance: the role of ephrins and Eph receptors.
AU Mendes, S. W. [Reprint Author]; Liebl, D. J.
CS Dept. Neurol., Univ. of Miami, Miami, FL, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 32.17. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Mar 2004
Last Updated on STN: 24 Mar 2004

L7 ANSWER 62 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2004:159726 BIOSIS
DN PREV200400159876
TI ***Ephrin*** - ***B3*** and EphB1 receptor deficiencies lead to defects in synaptic functions in the hippocampus.
AU Rodenas-Ruano, A. I. [Reprint Author]; Liebl, D. J. [Reprint Author]; Huizinga, C. [Reprint Author]
CS Neurosci., Univ. of Miami, Miami, FL, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 7.4. http://sfn.scholarone.com. e-file. Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Mar 2004
Last Updated on STN: 24 Mar 2004

L7 ANSWER 63 OF 159 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2003:11061 DISSABS Order Number: AAI3055126
TI Analysis of Eph receptors and ephrin ligands in the development of hippocamposeptal projections
AU Chen, Zhi-Yong [Ph.D.]; Zhou, Renping [adviser]
CS Rutgers The State University of New Jersey - New Brunswick and University of Medicine and Dentistry of New Jersey (0801)
SO Dissertation Abstracts International, (2002) Vol. 63, No. 5B, p. 2225. Order No.: AAI3055126. 162 pages.
ISBN: 0-493-69309-2.
DT Dissertation
FS DAI
LA English

L7 ANSWER 64 OF 159 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 18
AN 10203599 IFIPAT;IFIUDB;IFICDB
TI PEPTIDES THAT MODULATE THE INTERACTION OF B CLASS EPHRINS AND PDZ DOMAINS; PEPTIDE COMPLEX FOR USE IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS
IN Gish Gerald (CA); Lin Danny (CA); Pawson Anthony (CA)
PA Unassigned Or Assigned To Individual (68000)
PI US 2002147306 A1 20021010
AI US 2001-862179 20010521

US 1998-109158P 19981120 (Provisional)
FI US 2002147306 20021010
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 35
GI 8 Figure(s).

FIG. 1. Amino acid sequence of the cytoplasmic domains of the human B ephrins. Conserved residues among the three B ephrins are highlighted. Asterisks mark conserved tyrosines that are potential sites of phosphorylation. The potential PDZ domain binding site is underlined.

FIGS. 2A-D. Identification of PDZ domain-containing candidates for ephrin B binding. FIG. 2A, The preferred binding sequence of FAP-1 PDZ5 is shown below a schematic representation of the entire FAP-1 protein tyrosine phosphatase. FAP-1 PDZ5 domain specificity was deduced from an oriented peptide library technique (1). Residues within the optimal binding sequence that match the C-terminal sequence of B ephrins are indicated in bold. The organization of the PDZ domains of FAP-1 shown in this figure follows the numbering described by Sato et al. (33). FIG. 2B, Diagrammatic representations of the PDZ domaincontaining proteins identified through an expression screen with a biotinylated peptide probe of eprhin B3 C-terminal sequence. The brackets mark the portions of the protein encoded by the cDNAs isolated from the screen. PDZ domains are represented by grey boxes. FIG. 2C, Amino acid sequence alignment of FAP-1 PDZ5 and of the PDZ domains isolated in the expression screen. The numbering of the PDZ domains is as shown in FIG. 2B. Conserved residues are highlighted. The alignment was performed with the ClustalW program (55). FIG. 2D, Amino acid sequence alignment of PHIP and PAR-3. Conserved residues are highlighted and the PDZ domains are underlined. The alignment was performed with the Genestream Align program.

FIGS. 3A-C. FAP-1 PDZ5 and syntenin bind specifically to ephrin B1 in GST-mixes. Cos-1 cells were transiently transfected with either wild-type ephrin B1 (W. T.) or the ephrin B1 Val deletion (Val Delta) or were untransfected. Cell lysates were incubated with the GST fusion proteins as indicated and analyzed by immunoblotting with anti-ephrin B1 antibody. Immunoprecipitated ephrin B1 or ephrin B1 Val Delta were included as a positive control. FIG. 3A and FIG. 3B, GST-mixes with fusion proteins of FAP-1. C and D, GST-mixes with fusion proteins of syntenin.

FIGS. 4A and 4B. FAP-1 PDZ5 and syntenin binding to ephrin B1 can be blocked by addition of peptides corresponding to the Cterminal sequence of B ephrins. Peptides of the indicated sequence were included at a concentration of 100 mu M in incubations of GST fusion proteins with lysates of Cos-1 cells transfected with ephrin B1. Associated proteins were separated on a 10% polyacrylamide/SDS gel and analyzed by immunoblotting with antibodies against ephrin B1. FIG. 4A, Competition of FAP1 PDZ5 binding to ephrin B1 using the indicated peptides. A peptide of sequence DHQpYpYND was added at a concentration of 100 mu M as a negative control. Immunoprecipitation of ephrin B1 was included as a positive control. FIG. 4B, Peptide competition of the binding of full-length syntenin to ephrin B1.

FIGS. 5A and 5B. Fluorescence polarization analysis of GST-FAP-1 PDZ3, GST-FAP-1 PDZ5 and GST-syntenin binding to Fluoresceinlabelled peptides corresponding to the C-terminus of ephrin B1. FIG. 5 A, Solutions containing the indicated final concentration of GST-FAP-1 PDZ3 (FIG. 5B, A Binding of a GST fusion of full-length syntenin to the NIYYKV (

FIG. 6. Co-immunoprecipitation of syntenin-FLAG with ephrin B1. Cos-1 cells were co-transfected with either ephrin B1 and syntenin-FLAG or with the ephrin B1 Val deletion and synteninFLAG as indicated. Cell lysates were immunoprecipitated with antibodies against ephrin B1 or IL-3 receptor a or were treated with protein A sepharose only. Immunocomplexes were subjected to SDS-PAGE (10%) and blotted with anti-FLAG antibodies.

FIG. 7. Fluorescence polarization analysis of GST-PHIP PDZ3 binding to Fluorescein-labelled peptides corresponding to the Cterminus of ephrin B1. Solutions containing the indicated final concentration of GST-PHIP PDZ3 fusion protein in mixtures containing 25 nM fluorescein-labelled peptide probe, 20 mM phosphate pH 7.0, 100 mM NaCl, and 2 mM DTT were monitored for fluorescence polarization at 22 degrees C. The GST-PHIP PDZ3 fusion protein was measured for binding to the phosphorylated peptides, NIpYYKV (), NiYpYKV () and NIpYpYKV (

FIG. 8 PHIP PDZ3 binds specifically to V-Src phosphorylated ephrin B1 in GST-mixes. COS-1 cells were transiently cotransfected with V-Src and either wild-type ephrin B1 or the ephrin B1 Val deletion (VA) or were transfected with either wild-type ephrin B1 or ephrin B1 Val deletion alone. Cell lysates were incubated with the GST fusion proteins as indicated and analyzed by immunoblotting with antiphosphotyrosine

control.

L7 ANSWER 65 OF 159 USPATFULL on STN
AN 2002:99407 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002052308 A1 20020502
AI US 2001-925301 A1 20010810 (9)
RLI Continuation of Ser. No. WO 2000-US5882, filed on 8 Mar 2000, UNKNOWN
PRAI US 1999-124270P 19990312 (60)
DT Utility
FS APPLICATION
LN.CNT 30577
INCL INCLM: 514/001.000
INCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100; 530/350.000; 435/320.100; 435/325.000
NCL NCLM: 514/001.000
NCLS: 435/006.000; 435/007.100; 435/069.100; 435/183.000; 536/023.100; 530/350.000; 435/320.100; 435/325.000
IC [7]
ICM: A61K031-00
ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 66 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002297991 EMBASE
TI Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis.
AU Huynh-Do U.; Vindis C.; Liu H.; Cerretti D.P.; McGrew J.T.; Enriquez M.; Chen J.; Daniel T.O.
CS J. Chen, Vanderbilt-Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States. jin.chen@mcmail.vanderbilt.edu
SO Journal of Cell Science, (1 Aug 2002) 115/15 (3073-3081).
Refs: 39
ISSN: 0021-9533 CODEN: JNCSAI
CY United Kingdom
DT Journal; Article
FS 029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 67 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 19
AN 2003:97444 BIOSIS
DN PREV200300097444
TI Lac z histochemistry and immunohistochemistry reveal ephrin-B ligand expression in the inner ear.
AU Bianchi, Lynne M. [Reprint Author]; Dinsio, Kyl; Davoli, Katherine; Gale, Nicholas W.
CS Neuroscience Program, Oberlin College, Oberlin, OH, 44074, USA lynne.bianchi@oberlin.edu
SO Journal of Histochemistry & Cytochemistry, (December 2002) Vol. 50, No. 12, pp. 1641-1645. print.
ISSN: 0022-1554 (ISSN print).
DT Article
LA English
ED Entered STN: 12 Feb 2003
Last Updated on STN: 12 Feb 2003

L7 ANSWER 68 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002416014 EMBASE
TI EphB receptors influence growth of ephrin-B1-positive statoacoustic nerve fibers.
AU Bianchi L.M.; Gray N.A.
CS Dr. L.M. Bianchi, Neuroscience Program, Science Center A245, Woodland Ave, Oberlin, OH 44074, United States. lynne.bianchi@oberlin.edu
SO European Journal of Neuroscience, (2002) 14/8 (1499-1506).
Refs: 28
ISSN: 0953-816X CODEN: EJONEI
CY United Kingdom

FS 008 Neurology and Neurosurgery
029 Clinical Biochemistry
LA English
SL English

L7 ANSWER 69 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 20
AN 2002:632693 BIOSIS
DN PREV200200632693
TI ***Ephrin*** - ***B3*** -EphA4 interactions regulate the growth of specific thalamocortical axon populations in vitro.
AU Takemoto, Makoto; Fukuda, Tsuyoshi; Sonoda, Rie; Murakami, Fujio; Tanaka, Hideaki; Yamamoto, Nobuhiko [Reprint author]
CS Neuroscience Laboratories, Graduate School of Frontier Biosciences, Osaka University, Toyonaka, Osaka, 560-8531, Japan, Japan
nobuhiko@fbs.osaka-u.ac.jp
SO European Journal of Neuroscience, (September 2002 2002) Vol. 16, No. 6, pp. 1168-1172. print.
ISSN: 0953-816X.
DT Article
LA English
ED Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

L7 ANSWER 70 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 21
AN 2002:214449 BIOSIS
DN PREV200200214449
TI Coexpression of ephrin-Bs and their receptors in colon carcinoma.
AU Liu, Wenbiao; Ahmad, Syed A.; Jung, Young D.; Reinmuth, Niels; Fan, Fan; Bucana, Corazon D.; Ellis, Lee M. [Reprint author]
CS Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 444, Houston, TX, 77030-4009, USA
lellis@mdanderson.org
SO Cancer, (February 15, 2002) Vol. 94, No. 4, pp. 934-939. print.
CODEN: CANCAR. ISSN: 0008-543X.
DT Article
LA English
ED Entered STN: 27 Mar 2002
Last Updated on STN: 27 Mar 2002

L7 ANSWER 71 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 22
AN 2002:489520 BIOSIS
DN PREV200200489520
TI Human osteosarcoma expresses specific ephrin profiles: Implications for tumorigenicity and prognosis.
AU Varelias, Antiopi; Koblar, Simon A.; Cowled, Prudence A.; Carter, Christopher D.; Clayer, Mark [Reprint author]
CS Department of Orthopedics and Trauma, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville, South Australia, 5011, Australia
mark.clayer@nwahs.sa.gov.au
SO Cancer, (August 15, 2002) Vol. 95, No. 4, pp. 862-869. print.
CODEN: CANCAR. ISSN: 0008-543X.
DT Article
LA English
ED Entered STN: 18 Sep 2002
Last Updated on STN: 18 Sep 2002

L7 ANSWER 72 OF 159 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002344320 EMBASE
TI Expression of angiogenic and neurotrophic factors in the human amnion and choriodecidua.
AU Marvin K.W.; Keelan J.A.; Eykholt R.L.; Sato T.A.; Mitchell M.D.
CS Dr. K.W. Marvin, Liggins Institute, Faculty of Medical Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.
k.marvin@auckland.ac.nz
SO American Journal of Obstetrics and Gynecology, (2002) 187/3 (728-734).
Refs: 27
ISSN: 0002-9378 CODEN: AJOGAH
CY United States
DT Journal; Article
FS 010 Obstetrics and Gynecology
026 Immunology, Serology and Transplantation

SL English

L7 ANSWER 73 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:204763 CAPLUS
DN 137:123344
TI Insights into the pathobiology of hepatitis C virus-associated cirrhosis: Analysis of intrahepatic differential gene expression
AU Shackel, Nicholas A.; McGuinness, Peter H.; Abbott, Catherine A.; Gorrell, Mark D.; McCaughan, Geoffrey W.
CS A. W. Morrow Gastroenterology and Liver Centre, Centenary Institute of Cancer Medicine and Cell Biology, Royal Prince Alfred Hospital, Sydney, Australia
SO American Journal of Pathology (2002), 160(2), 641-654
CODEN: AJPAA4; ISSN: 0002-9440
PB American Society for Investigative Pathology
DT Journal
LA English
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 74 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 23
AN 2002:481248 BIOSIS
DN PREV200200481248
TI EphB forward signaling controls directional branch extension and arborization required for dorsal-ventral retinotopic mapping.
AU Hindges, Robert; McLaughlin, Todd; Genoud, Nicolas; Henkemeyer, Mark; O'Leary, Dennis D. M. [Reprint author]
CS Molecular Neurobiology Laboratory, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA, 92037, USA
doleary@salk.edu
SO Neuron, (August 1, 2002) Vol. 35, No. 3, pp. 475-487. print.
ISSN: 0896-6273.
DT Article
LA English
ED Entered STN: 11 Sep 2002
Last Updated on STN: 11 Sep 2002

L7 ANSWER 75 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:363492 BIOSIS
DN PREV200200363492
TI New insights into the organization of the mammalian locomotor CPG.
AU Kiehn, O. [Reprint author]
CS Department of Neuroscience, Karolinska Institutet, Retzius vag 8, 171 77, Stockholm, Sweden
SO Pfluegers Archiv European Journal of Physiology, (March, 2002) Vol. 443, No. Supplement 1, pp. S386-S387. print.
Meeting Info.: 81st Annual Joint Meeting of the Physiological Society, the Scandinavian Physiological Society and the German Physiological Society. Tuebingen, Germany. March 15-19, 2002.
CODEN: PFLABK. ISSN: 0031-6768.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Jul 2002
Last Updated on STN: 3 Jul 2002

L7 ANSWER 76 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:88312 CAPLUS
DN 137:30823
TI Dissection of HEF1-dependent functions in motility and transcriptional regulation
AU Fashena, Sarah J.; Einarson, Margret B.; O'Neill, Geraldine M.; Patriotis, Christos; Golemis, Erica A.
CS Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
SO Journal of Cell Science (2002), 115(1), 99-111
CODEN: JNCSAI; ISSN: 0021-9533
PB Company of Biologists Ltd.
DT Journal
LA English
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 77 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on

AN 2003:326113 BIOSIS
DN PREV200300326113
TI EXPRESSION CHARACTERISTICS OF EPHB1 AND ***EPHRIN*** - ***B3*** IN THE DEVELOPING MOUSE STRIATUM.
AU Richards, A. B. [Reprint Author]; Yokoyama, N.; Kinnunen, A.; Henkemeyer, M.; Kromer, L. K. [Reprint Author]
CS Department of Neuroscience, Georgetown University, Washington, DC, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 729.3. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L7 ANSWER 78 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:326112 BIOSIS
DN PREV200300326112
TI EPHB RECEPTOR SIGNALING CONTROLS DISTINCT AXON TARGETING MECHANISMS REQUIRED FOR RETINOTOPIC MAPPING.
AU McLaughlin, T. [Reprint Author]; Hindges, R. [Reprint Author]; Genoud, N. [Reprint Author]; Henkemeyer, M.; O'Leary, D. D. M. [Reprint Author]
CS Molecular Neurobiology Lab, The Salk Institute, La Jolla, CA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 729.2. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L7 ANSWER 79 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:303922 BIOSIS
DN PREV200300303922
TI TEMPORAL EXPRESSION OF EPHB1 AND ***EPHRIN*** - ***B3*** IN GLIA DURING CNS MATURATION IN GENETICALLY ALTERED MICE.
AU Kromer, L. F. [Reprint Author]; Richards, A. B. [Reprint Author]; Bundensen, L. Q. [Reprint Author]; Kinnunen, A.; Yokoyama, N.; Henkemeyer, M.
CS Dept Neurosci, Georgetown Univ Med Ctr, Washington, DC, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 424.13. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 2 Jul 2003
Last Updated on STN: 2 Jul 2003

L7 ANSWER 80 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2003:268120 BIOSIS
DN PREV200300268120
TI REGULATION OF HIPPOCAMPAL AXON DEFASCICULATION BY THE EPHB RECEPTORS.
AU Zhou, R. [Reprint Author]; Chen, Z. [Reprint Author]; Yue, Y. [Reprint Author]; Sun, C. [Reprint Author]; Bergemann, A.; Henkemeyer, M.
CS Chemical Biology, Rutgers University College of Pharmacy, Piscataway, NJ, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 27.10. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 11 Jun 2003

L7 ANSWER 81 OF 159 MEDLINE on STN
AN 2001269809 MEDLINE
DN PubMed ID: 11286777
TI Looking into mirror movement disorder.
AU Rutherford A
SO Trends in molecular medicine, (2001 Mar) 7 (3) 101.
Journal code: 100966035. ISSN: 1471-4914.
CY England: United Kingdom
DT News Announcement
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010529
Last Updated on STN: 20010529
Entered Medline: 20010521

L7 ANSWER 82 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:613243 CAPLUS
DN 135:302757
TI A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling
AU Geiss, Gary; Jin, Ge; Guo, Jinjiao; Bumgarner, Roger; Katze, Michael G.; Sen, Ganes C.
CS Department of Microbiology, University of Washington, Seattle, WA, 98195, USA
SO Journal of Biological Chemistry (2001), 276(32), 30178-30182
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 83 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:936919 CAPLUS
DN 136:194627
TI Commissural axon pathfinding on the contralateral side of the floor plate: a role for B-class ephrins in specifying the dorsoventral position of longitudinally projecting commissural axons
AU Imondi, Ralph; Kaprielian, Zaven
CS Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, 10461, USA
SO Development (Cambridge, United Kingdom) (2001), 128(23), 4859-4871
CODEN: DEVPED; ISSN: 0950-1991
PB Company of Biologists Ltd.
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 84 OF 159 MEDLINE on STN
AN 2001266248 MEDLINE
DN PubMed ID: 11306625
TI Ephrin B1 is expressed on neuroepithelial cells in correlation with neocortical neurogenesis.
AU Stuckmann I; Weigmann A; Shevchenko A; Mann M; Huttner W B
CS Department of Neurobiology, University of Heidelberg, D-69120 Heidelberg, Germany.
SO Journal of neuroscience : official journal of the Society for Neuroscience, (2001 Apr 15) 21 (8) 2726-37.
Journal code: 8102140. ISSN: 1529-2401.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200106
ED Entered STN: 20010611
Last Updated on STN: 20010611
Entered Medline: 20010607

L7 ANSWER 85 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:574322 BIOSIS
DN PREV200100574322

AU Mecteau, M. [Reprint author]; Lemaire, C. [Reprint author]; Rossignol, S.; Kessous, A. [Reprint author]; Provencher, J.; Doucet, G. [Reprint author]
CS Pathol Biol Cell, Universite de Montreal, Montreal, PQ, Canada
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2032. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 12 Dec 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 86 OF 159 MEDLINE on STN
AN 2002045989 MEDLINE
DN PubMed ID: 11754835
TI Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity.
AU Grunwald I C; Korte M; Wolfer D; Wilkinson G A; Unsicker K; Lipp H P; Bonhoeffer T; Klein R
CS Department of Molecular Neurobiology, Max-Planck-Institute of Neurobiology, Am Klopferspitz 18a, D-82152, Martinsried, Germany.
SO Neuron, (2001 Dec 20) 32 (6) 1027-40.
Journal code: 8809320. ISSN: 0896-6273.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200210
ED Entered STN: 20020124
Last Updated on STN: 20021002
Entered Medline: 20021001

L7 ANSWER 87 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:519962 BIOSIS
DN PREV200100519962
TI Eph receptors and ephrins participate in spinal cord reorganization after injury.
AU Bundesen, L. Q. [Reprint author]; Scheel, T. A. [Reprint author]; Bregman, B. S. [Reprint author]; Kromer, L. F. [Reprint author]
CS Dept Neurosci, Georgetown Univ, Washington, DC, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 965. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 7 Nov 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 88 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 24
AN 2001:226778 BIOSIS
DN PREV200100226778
TI ***Ephrin*** - ***B3*** is the midline barrier that prevents corticospinal tract axons from recrossing, allowing for unilateral motor control.
AU Kullander, Klas; Croll, Susan D.; Zimmer, Manuel; Pan, Li; McClain, Joyce; Hughes, Virginia; Zabski, Stephanie; DeChiara, Thomas M.; Klein, Ruediger; Yancopoulos, George D.; Gale, Nicholas W. [Reprint author]
CS Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591-6707, USA
nicholas.gale@regeneron.com
SO Genes and Development, (April 1, 2001) Vol. 15, No. 7, pp. 877-888. print.
CODEN: GEDEEP. ISSN: 0890-9369.
DT Article
LA English
ED Entered STN: 9 May 2001
Last Updated on STN: 18 Feb 2002

L7 ANSWER 89 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:416087 CAPLUS
DN 135:164797

B signaling
AU Chan, Joanne; Mably, John D.; Serluca, Fabrizio C.; Chen, Jau-Nian; Goldstein, Nathaniel B.; Thomas, Matthew C.; Cleary, Jennifer A.; Brennan, Caroline; Fishman, Mark C.; Roberts, Thomas M.
CS Department of Cancer Biology and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
SO Developmental Biology (Orlando, FL, United States) (2001), 234(2), 470-482
CODEN: DEBIAO; ISSN: 0012-1606
PB Academic Press
DT Journal
LA English
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 90 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 25
AN 2001:379555 BIOSIS
DN PREV200100379555
TI Development and reorganization of corticospinal projections in EphA4 deficient mice.
AU Coonan, Jason R.; Greferath, Ursula; Messenger, Jonathan; Hartley, Lynne; Murphy, Mark; Boyd, Andrew W.; Dottori, Mirella; Galea, Mary P.; Bartlett, Perry F. [Reprint author]
CS Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, VIC, 3050, Australia
bartlett@wehi.edu.au
SO Journal of Comparative Neurology, (July 23, 2001) Vol. 436, No. 2, pp. 248-262. print.
CODEN: JCNEAM. ISSN: 0021-9967.
DT Article
LA English
ED Entered STN: 8 Aug 2001
Last Updated on STN: 19 Feb 2002

L7 ANSWER 91 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 26
AN 2001:135462 BIOSIS
DN PREV200100135462
TI Forward signaling mediated by ***ephrin*** - ***B3*** prevents contralateral corticospinal axons from recrossing the spinal cord midline.
AU Yokoyama, Nobuhiko; Romero, Mario I.; Cowan, Chad A.; Galvan, Pedro; Helmbacher, Francoise; Charnay, Patrick; Parada, Luis F.; Henkemeyer, Mark [Reprint author]
CS Center for Developmental Biology and Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
henk@utsw.swmed.edu
SO Neuron, (January, 2001) Vol. 29, No. 1, pp. 85-97. print.
ISSN: 0896-6273.
DT Article
LA English
ED Entered STN: 14 Mar 2001
Last Updated on STN: 15 Feb 2002

L7 ANSWER 92 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 27
AN 2000:368418 CAPLUS
DN 133:27865
TI Peptides that modulate the interaction of B class ephrins and PDZ domains
IN Lin, Danny; Pawson, Anthony
PA Mount Sinai Hospital, Can.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2000031124 | A2 | 20000602 | WO 1999-CA1101 | 19991119 |
| WO 2000031124 | A3 | 20001123 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1131351 A2 20010912 EP 1999-955608 19991119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 2002147306 A1 20021010 US 2001-862179 20010521

PRAI US 1998-109158P P 19981120
WO 1999-CA1101 W 19991119

OS MARPAT 133:27865

L7 ANSWER 93 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 28

AN 2000:490524 BIOSIS

DN PREV200000490645

TI Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

AU Tang, Xao X.; Zhao, Huaqing; Robinson, Marjorie E.; Cohen, Brian; Cnaan, Avital; London, Wendy; Cohn, Susan L.; Cheung, Nai-Kong V.; Brodeur, Garrett M.; Evans, Audrey E.; Ikegaki, Naohiko [Reprint author]

CS Division of Oncology, The Children's Hospital of Philadelphia, 3516 Civic Center Boulevard, ARC Suite 902, Philadelphia, PA, 19104-4318, USA

SO Proceedings of the National Academy of Sciences of the United States of America, (September 26, 2000) Vol. 97, No. 20, pp. 10936-10941. print.
CODEN: PNASA6. ISSN: 0027-8424.

DT Article

LA English

ED Entered STN: 15 Nov 2000
Last Updated on STN: 10 Jan 2002

L7 ANSWER 94 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:395628 CAPLUS

DN 133:130254

TI Expression of Eph receptors and ephrins is differentially regulated by E-cadherin

AU Orsulic, Sandra; Kemler, Rolf

CS Max-Planck-Institut fur Immunbiologie, Freiburg, D-79108, Germany

SO Journal of Cell Science (2000), 113(10), 1793-1802
CODEN: JNCSAI; ISSN: 0021-9533

PB Company of Biologists Ltd.

DT Journal

LA English

RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 95 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 29

AN 2001:26460 BIOSIS

DN PREV200100026460

TI Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.

AU Tang, Xao X.; Zhao, Huaqing; Robinson, Marjorie E.; Cnaan, Avital; London, Wendy; Cohn, Susan L.; Cheung, Nai-Kong V.; Brodeur, Garrett M.; Evans, Audrey E.; Ikegaki, Naohiko [Reprint author]

CS Division of Oncology, The Children's Hospital of Philadelphia, 3516 Civic Center Blvd., ARC Suite 902, Philadelphia, PA, 19104-4318, USA
IKEGAKI@email.chop.edu

SO Medical and Pediatric Oncology, (December, 2000) Vol. 35, No. 6, pp. 656-658. print.
CODEN: MPONDB. ISSN: 0098-1532.

DT Article

LA English

ED Entered STN: 3 Jan 2001
Last Updated on STN: 12 Feb 2002

L7 ANSWER 96 OF 159 CANCERLIT on STN DUPLICATE 30

AN 2000431852 CANCERLIT

DN 20431852 PubMed ID: 10969208

TI [Involvement of ephrins and their receptors in oncogenesis].
L'implication des ephrines et de leurs recepteurs en oncogenese.

AU L'Allemain G

CS Institut de recherches signalisation, biologie du developpement et cancer, CNRS UMR 6543, Centre de biochimie, Parc Valrose, 06108 Nice Cedex 2.

SO BULLETIN DU CANCER, (2000 Jul) 87 (7-8) 529-30.
Journal code: 0072416. ISSN: 0007-4551.

CY France

LA French
FS MEDLINE; Priority Journals
OS MEDLINE 2000454923
EM 200009
ED Entered STN: 20001128
Last Updated on STN: 20001128

L7 ANSWER 97 OF 159 MEDLINE on STN
AN 2000072613 MEDLINE
DN PubMed ID: 10603345
TI The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis.
AU Helbling P M; Saulnier D M; Brandli A W
CS Institute of Cell Biology, Swiss Federal Institute of Technology, ETH-Honggerberg, CH-8093 Zurich, Switzerland.
SO Development (Cambridge, England), (2000 Jan) 127 (2) 269-78. Journal code: 8701744. ISSN: 0950-1991.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200002
ED Entered STN: 20000229
Last Updated on STN: 20000229
Entered Medline: 20000216

L7 ANSWER 98 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:272012 BIOSIS
DN PREV200100272012
TI The role of Eph receptors and ligands in the formation of thalamocortical projections.
AU Fukuda, Tsuyoshi [Reprint author]; Takemoto, Makoto [Reprint author]; Fujio, Murakami [Reprint author]; Nobuhiko, Yamamoto [Reprint author]
CS Laboratory of Neuroscience, Division of Biophysical Engineering, Graduate School of Engineering Science, Osaka University, Toyonaka, Japan
SO Neuroscience Research Supplement, (2000) No. 24, pp. S136. print. Meeting Info.: 23rd Annual Meeting of the Japan Neuroscience Society and the 10th Annual Meeting of the Japanese Neural Network Society. Yokohama, Japan. September 04-06, 2000. Japan Neuroscience Society; Japanese Neural Network Society.
ISSN: 0921-8696.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 6 Jun 2001
Last Updated on STN: 19 Feb 2002

L7 ANSWER 99 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:253840 CAPLUS
DN 133:116216
TI Eph receptors and ephrins are key regulators of morphogenesis
AU Holder, N.; Durbin, L.; Cooke, J.
CS Department of Anatomy and Developmental Biology, University College, London, WC1 6BT, UK
SO Ernst Schering Research Foundation Workshop (2000), 29(Of Fish, Fly, Worm, and Man), 123-147
CODEN: ESRWEL; ISSN: 0947-6075
PB Springer-Verlag
DT Journal; General Review
LA English
RE.CNT 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 100 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 31
AN 2000:93783 BIOSIS
DN PREV200000093783
TI Expression of EphA4 in developing inner ears of the mouse and guinea pig.
AU van Heumen, Walter R. A.; Claxton, Christina; Pickles, James O. [Reprint author]
CS Vision, Touch and Hearing Research Centre, Department of Physiology and Pharmacology, University of Queensland, Brisbane, QLD, 4072, Australia
SO Hearing Research, (Jan., 2000) Vol. 139, No. 1-2, pp. 42-50. print.
CODEN: HERED3. ISSN: 0378-5955.

LA English
ED Entered STN: 10 Mar 2000
Last Updated on STN: 3 Jan 2002

L7 ANSWER 101 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:87122 BIOSIS
DN PREV200100087122
TI Aberrant retinocollicular mapping in EphB2/EphB3 double knockout mice.
AU Hindges, R. [Reprint author]; McLaughlin, T.; Henkemeyer, M.; O'Leary, D. D.
CS The Salk Institute, La Jolla, CA, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-218.1. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L7 ANSWER 102 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:87002 BIOSIS
DN PREV200100087002
TI Distinct functions of EphA and EphB receptors in hippocamposeptal topographic map formation.
AU Chen, Z. [Reprint author]; Yue, Y.; Su, J.; Sun, C.; Henkemeyer, M.; Zhou, R.
CS Rutgers University, Piscataway, NJ, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-108.4. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L7 ANSWER 103 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:96762 BIOSIS
DN PREV200100096762
TI Ephrin-B2 and ***ephrin*** - ***B3*** expression in the inner ear.
AU Bianchi, L. M. [Reprint author]; Dinsio, K.; Gale, N. W.; Henkemeyer, M.; Fritzsch, B.
CS Oberlin College, Oberlin, OH, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-330.17. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Feb 2001
Last Updated on STN: 15 Feb 2002

L7 ANSWER 104 OF 159 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2000:8846 DISSABS Order Number: AAIMQ42194
TI IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES DURING DIFFERENTIATION OF A NOVEL HUMAN VASCULAR SMOOTH MUSCLE CELL LINE
AU PRAVDA, ZUZANA HEDRIKA [M.SC.]; PICKERING, J. G. [adviser]
CS THE UNIVERSITY OF WESTERN ONTARIO (CANADA) (0784)
SO Masters Abstracts International, (1999) Vol. 38, No. 1, p. 163. Order No.: AAIMQ42194. 150 pages.
ISBN: 0-612-42194-5.
DT Dissertation
FS MAI
LA English

L7 ANSWER 105 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 32
AN 1999:134203 BIOSIS
DN PREV199900134203
TI The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif.
AU Lin, Dan; Gish, Gerald D.; Songyang, Zhou; Pawson, Tony [Reprint author]
CS Programmne Mol. Biol. Cancer, Samuel Lunenfeld Res. Inst., Mt. Sinai Hosp., 600 University Ave., Toronto, ON M5G 1X5, Canada
SO Journal of Biological Chemistry, (Feb. 5, 1999) Vol. 274, No. 6, pp. 3726-3733. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 31 Mar 1999
Last Updated on STN: 31 Mar 1999

L7 ANSWER 106 OF 159 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:975353 SCISEARCH
GA The Genuine Article (R) Number: 250YD
TI ***EphrinB3*** and EphB3 are coordinately upregulated during human smooth muscle cell maturation
AU Pravda Z (Reprint); Li S; Rajakumar N; Ruschlow W; Verdi J; Brown A; Pickering J G
CS JOHN P ROBARTS RES INST, LONDON, ON N6A 5K8, CANADA; UNIV WESTERN ONTARIO, LONDON, ON, CANADA
CYA CANADA
SO CIRCULATION, (2 NOV 1999) Vol. 100, No. 18, Supp. [S], pp. 3636-3636.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621.
ISSN: 0009-7322.
DT Conference; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 0

L7 ANSWER 107 OF 159 CANCERLIT on STN DUPLICATE 33
AN 1999316799 CANCERLIT
DN 99316799 PubMed ID: 10389937
TI High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.
AU Tang X X; Evans A E; Zhao H; Cnaan A; London W; Cohn S L; Brodeur G M; Ikegaki N
CS Division of Oncology, The Children's Hospital of Philadelphia, Abramson Research Center, Pennsylvania 19104-4318, USA.
NC CA70958 (NCI)
F32 CA75748 (NCI)
NS34514 (NINDS)
SO CLINICAL CANCER RESEARCH, (1999 Jun) 5 (6) 1491-6.
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 1999316799
EM 199909
ED Entered STN: 19991112
Last Updated on STN: 19991112

L7 ANSWER 108 OF 159 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:223544 CAPLUS
DN 131:30116
TI EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains
AU Bruckner, Katja; Labrador, Juan Pablo; Scheiffele, Peter; Herb, Anne; Seeburg, Peter H.; Klein, Rudiger
CS Developmental Biology Programme, European Molecular Biology Laboratory, Heidelberg, D-69117, Germany
SO Neuron (1999), 22(3), 511-524
CODEN: NERNET; ISSN: 0896-6273
PB Cell Press
DT Journal
LA English
RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD

L7 ANSWER 109 OF 159 CANCERLIT on STN DUPLICATE 34
AN 1999154801 CANCERLIT
DN 99154801 PubMed ID: 10037197
TI Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.
AU Tang X X; Brodeur G M; Campling B G; Ikegaki N
CS Division of Oncology, The Children's Hospital of Philadelphia, Pennsylvania 19104-4318, USA.
NC CA70958 (NCI)
F32 CA75748 (NCI)
NS34514 (NINDS)
SO CLINICAL CANCER RESEARCH, (1999 Feb) 5 (2) 455-60.
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 1999154801
EM 199904
ED Entered STN: 19990622
Last Updated on STN: 19990622

L7 ANSWER 110 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 35
AN 2000:51186 BIOSIS
DN PREV200000051186
TI Comparative analysis of embryonic gene expression defines potential interaction sites for Xenopus EphB4 receptors with ephrin-B ligands.
AU Helbling, Paul M.; Saulnier, Didier M.E.; Robinson, Vicky; Christiansen, Jeff H.; Wilkinson, David G.; Brandli, Andre W. [Reprint author]
CS Institute of Cell Biology, Swiss Federal Institute of Technology, ETH-Honggerberg, CH-8093, Zurich, Switzerland
SO Developmental Dynamics, (Dec., 1999) Vol. 216, No. 4-5, pp. 361-373. print.
CODEN: DEDYEI. ISSN: 1058-8388.
DT Article
LA English
ED Entered STN: 3 Feb 2000
Last Updated on STN: 3 Jan 2002

L7 ANSWER 111 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:143675 BIOSIS
DN PREV199900143675
TI Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/ venous domains, vascular morphogenesis, and sprouting angiogenesis.
AU Adams, Ralf H.; Wilkinson, George A.; Weiss, Cornelia; Diella, Francesca; Gale, Nicholas W.; Deutsch, Urban; Risau, Werner; Klein, Ruediger [Reprint author]
CS European Mol. Biol. Lab., D-69117 Heidelberg, Germany
SO Genes and Development, (Feb. 1, 1999) Vol. 13, No. 3, pp. 295-306. print.
CODEN: GEDEEP. ISSN: 0890-9369.
DT Article
LA English
ED Entered STN: 31 Mar 1999
Last Updated on STN: 31 Mar 1999

L7 ANSWER 112 OF 159 MEDLINE on STN
AN 1999210443 MEDLINE
DN PubMed ID: 10192794
TI Induction of Eph B3 after spinal cord injury.
AU Miranda J D; White L A; Marcillo A E; Willson C A; Jagid J; Whittemore S R
CS Department of Neurological Surgery, University of Miami School of Medicine, 1600 Northwest 10th Avenue, R-48, Miami, Florida 33136, USA.
NC NS10304 (NINDS)
NS26887 (NINDS)
SO Experimental neurology, (1999 Mar) 156 (1) 218-22.
Journal code: 0370712. ISSN: 0014-4886.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199904

Last Updated on STN: 20000303
Entered Medline: 19990421

L7 ANSWER 113 OF 159 MEDLINE on STN
AN 1999172312 MEDLINE
DN PubMed ID: 10072375
TI Eph receptors and ephrins in neural development.
AU O'Leary D D; Wilkinson D G
CS Molecular Neurobiology Laboratory The Salk Institute 10010 North Torrey Pines Road La Jolla California 92037 USA.. dennis_oleary@qm.salk.edu
NC EY07025 (NEI)
NS31558 (NINDS)
SO Current opinion in neurobiology, (1999 Feb) 9 (1) 65-73. Ref: 74
Journal code: 9111376. ISSN: 0959-4388.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW LITERATURE)
LA English
FS Priority Journals
EM 199905
ED Entered STN: 19990607
Last Updated on STN: 19990607
Entered Medline: 19990524

L7 ANSWER 114 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:25109 BIOSIS
DN PREV200000025109
TI ***EphrinB3*** and EphB3 are coordinately upregulated during human smooth muscle cell maturation.
AU Pravda, Zuzana [Reprint author]; Li, Shaohua [Reprint author]; Rajakumar, N.; Ruschlow, Walter; Verdi, Joseph; Brown, Arthur; Pickering, J. Geoffrey
CS John P Robarts Res Inst, London, ON, Canada
SO Circulation, (Nov. 2, 1999) Vol. 100, No. 18 SUPPL., pp. I.689. print.
Meeting Info.: 72nd Scientific Sessions of the American Heart Association. Atlanta, Georgia, USA. November 7-10, 1999.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 29 Dec 1999
Last Updated on STN: 31 Dec 2001

L7 ANSWER 115 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:64189 BIOSIS
DN PREV199900064189
TI Induction of EPH B3 RPTK after spinal cord injury.
AU Miranda, J. D.; White, L. A.; Willson, C. A.; Marcillo, A.; Jagid, J.; Whittemore, S. R.
CS Miami Project Dep. Neurolgoical Surgery, Univ. Miami Sch. Med., Miami, FL 33136, USA
SO Society for Neuroscience Abstracts, (1998) Vol. 24, No. 1-2, pp. 741. print.
Meeting Info.: 28th Annual Meeting of the Society for Neuroscience, Part 1. Los Angeles, California, USA. November 7-12, 1998. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 16 Feb 1999
Last Updated on STN: 16 Feb 1999

L7 ANSWER 116 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 36
AN 1998:132637 BIOSIS
DN PREV199800132637
TI ***Ephrin*** - ***B3*** , a ligand for the receptor EphB3, expressed at the midline of the developing neural tube.
AU Bergemann, Andrew D.; Zhang, Lee; Chiang, Ming-Ko; Brambilla, Riccardo; Klein, Ruediger; Flanagan, John G. [Reprint author]
CS Dep. Cell Biol., Harv. Med. Sch., 240 Longwood Ave., Boston, MA 02115, USA

CODEN: ONCNES. ISSN: 0950-9232.
DT Article
LA English
ED Entered STN: 20 Mar 1998
Last Updated on STN: 20 Mar 1998

L7 ANSWER 117 OF 159 MEDLINE on STN
AN 1998191577 MEDLINE
DN PubMed ID: 9530499
TI The ephrins and Eph receptors in neural development.
AU Flanagan J G; Vanderhaeghen P
CS Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.. Flanagan@warren.med.harvard.edu
SO Annual review of neuroscience, (1998) 21 309-45. Ref: 185
Journal code: 7804039. ISSN: 0147-006X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199805
ED Entered STN: 19980514
Last Updated on STN: 20000303
Entered Medline: 19980504

L7 ANSWER 118 OF 159 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:26185 BIOSIS
DN PREV199900026185
TI Loss of EphB2 and B3 receptor tyrosine kinases results in pathfinding errors of retinal ganglion cell axons to the optic disc.
AU Birgbauer, E. [Reprint author]; Henkemeyer, M.; Sretavan, D. [Reprint author]
CS U.C. San Francisco, San Francisco, CA, USA
SO Molecular Biology of the Cell, (Nov., 1998) Vol. 9, No. SUPPL., pp. 228A. print.
Meeting Info.: 38th Annual Meeting of the American Society for Cell Biology. San Francisco, California, USA. December 12-16, 1998. American Society for Cell Biology.
CODEN: MBCEEV. ISSN: 1059-1524.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 20 Jan 1999
Last Updated on STN: 20 Jan 1999

L7 ANSWER 119 OF 159 MEDLINE on STN
AN 97271551 MEDLINE
DN PubMed ID: 9126477
TI cDNA cloning, chromosomal localization, and expression pattern of EPLG8, a new member of the EPLG gene family encoding ligands of EPH-related protein-tyrosine kinase receptors.
AU Tang X X; Pleasure D E; Ikegaki N
CS Division of Neurology Research, Children's Hospital of Philadelphia, Pennsylvania 19104-4318, USA.
NC NS08075 (NINDS)
NS25044 (NINDS)
SO Genomics, (1997 Apr 1) 41 (1) 17-24.
Journal code: 8800135. ISSN: 0888-7543.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-U66406
EM 199705
ED Entered STN: 19970602
Last Updated on STN: 20000303
Entered Medline: 19970520

L7 ANSWER 120 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABU07846 Protein DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an Ephrin ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an Ephrin in the presence of a putative

IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR N-PSDB: ABX12547
DESC Mouse ***ephrin*** - ***B3*** ligand.

L7 ANSWER 121 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABU07845 Protein DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an Ephrin ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an Ephrin in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR N-PSDB: ABX12546
DESC Human ***ephrin*** - ***B3*** ligand.

L7 ANSWER 122 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAY71438 peptide DGENE
TI Isolated complex for treating proliferative or differentiative disorders comprises B class ephrin and PDZ domain containing protein -
IN Lin D; Pawson A
PA (MOUN) MOUNT SINAI HOSPITAL.
PI WO 2000031124 A2 20000602 59p
AI WO 1999-CA1101 19991119
PRAI US 1998-109158 19981120
DT Patent
LA English
OS 2000-400038 [34]
DESC Human ***ephrin*** ***B3*** C-terminal cytoplasmic domain.

L7 ANSWER 123 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAY71415 peptide DGENE
TI Isolated complex for treating proliferative or differentiative disorders comprises B class ephrin and PDZ domain containing protein -
IN Lin D; Pawson A
PA (MOUN) MOUNT SINAI HOSPITAL.
PI WO 2000031124 A2 20000602 59p
AI WO 1999-CA1101 19991119
PRAI US 1998-109158 19981120
DT Patent
LA English
OS 2000-400038 [34]
DESC EphrinB-3 C-terminal peptide biotinylated probe, comprising PDZ domain.

L7 ANSWER 124 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91614 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) forward PCR primer, SEQ ID NO:15.

L7 ANSWER 125 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) antisense S-oligonucleotide, SEQ ID NO:100.

L7 ANSWER 126 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91706 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) control S-oligonucleotide, SEQ ID NO:107.

L7 ANSWER 127 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91703 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) control S-oligonucleotide, SEQ ID NO:104.

L7 ANSWER 128 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91698 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) antisense S-oligonucleotide, SEQ ID NO:99.

L7 ANSWER 129 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) antisense S-oligonucleotide, SEQ ID NO:103.

L7 ANSWER 130 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91707 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) control S-oligonucleotide, SEQ ID NO:108.

L7 ANSWER 131 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91705 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) control S-oligonucleotide, SEQ ID NO:106.

L7 ANSWER 132 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91701 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) antisense S-oligonucleotide, SEQ ID NO:102.

L7 ANSWER 133 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) reverse PCR primer, SEQ ID NO:16.

L7 ANSWER 134 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91704 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) control S-oligonucleotide, SEQ ID NO:105.

L7 ANSWER 135 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ADL91700 DNA DGENE
TI Use of a compound or composition for diagnosing, treating or preventing synovial sarcoma or a disease associated with Frizzled homologue 10, e.g. colorectal cancer, gastric cancer, chronic myeloid leukemia or acute myeloid leukemia.
IN Nakamura Y; Katagiri T
PA (ONCO-N) ONCOTHERAPY SCI INC.
(UYTY) UNIV TOKYO.
PI WO 2004020668 A2 20040311 143p
AI WO 2003-JP10591 20030821
PRAI US 2002-407506P 20020830
US 2003-486195P 20030711
DT Patent
LA English
OS 2004-239208 [22]
DESC ***Ephrin*** - ***B3*** (SYX 8) antisense S-oligonucleotide, SEQ ID NO:101.

L7 ANSWER 136 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABX12547 cDNA DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an Ephrin ligand, useful for promoting neovascularization, comprises contacting a Tie receptor with an Ephrin in the presence of a putative modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR P-PSDB: ABU07846
DESC cDNA encoding mouse ***ephrin*** - ***B3*** ligand.

L7 ANSWER 137 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABX12546 cDNA DGENE
TI Identifying modulators of binding between a Tie receptor tyrosine kinase and an Ephrin ligand, useful for promoting neovascularization, comprises

modulator -
IN Alitalo K; Kubo H
PA (LICN) LICENTIA LTD.
PI WO 2003004529 A2 20030116 199p
AI WO 2002-IB2524 20020702
PRAI US 2001-302960P 20010702
DT Patent
LA English
OS 2003-210341 [20]
CR P-PSDB: ABU07845
DESC cDNA encoding human ***ephrin*** - ***B3*** ligand.

L7 ANSWER 138 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAA52948 DNA DGENE
TI Method of facilitating regeneration, growth and/or development of a central nervous system in an animal or bird, for treating disease or trauma comprises modifying levels of Eph receptor -
IN Bartlett P F; Hartley L; Pilizzotto M; Kilpatrick T; Kontgen F; Coonan J; Greferath U; Boyd A W; Dottori M; Galea M; Paxinos G; Murphy M
PA (HALL-N) HALL INST MEDICAL RES WALTER & ELIZA.
(COUN-N) COUNCIL QUEENSLAND INST MEDICAL RES.
(UYME) UNIV MELBOURNE.
PI WO 2000024413 A1 20000504 48p
AI WO 1999-AU931 19991027
PRAI AU 1998-6748 19981027
DT Patent
LA English
OS 2000-350585 [30]
DESC Mouse ***Ephrin*** ***B3*** cDNA PCR primer #2.

L7 ANSWER 139 OF 159 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAA52947 DNA DGENE
TI Method of facilitating regeneration, growth and/or development of a central nervous system in an animal or bird, for treating disease or trauma comprises modifying levels of Eph receptor -
IN Bartlett P F; Hartley L; Pilizzotto M; Kilpatrick T; Kontgen F; Coonan J; Greferath U; Boyd A W; Dottori M; Galea M; Paxinos G; Murphy M
PA (HALL-N) HALL INST MEDICAL RES WALTER & ELIZA.
(COUN-N) COUNCIL QUEENSLAND INST MEDICAL RES.
(UYME) UNIV MELBOURNE.
PI WO 2000024413 A1 20000504 48p
AI WO 1999-AU931 19991027
PRAI AU 1998-6748 19981027
DT Patent
LA English
OS 2000-350585 [30]
DESC Mouse ***Ephrin*** ***B3*** cDNA PCR primer #1.

L7 ANSWER 140 OF 159 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:191375 FEDRIP
NR CRISP 2P01HD23315-16 0006
TI EPH FAMILY RECEPTORS & LIGANDS IN HIPPOCAMPAL SYSTEM
SF Principal Investigator: ZHOU, RENPING; UMDNJ-ROBERT W JOHNSON MED SCH, 675 HOES LANE
CSP UNIV OF MED/DENT NJ-R W JOHNSON MED SCH, PISCATAWAY, NEW JERSEY
CSS Supported By: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
DB 2007 (/01/87)
FYR 2003
DE 2003 (/31/08)
FU Competing Continuation (Type 2)
FS National Institutes of Health

L7 ANSWER 141 OF 159 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:164868 FEDRIP
NR CRISP 5R01CA85519-03
TI Functions of EPH Receptors and Ephrins in Neuroblastoma
SF Principal Investigator: IKEGAKI, NAOHIKO; IKEGAKI@EMAIL.CHOP.EDU, CHILDREN'S HOSPITAL OF PHILADELP, 3516 CIVIC CENTER BLVD
CSP CHILDREN'S HOSPITAL OF PHILADELPHIA, PHILADELPHIA, PENNSYLVANIA
CSS Supported By: NATIONAL CANCER INSTITUTE
DB 2007 (/01/01)
FYR 2003
DE 2006 (/30/06)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L7 ANSWER 142 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BV209208 GenBank (R)
GenBank ACC. NO. (GBN): BV209208
GenBank VERSION (VER): BV209208.1 GI:51853752
CAS REGISTRY NO. (RN): 753950-77-5
SEQUENCE LENGTH (SQL): 706
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Sequence Tag Site
DATE (DATE): 2 Sep 2004
DEFINITION (DEF): EFNB3_3177 Rhesus macaque genomic DNA Macaca mulatta STS genomic clone MMA3177, sequence tagged site.
KEYWORDS (ST): STS
SOURCE: Macaca mulatta (rhesus monkey)
ORGANISM (ORGN): Macaca mulatta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Cercopithecinae; Macaca

COMMENT:
Contact: Spindel ER
Division of Neuroscience
Oregon National Primate Research Center
505 NW 185th Avenue, Beaverton, OR 97006, USA
Tel: 403-690-5388
Fax: 503-690-5384
Email: spindele@ohsu.edu
Primer A: gactgtaagaggttagaggtg
Primer B: aattcaagtccagtcattct
STS size: 706
PCR Profile:
Hot Start: 95 degrees C for 2.00 min
Denaturation: 95 degrees C for 0.50 min
Annealing: 51 degrees C for 0.50 min
Polymerization: 72 degrees C for 1.00 min
PCR Cycles: 35
Extension 72 degrees C for 7.0 min
Thermal Cycler: MJ Instruments PTC100
Protocol:
Template: 200 ng
Primer: each 1uM
dNTP's: each 200 uM
Taq Polymerase: 0.05 units/ul (Fast Start High Fidelity, Roche)
Total Vol: 50 ul
Buffer:
MgCl2: 1.8 mM
Fast Start polymerase reaction buffer (Roche)
Bases 1-697 are 95% homologous (Blast) to bases 2529-3219 of NM_001406.2. Primers were chosen to amplify genomic DNA in the 3' region of EFNB3. As human sequence was used to design the primers, the primer sequences are not included in the rhesus sequence provided below. To obtain additional information regarding primers or clones contact: Dr. Robert Norgren; Dept of Genetics, Cell Biology & Anatomy; University of Nebraska Medical Center; 986395 Nebraska Medical Center; Omaha, NE 68198. Email: rnorgren@unmc.edu
A database containing sequences associated with this project can be found at: http://rhesusgenechip.unomaha.edu/index.html.

REFERENCE: 1 (bases 1 to 706)
AUTHOR (AU): Spindel,E.R.; Pauley,M.; Jia,Y.; Boyle,N.; Jiang,S.; Gravett,C.; Lupo,S.L.; Ali,H.; Ojeda,S.R.; Norgren,R.B.
TITLE (TI): Targeted amplification of the 3' end of rhesus macaque orthologs of human genes
JOURNAL (SO): Unpublished (2004)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..706 | /organism="Macaca mulatta"<br>/mol-type="genomic DNA"<br>/strain="Indian orgin"<br>/db-xref="taxon:9544"<br>/clone="MMA3177"<br>/clone-lib="Rhesus macaque genomic DNA" |

/note="Organ: Liver; Vector: pGEM-T Easy; V-type: Plasmid; cDNA amplified from rhesus genomic DNA with the human forward and reverse primers listed above and subcloned into pGEM-T Easy

gene 1..706 /gene="EFNB3" /note="ephrin-B3"

STS <1..>706 /gene="EFNB3"

SEQUENCE (SEQ):

```
     1 gaccgagaag gacttttccc agtcttcagt ggcacttccc aagatctccc ttcccttgtg
    61 ctctgtgctg attttaggac agctaagatg actgccatgc gctgtggcag gcccaatttg
   121 tcttgttctt tcctttccat atcccagtat aatctctgtt catcaacagt actaccccaa
   181 gaatccatgt gttctcccga gtaacccaga tggctgtctt gttcattcca tcctccattt
   241 ccgactcctt tcagactcaa catagttccc ttcttagtga ccaaaatggt ggcctactgg
   301 ctggtctagc tgacggtggt ggtatttagc aaaggccact gttcccatag tgaccagctg
   361 ataccacttc ctgccctcta gtgtgcaatt gggtgttgcc tcagtttcct cccagctcag
   421 ttttattaga tcaaagctgc tgttgggcac caggtcggcc acctcaatca ccagccaaga
   481 tggttgcttt gtccaccaga ggtcaatcac ctctctggtg ctgtagttcc cagctccttc
   541 ctgatttttc taatcgctcc ttctgggaaa caggaagttg atattgccat ggtggcgggg
   601 tatgccgtca cctcaatagt tttactgtaa aagggaaatt tgaacaacaa aaaccaaaaa
   661 aataaaaata aaaataaaaa acttcaaaag ttaacaagaa ggctgg
```

L7 ANSWER 143 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BC058617 GenBank (R)
GenBank ACC. NO. (GBN): BC058617
GenBank VERSION (VER): BC058617.1 GI:35193185
CAS REGISTRY NO. (RN): 593907-44-9
SEQUENCE LENGTH (SQL): 3135
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Rodents
DATE (DATE): 30 Jun 2004
DEFINITION (DEF): Mus musculus ***ephrin*** ***B3*** , mRNA (cDNA clone MGC:64741 IMAGE:5695418), complete cds.
KEYWORDS (ST): MGC
SOURCE: Mus musculus (house mouse)
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus

COMMENT:
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Dr. Jim Lin, University of Iowa
cDNA Library Preparation: M. Bento Soares, University of Iowa
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: University of Iowa, Dr. M. Bento Soares and Dr. Thomas L. Casavant.
Web site: http://genome.uiowa.edu
Contact: bento-soares@uiowa.edu; tom-casavant@uiowa.edu
Bonaldo,M.F., Akabogu,I., Bair,T., Bair,J., Crouch,K., Davis,A., Fishler,K., Keppel,C., Kucaba,T., Lebeck,M., Melo,A., Schaefer,K., Scheetz,T., Smith,C., Snir,E., Tack,D., Trout,K., Walters,J., Casavant,T., Soares,M.B.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: Plate: Row: Column: 0
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 24475899.

REFERENCE: 1 (bases 1 to 3135)
AUTHOR (AU): Strausberg,R.L.; Feingold,E.A.; Grouse,L.H.; Derge,J.G.; Klausner,R.D.; Collins,F.S.; Wagner,L.; Shenmen,C.M.; Schuler,G.D.; Altschul,S.F.; Zeeberg,B.; Buetow,K.H.; Schaefer,C.F.; Bhat,N.K.; Hopkins,R.F.; Jordan,H.; Moore,T.; Max,S.I.; Wang,J.; Hsieh,F.; Diatchenko,L.; Marusina,K.; Farmer,A.A.; Rubin,G.M.; Hong,L.; Stapleton,M.; Soares,M.B.; Bonaldo,M.F.; Casavant,T.L.; Scheetz,T.E.; Brownstein,M.J.; Usdin,T.B.; Toshiyuki,S.; Carninci,P.; Prange,C.; Raha,S.S.; Loquellano,N.A.; Peters,G.J.; Abramson,R.D.; Mullahy,S.J.; Bosak,S.A.; McEwan,P.J.; McKernan,K.J.; Malek,J.A.; Gunaratne,P.H.; Richards,S.; Worley,K.C.; Hale,S.; Garcia,A.M.; Gay,L.J.; Hulyk,S.W.;

Gibbs,R.A.; Fahey,J.; Helton,E.; Ketteman,M.; Madan,A.; Rodrigues,S.; Sanchez,A.; Whiting,M.; Madan,A.; Young,A.C.; Shevchenko,Y.; Bouffard,G.G.; Blakesley,R.W.; Touchman,J.W.; Green,E.D.; Dickson,M.C.; Rodriguez,A.C.; Grimwood,J.; Schmutz,J.; Myers,R.M.; Butterfield,Y.S.; Krzywinski,M.I.; Skalska,U.; Smailus,D.E.; Schnerch,A.; Schein,J.E.; Jones,S.J.; Marra,M.A.

TITLE (TI): Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

JOURNAL (SO): Proc. Natl. Acad. Sci. U.S.A., 99 (26), 16899-16903 (2002)

OTHER SOURCE (OS): CA 138:67676

REFERENCE: 2 (bases 1 to 3135)

AUTHOR (AU): Strausberg,R.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (22-SEP-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..3135 | /organism="Mus musculus"<br>/mol-type="mRNA"<br>/strain="C57BL/6"<br>/db-xref="taxon:10090"<br>/clone="MGC:64741 IMAGE:5695418"<br>/tissue-type="Brain, day 18.5pc (3-4 kb fragment)"<br>/clone-lib="NIH-BMAP-EH0p"<br>/lab-host="DH10B"<br>/note="Vector: pYX-ASC" |
| gene | 1..3135 | /gene="Efnb3"<br>/note="synonyms: Elk-L3, EFL-6, ELF-3, LERK-8, NLERK-2"<br>/db-xref="LocusID:13643"<br>/db-xref="MGI:109196" |
| CDS | 358..1380 | /gene="Efnb3"<br>/codon-start=1<br>/product="ephrin B3"<br>/protein-id="AAH58617.1"<br>/db-xref="GI:35193186"<br>/db-xref="LocusID:13643"<br>/db-xref="MGI:109196"<br>/translation="MGAPHFGPGGVQVGALLLLG<br>FAGLVSGLSLEPVYWNSANKRFQA<br>EGGYVLYPQIGDRLDLLCPRARPPGPHSSPSYEF<br>YKLYLVEGAQGRRCEAPPAPNLLL<br>TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY<br>IIATSDGTREGLESLQGGVCLTRG<br>MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH<br>SAEPGRDTIPGDPSSNATSRGAEG<br>PLPPPSMPAVAGAAGGMALLLLGVAGAGGAMCWR<br>RRRAKPSESRHPGPGSFGRGGSLG<br>LGGGGGMGPREAEPGELGIALRGGGTADPPFCPH<br>YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV" |

SEQUENCE (SEQ):

```
     1 cgaggctggg gctccagctc ggtgtctcct tcttcgctcc cttgcccggc gcctcatgtt
    61 gccccccgccc ggccctcggc tccccatgtc ccccacgtag cggggcgcac aaatcccgag
   121 gtgcggcgcg tgggccgggg gcgcgtaagg cgcctgcaga cggcccctgc aagggttctt
   181 gtggggctga gcgctctgga gccggggagc aagcatcgca gaaaagaggg tccttgtggg
   241 agctgggggt gactagccac ccaccagggt gactggggtt ccacagcgtg gtagccaccc
   301 ctgggggtga gagactttgg gggagttggt gccccgcccc caggccttgg tagggtcatg
   361 ggggcccccc attttgggcc agggggtgtg caagtcgggg ccctgctgct gttaggtttt
   421 gcggggctgg tatctggact cagcctggag cctgtctact ggaactcggc gaataagagg
   481 ttccaggcag agggcggtta cgtgctttat cctcagatcg gggaccggct agatctactt
   541 tgtccccggg ctcggcctcc tggcccccac tcctctccta gttatgagtt ctacaaactg
   601 tacctggtag agggtgccca gggtcggcgt tgtgaggcac cccctgcccc aaaccttctt
   661 ctcacatgtg accggccaga cctggacctc cgcttcacca tcaagttcca ggaatacagc
   721 cctaacctct ggggccacga gttccgatcc caccacgatt actacataat tgccacatca
   781 gacgggaccc gggaaggcct tgagagcttg caaggaggcg tgtgcctaac cagaggcatg
   841 aaggtgcttc tgcgagtggg acaaagtccc cgaggaggag ctgtaccccg aaaacctgtg
```

```
   961 accatacctg gtgacccctg ctgcaatgtc acctcccggg gtgctgaagg ccccctgccc
  1021 cctcccagca tgcccgcagt ggctggggca gcaggggtga tggcgctgct cttgctgggc
  1081 gtggcagggg ctgggggtgc catgtgttgg cggagacggc gggccaagcc ttcggagagt
  1141 cgccaccctg gtcctggctc ctttgggagg ggagggtctc tgggcctggg tggtggagga
  1201 gggatggggc ctcgggaagc tgagcctggg gagctaggaa tagccctgcg gggtggtggg
  1261 actgcagacc ccccttctg ccctcactac gagaaggtga gcggtgacta tgggcaccct
  1321 gtgtacattg tgcaggatgg gccccccccag agccctccga acatctatta caaggtatga
  1381 gggctcctcc cacctggctc tcctcaatct agccgtccat ggggtgctcc tccagtgtaa
  1441 ttcatggtat gagggacacc tgcgccatga ctttggcccc ctttgcccta ccagctcttt
  1501 ggctcctcct ggctatagcc ctcatctcca attttaggat cccttaagac ttgactacac
  1561 cttttcctga cctccccgac tgaccctcat ttgactgtgg gcactcctct gtttctgcct
  1621 cttaggggag gggggtcaca ggctcagcct cccttaatca ctacccaggt gtcctttctc
  1681 cctcacccac ccagagtggg ggtggggaca gtctgtcttt tggttggcac ctctttctgc
  1741 ctctcaccat ttttctcttc tctctatttc ttattctctc tctctcctgt gtctaggtct
  1801 gttctcttcc tcctccctag cctcctcctt acatctcctt ttaccctctc ggcttcttgt
  1861 ccttcctgtg cctctcacgt gtctcctggg ttggggcatc aaagcatctc tcctctttgc
  1921 tcttggccct ttccaacctt tcataccaac tgctcccctc tgtccgccaa aaacgggggc
  1981 ttgcgggggg tgggggggag attctggaac tctacccccc cagctccagg catgggcaca
  2041 gggcctcttt ccctgccttt ctgtgtactt actccagcca tttggggtgg ttattgggcc
  2101 acaactacta ccatgagaag aagtgtcctg ttgtggccag tggctgatag gaagacatga
  2161 agcagtgtgg acatgatgga ctgtgtctga tgccgaatgg gcatcagata ggaagtgact
  2221 cgttccagac aagaagtgac caggcctgga cagaaatggc ctgggaagtg tccgcagcag
  2281 gaactggaag tgccttcatc cagaacagga agtcgcactt ctgaaatagg aagtggtctg
  2341 gctggaattc caagtggctt agtctgggga ggtggcctgg gtgggggtgg gggcatggga
  2401 agtggatggt tcttaccctg tggagaaagg ggcaggagga actccctgct ttaggaggaa
  2461 gctggaactt accactgtga gaggacagat gtggactgag agttttctta gtgttcagtg
  2521 gcacttccca aggacccctt cccttgtgct ctgtgcagtt tttaggacag ctaagatgac
  2581 tgccacttgc tgtggcaggc ccaatttgtc ttgttctccc cttactgtac cccagtataa
  2641 tctctgttga tcaacagaac taccccaaga acccacatgt tctccccacc taaccagacg
  2701 gctgtctggc tgatgccttc ctcccttcaa gcccaacaca gcgcccttgt cagtgaagag
  2761 gtggtccatg gactggtcta gctgatggca gttattagca ctggttgctg tttccatagt
  2821 gacaagccta tacctcttcc cgctctttag tgtgcagtgg gctgctgcct cggtgttctc
  2881 ccgcctcagt tttattagat caaagctgcc cttggccatc atgttggcca cctcaatcac
  2941 cagccaaaat ggttgctttg tccaccagag gtcaagccat ctctctggcg ctgtagttcc
  3001 cagctccttc tagggaacag gaagttgata ttgccattgg ggaggtggcg gggtatggcc
  3061 gtcacctcga tagttttatt gtaaaaggga aatttgaaca acaacaaaaa aaaaaaaaaa
  3121 aaaaaaaaaa aaaaa
```

L7 ANSWER 144 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BC052001 GenBank (R)
GenBank ACC. NO. (GBN): BC052001
GenBank VERSION (VER): BC052001.1 GI:30354178
CAS REGISTRY NO. (RN): 513370-12-2
SEQUENCE LENGTH (SQL): 3039
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Rodents
DATE (DATE): 30 Jun 2004
DEFINITION (DEF): Mus musculus ***ephrin*** ***B3*** , mRNA (cDNA clone MGC:62320 IMAGE:5695429), complete cds.
KEYWORDS (ST): MGC
SOURCE: Mus musculus (house mouse)
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus

COMMENT:
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Dr. Jim Lin, University of Iowa
cDNA Library Preparation: M. Bento Soares, University of Iowa
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriquez, A., and Myers, R. M.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 114 Row: d Column: 9
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 24475899.

REFERENCE: 1 (bases 1 to 3039)
AUTHOR (AU): Strausberg,R.L.; Feingold,E.A.; Grouse,L.H.;

Sheñmen,C.M.; Schuler,G.D.; Altschul,S.F.; Žeeberg,B.; Buetow,K.H.; Schaefer,C.F.; Bhat,N.K.; Hopkins,R.F.; Jordan,H.; Moore,T.; Max,S.I.; Wang,J.; Hsieh,F.; Diatchenko,L.; Marusina,K.; Farmer,A.A.; Rubin,G.M.; Hong,L.; Stapleton,M.; Soares,M.B.; Bonaldo,M.F.; Casavant,T.L.; Scheetz,T.E.; Brownstein,M.J.; Usdin,T.B.; Toshiyuki,S.; Carninci,P.; Prange,C.; Raha,S.S.; Loquellano,N.A.; Peters,G.J.; Abramson,R.D.; Mullahy,S.J.; Bosak,S.A.; McEwan,P.J.; McKernan,K.J.; Malek,J.A.; Gunaratne,P.H.; Richards,S.; Worley,K.C.; Hale,S.; Garcia,A.M.; Gay,L.J.; Hulyk,S.W.; Villalon,D.K.; Muzny,D.M.; Sodergren,E.J.; Lu,X.; Gibbs,R.A.; Fahey,J.; Helton,E.; Ketteman,M.; Madan,A.; Rodrigues,S.; Sanchez,A.; Whiting,M.; Madan,A.; Young,A.C.; Shevchenko,Y.; Bouffard,G.G.; Blakesley,R.W.; Touchman,J.W.; Green,E.D.; Dickson,M.C.; Rodriguez,A.C.; Grimwood,J.; Schmutz,J.; Myers,R.M.; Butterfield,Y.S.; Krzywinski,M.I.; Skalska,U.; Smailus,D.E.; Schnerch,A.; Schein,J.E.; Jones,S.J.; Marra,M.A.

TITLE (TI): Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

JOURNAL (SO): Proc. Natl. Acad. Sci. U.S.A., 99 (26), 16899-16903 (2002)

OTHER SOURCE (OS): CA 138:67676

REFERENCE: 2 (bases 1 to 3039)

AUTHOR (AU): Strausberg,R.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (01-MAY-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..3039 | /organism="Mus musculus"<br>/mol-type="mRNA"<br>/strain="C57BL/6"<br>/db-xref="taxon:10090"<br>/clone="MGC:62320 IMAGE:5695429"<br>/tissue-type="Brain, day 18.5pc (3 -4 kb fragment)"<br>/clone-lib="NIH-BMAP-EH0p"<br>/lab-host="DH10B"<br>/note="Vector: pYX-ASC" |
| gene | 1..3039 | /gene="Efnb3"<br>/note="synonyms: Elk-L3, EFL-6, ELF-3, LERK-8, NLERK-2"<br>/db-xref="LocusID:13643"<br>/db-xref="MGI:109196" |
| CDS | 242..1264 | /gene="Efnb3"<br>/codon-start=1<br>/product="ephrin B3"<br>/protein-id="AAH52001.1"<br>/db-xref="GI:30354179"<br>/db-xref="LocusID:13643"<br>/db-xref="MGI:109196"<br>/translation="MGAPHFGPGGVQVGALLLLG<br>FAGLVSGLSLEPVYWNSANKRFQA<br>EGGYVLYPQIGDRLDLLCPRARPPGPHSSPSYEF<br>YKLYLVEGAQGRRCEAPPAPNLLL<br>TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY<br>IIATSDGTREGLESLQGGVCLTRG<br>MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH<br>SAEPGRDTIPGDPSSNATSRGAEG<br>PLPPPSMPAVAGAAGGMALLLLGVAGAGGAMCWR<br>RRRAKPSESRHPGPGSFGRGGSLG<br>LGGGGGMGPREAEPGELGIALRGGGTADPPFCPH<br>YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV" |

SEQUENCE (SEQ):

```
     1 cgaggtgcgg cgcgtgggcc gggggcgcgt aaggcgcctg cagacggccc ctgcaagggt
    61 tcttgtgggg ctgagcgctc tggagccggg gagcaagcat cgcagaaaag agggtccttg
   121 tgggagctgg gggtgactag ccacccacca gggtgactgg ggttccacag cgtggtagcc
```

```
   241 catgggggcc ccccatttg ggccagggg tgtgcaagtc ggggccctgc tgctgttagg
   301 ttttgcgggg ctggtatctg gactcagcct ggagcctgtc tactggaact cggcgaataa
   361 gaggttccag gcagagggcg gttacgtgct ttatcctcag atcggggacc ggctagatct
   421 actttgtccc cgggctcggc ctcctggccc ccactcctct cctagttatg agttctacaa
   481 actgtacctg gtagagggtg cccagggtcg gcgttgtgag gcacccccctg ccccaaacct
   541 tcttctcaca tgtgaccggc cagacctgga cctccgcttc accatcaagt tccaggaata
   601 cagccctaac ctctggggcc acgagttccg atcccaccac gattactaca taattgccac
   661 atcagacggg acccgggaag gccttgagag cttgcaagga ggcgtgtgcc taaccagagg
   721 catgaaggtg cttctgcgag tgggacaaag tccccgagga ggagctgtac cccgaaaacc
   781 tgtgtctgaa atgcccatgg agagagacag aggggcagct cacagcgcgg aacctgggag
   841 ggacaccata ccaggtgacc ccagcagcaa tgcaacctcc cggggtgctg aaggcccccc
   901 gccccctccc agcatgcccg cagtggctgg ggcagcaggg gggatggcgc tgctcttgct
   961 gggcgtggca ggggctgggg gtgccatgtg ttggcggaga cggcgggcca agccttcgga
  1021 gagtcgccac cctggtcctg gctcctttgg gaggggaggg tctctgggcc tgggtggtgg
  1081 aggagggatg gggcctcggg aagctgagcc tggggagcta ggaatagccc tgcggggtgg
  1141 tgggactgca gacccccccc tctgccctca ctacgagaag gtgagcggtg actatgggca
  1201 ccctgtgtac attgtgcagg atgggccccc ccagagccct ccgaacatct attacaaggt
  1261 atgagggctc ctcccacctg gctctcctca atctagccgt ccatggggtg ctcctccagt
  1321 gtaattcatg gtatgaggga cacctgcgcc atgactttgg ccccctttgc cctaccagct
  1381 ctttggctcc tcctggctat agccctcatc tccaatttta ggatccctta agacttgact
  1441 acacctttc ctgacctccc cgactgaccc tcatttgact gtgggcactc ctctgtttct
  1501 gcctcttagg ggaggggggt cacaggctca gcctccctta atcactaccc aggtgtcctt
  1561 tctccctcac ccacccagag tgggggtggg gacagtctgt cttttggttg gcacctcttt
  1621 ctgcctctca ccatttttct cttctctcta tttcttattc tctctctctc ctgtgtctag
  1681 gtctgttctc ttcctcctcc ctagcctcct ccttacatct ccttttaccc tctcggcttc
  1741 ttgtccttcc tgtgcctctc acgtgtctcc tgggttgggg catcaaagca tctctcctct
  1801 ttgctcttgg ccctttccaa cctttcatac caactgctcc cctctgtccg ccaaaaacgg
  1861 gggcttgcgg ggggtggggg ggagattctg gaactctacc cccccagctc caggcatggg
  1921 cacagggcct ctttccctgc ctttctgtgt acttactcca gccatttggg gtggttattg
  1981 ggccacaact actaccatga gaagaagtgt cctgttgtgg ccagtggctg ataggaagac
  2041 atgaagcagt gtggacatga tggactgtgt ctgatgccga atgggcatca gataggaagt
  2101 gactcgttcc agacaagaag tgaccaggcc tggacagaaa tggcctggga agtgtccgca
  2161 gcaggaactg gaagtgcctt catccagaac aggaagtcgc acttctgaaa taggaagtgg
  2221 tctggctgga attccaagtg gcttagtctg gggaggtggc ctgggtgggg gtgggggcat
  2281 gggaagtgga tggttcttac cctgtggaga aaggggcagg aggaactccc tgctttagga
  2341 ggaagctgga acttaccact gtgagaggac agatgtggac tgagagtttt cttagtgttc
  2401 agtggcactt cccaaggacc ccttcccttg tgctctgtgc agtttttagg acagctaaga
  2461 tgactgccac ttgctgtggc aggcccaatt tgtcttgttc tcccccttact gtaccccagt
  2521 ataatctctg ttgatcaaca gaactacccc aagaacccac atgttctccc cacctaacca
  2581 gacggctgtc tggctgatgc cttcctccct tcaagcccaa cacagcgccc ttgtcagtga
  2641 agaggtggtc catggactgg tctagctgat ggcagttatt agcactggtt gctgtttcca
  2701 tagtgacaag cctatacctc ttcccgctct ttagtgtgca gtgggctgct gcctcggtgt
  2761 tctcccgcct cagttttatt agatcaaagc tgcccttggc catcatgttg gccacctcaa
  2821 tcaccagcca aaatggttgc tttgtccacc agaggtcaag ccatctctct ggcgctgtag
  2881 ttcccagctc cttctaggga acaggaagtt gatattgcca ttggggaggt ggcggggtat
  2941 ggccgtcacc tcgatagttt tattgtaaaa gggaaatttg aacaacaaca aaaaaactga
  3001 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa
```

L7 ANSWER 145 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AX671064 GenBank (R)
GenBank ACC. NO. (GBN): AX671064
GenBank VERSION (VER): AX671064.1 GI:29329529
CAS REGISTRY NO. (RN): 504048-07-1
SEQUENCE LENGTH (SQL): 1023
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 27 Mar 2003
DEFINITION (DEF): Sequence 19 from Patent WO03004529.
SOURCE: Mus musculus (house mouse)
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Rodentia;
Sciurognathi; Muridae; Murinae; Mus
NUCLEIC ACID COUNT (NA): 191 a 296 c 341 g 195 t
REFERENCE: 1
AUTHOR (AU): Alitalo,K.; Kubo,H.
TITLE (TI): Ephrin-tie receptor materials and methods
JOURNAL (SO): Patent: WO 03004529-A 19 16-JAN-2003; Licentia Ltd. (FI)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..1023 | /organism="Mus musculus" |

CDS 1..1023 /note="unnamed protein product; ephrin-B3"
/codon-start=1
/protein-id="CAD83766.1"
/db-xref="GI:29329530"
/translation="MGAPHFGPGGVQVGALLLLG
FAGLVSGLSLEPVYWNSANKRFQA
EGGYVLYPQIGDRLDLLCPRARPPGPHSSPSYEF
YKLYLVEGAQGRRCEAPPAPNLLL
TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY
IIATSDGTREGLESLQGGVCLTRG
MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH
SAEPGRDTIPGDPSSNATSRGAEG
PLPPPSMPAVAGAAGGMALLLLGVAGAGGAMCWR
RRRAKPSESRHPGPGSFGRGGSLG
LGGGGGMGPREAEPGELGIALRGGGTADPPFCPH
YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV"

SEQUENCE (SEQ):

```
     1 atgggggccc cccattttgg gccagggggt gtgcaagtcg gggccctgct gctgttaggt
    61 tttgcggggc tggtatctgg actcagcctg gagcctgtct actggaactc ggcgaataag
   121 aggttccagg cagagggcgg ttacgtgctt tatcctcaga tcggggaccg gctagatcta
   181 ctttgtcccc gggctcggcc tcctggcccc cactcctctc ctagttatga gttctacaaa
   241 ctgtacctgg tagagggtgc ccagggtcgg cgttgtgagg cacccccctgc cccaaacctt
   301 cttctcacat gtgaccggcc agacctggac ctccgcttca ccatcaagtt ccaggaatac
   361 agccctaacc tctggggcca cgagttccga tcccaccacg attactacat aattgccaca
   421 tcagacggga cccgggaagg ccttgagagc ttgcaaggag gcgtgtgcct aaccagaggc
   481 atgaaggtgc ttctgcgagt gggacaaagt ccccgaggag gagctgtacc ccgaaaacct
   541 gtgtctgaaa tgcccatgga gagagacaga ggggcagctc acagcgcgga acctgggagg
   601 gacaccatac caggtgaccc cagcagcaat gcaacctccc ggggtgctga aggccccctg
   661 ccccctccca gcatgcccgc agtggctggg gcagcagggg ggatggcgct gctcttgctg
   721 ggcgtggcag gggctggggg tgccatgtgt tggcggagac ggcgggccaa gccttcggag
   781 agtcgccacc ctggtcctgg ctcctttggg aggggagggt ctctgggcct gggtggtgga
   841 ggagggatgg ggcctcggga agctgagcct ggggagctag gaatagccct gcggggtggt
   901 gggactgcag acccccccctt ctgccctcac tacgagaagg tgagcggtga ctatgggcac
   961 cctgtgtaca ttgtgcagga tgggcccccc cagagccctc cgaacatcta ttacaaggta
  1021 tga
```

L7 ANSWER 146 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AX671062 GenBank (R)
GenBank ACC. NO. (GBN): AX671062
GenBank VERSION (VER): AX671062.1 GI:29329527
CAS REGISTRY NO. (RN): 504048-06-0
SEQUENCE LENGTH (SQL): 2987
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 27 Mar 2003
DEFINITION (DEF): Sequence 17 from Patent WO03004529.
SOURCE: Homo sapiens (human)
ORGANISM (ORGN): Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo
NUCLEIC ACID COUNT (NA): 529 a 886 c 864 g 708 t
REFERENCE: 1
AUTHOR (AU): Alitalo,K.; Kubo,H.
TITLE (TI): Ephrin-tie receptor materials and methods
JOURNAL (SO): Patent: WO 03004529-A 17 16-JAN-2003; Licentia Ltd. (FI)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..2987 | /organism="Homo sapiens"<br>/db-xref="taxon:9606" |
| CDS | 214..1236 | /note="unnamed protein product; ephrin-B3"<br>/codon-start=1<br>/protein-id="CAD83765.1"<br>/db-xref="GI:29329528"<br>/translation="MGPPHSGPGGVRVGALLLLG<br>VLGLVSGLSLEPVYWNSANKRFQA<br>EGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEF<br>YKLYLVGGAQGRRCEAPPAPNLLL |

IIATSDGTREGLESLQGGVCLTRG
MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH
SLEPGKENLPGDPTSNATSRGAEG
PLPPPSMPAVAGAAGGLALLLLGVAGAGGAMCWR
RRRAKPSESRHPGPGSFGRGGSLG
LGGGGGMGPREAEPGELGIALRGGGAADPPFCPH
YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV"

SEQUENCE (SEQ):

```
      1 ggcgcctgca gacggcccct ggaagggctc tggtggggct gagcgctctg ccgcgggggc
     61 gcgggcacag caggaagcag gtccgcgtgg gcgctggggg catcagctac cggggtggtc
    121 cgggctgaag agccaggcag ccaaggcagc caccccgggg ggtgggcgac tttgggggag
    181 ttggtgcccc gccccccagg ccttggcggg gtcatggggc ccccccattc tgggccgggg
    241 ggcgtgcgag tcggggccct gctgctgctg ggggttttgg ggctggtgtc tgggctcagc
    301 ctggagcctg tctactggaa ctcggcgaat aagaggttcc aggcagaggg tggttatgtg
    361 ctgtaccctc agatcgggga ccggctagac ctgctctgcc cccgggcccg gcctcctggc
    421 cctcactcct ctcctaatta tgagttctac aagctgtacc tggtaggggg tgctcagggc
    481 cggcgctgtg aggcaccccc tgccccaaac ctccttctca cttgtgatcg cccagacctg
    541 gatctccgct tcaccatcaa gttccaggag tatagcccta atctctgggg ccacgagttc
    601 cgctcgcacc acgattacta catcattgcc acatcggatg ggacccggga gggcctggag
    661 agcctgcagg gaggtgtgtg cctaaccaga ggcatgaagg tgcttctccg agtgggacaa
    721 agtccccgag gaggggctgt cccccgaaaa cctgtgtctg aaatgcccat ggaaagagac
    781 cgaggggcag cccacagcct ggagcctggg aaggagaacc tgccaggtga ccccaccagc
    841 aatgcaacct cccggggtgc tgaaggcccc ctgccccctc ccagcatgcc tgcagtggct
    901 ggggcagcag gggggctggc gctgctcttg ctgggcgtgg caggggctgg gggtgccatg
    961 tgttggcgga gacggcgggc caagccttcg gagagtcgcc accctggtcc tggctccttc
   1021 gggaggggag ggtctctggg cctggggggt ggaggtggga tgggacctcg ggaggctgag
   1081 cctggggagc tagggatagc tctgcggggt ggcggggctg cagatccccc cttctgcccc
   1141 cactatgaga aggtgagtgg tgactatggg catcctgtgt atatcgtgca ggatgggccc
   1201 ccccagagcc ctccaaacat ctactacaag gtatgagggc tcctctcacg tggctatcct
   1261 gaatccagcc cttcttgggg tgctcctcca gtttaattcc tggtttgagg gacacctcta
   1321 acatctcggc cccctgtgcc cccccagccc cttcactcct cccggctgct gtcctcgtct
   1381 ccacttttag gattccttag gattcccact gccccacttc ctgccctccc gtttggccat
   1441 gggtgccccc ctctgtctca gtgtccctgg atccttttc cttggggagg ggcacaggct
   1501 cagcctcctc tctgaccatg acccaggcat ccttgtcccc ctcacccacc cagagctagg
   1561 ggcgggaaca gcccaccttt tggttggcac cgccttcttt ctgcctctca ctggttttct
   1621 cttctctatc tcttattctt tccctctctt ccgtctctag gtctgttctt cttccctagc
   1681 atcctcctcc ccacatctcc tttcaccctc ttggcttctt atcctgtgcc tctcccatct
   1741 cctgggtggg ggcatcaaag catttctccc cttagctttc agccccccct ctgacctctc
   1801 ataccaacca ctccccctcag tctgccaaaa atgggggcct tatggggaag gctctgacac
   1861 tccaccccag ctcaggccat gggcagcagg gctccattct ctggcctggc ccaggcctct
   1921 acatacttac tccagccatt tggggtggtt gggtcatgac agctaccatg agaagaagtg
   1981 tcccgttttg tccagtggcc aatagcaaga tatgaaccgg tcgggacatg tatggacttg
   2041 gtctgatgct gaatgggcca cttgggaccg gaagtgactt gctccagaca agaggtgacc
   2101 aggcccggac agaaatggcc tgggaagtag cagaagcagt gcagcaggaa ctggaagtgc
   2161 cttcatccag gacaggaagt agcacttctg aaacaggaag tggtctggct ggaactccaa
   2221 gtggcttagt ctgggggatc aggaggtggg aggtggatgg ttcttattct gtggagaaga
   2281 agggcgggaa gaacttcctt tcaggaggaa gctggaactt actgactgta agaggttaga
   2341 ggtggaccga gaaggacttt tcccagtctt cagtggcact tcccaagatc tcccttccct
   2401 tgtgctctgt gctgatttta ggacagctaa gatgactgcc atgtgctgtg gcaggcctaa
   2461 tttgtcttgt tcttttcttt ccatatccca gtataatctc tgttaatcaa caggactacc
   2521 ccaagaaccc atgtgctctc ccgagtaacc cagatggctg tcttgttcat tccatcctac
   2581 atttctgact cctttcagac tcaacacagt tcccttctta gtgaccaaaa tggtggccta
   2641 ctggctggtc tagctgacag tggtacttag caaaggccac tgtttccata gtgaccagct
   2701 gatacctctt cctgccctct agtgtgcaat tgggtgttgc ctcagtttcc tcccagctca
   2761 gttttattag atccaaagctg ttgttgggca ccaggttggc cacctcaatc accagccaag
   2821 atggttgctt tgtccaccag aggtcaagtt cacctctctg gtgctgtagt tcccagctcc
   2881 ttcctgattt ttctaatcgc tccttctggg gaacaggaag ttgatattgc catggtggcg
   2941 gggtatgccg tcacctcagt agttttactg taaaagggaa atttgaa
```

L7 ANSWER 147 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BC042944 GenBank (R)
GenBank ACC. NO. (GBN): BC042944
GenBank VERSION (VER): BC042944.2 GI:34193522
CAS REGISTRY NO. (RN): 495664-88-5
SEQUENCE LENGTH (SQL): 2338
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Primates
DATE (DATE): 30 Jun 2004
DEFINITION (DEF): Homo sapiens ***ephrin*** - ***B3*** , mRNA (cDNA clone MGC:41892 IMAGE:5286243), complete cds.
KEYWORDS (ST): MGC
SOURCE: Homo sapiens (human)
ORGANISM (ORGN): Homo sapiens

Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo

COMMENT:
On Aug 25, 2003 this sequence version replaced gi:27696534.
Contact: MGC help desk
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Miklos Palkovits, M.D., Ph.D.
cDNA Library Preparation: Michael J. Brownstein (NHGRI) & Shiraki Toshiyuki and Piero Carninci (RIKEN)
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Genome Sequence Centre,
BC Cancer Agency, Vancouver, BC, Canada
info@bcgsc.bc.ca
Steve Jones, Sarah Barber, Mabel Brown-John, Yaron Butterfield, Andy Chan, Steve S. Chand, William Chow, Alison Cloutier, Ruth Featherstone, Malachi Griffith, Obi Griffith, Ran Guin, Nancy Liao, Kim MacDonald, Amara Masson, Mike R. Mayo, Josh Moran, Ryan Morin, Teika Olson, Diana Palmquist, Anca Petrescu, Anna Liisa Prahbu, Parvaneh Saeedi, JR Santos, Angelique Schnerch, Ursula Skalska, Duane Smailus, Jeff Stott, Miranda Tsai, George Yang, Jacquie Schein, Asim Siddiqui, Rob Holt, Marco Marra.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAK Plate: 76 Row: a Column: 9
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 27894382.

REFERENCE: 1 (bases 1 to 2338)
AUTHOR (AU): Strausberg,R.L.; Feingold,E.A.; Grouse,L.H.; Derge,J.G.; Klausner,R.D.; Collins,F.S.; Wagner,L.; Shenmen,C.M.; Schuler,G.D.; Altschul,S.F.; Zeeberg,B.; Buetow,K.H.; Schaefer,C.F.; Bhat,N.K.; Hopkins,R.F.; Jordan,H.; Moore,T.; Max,S.I.; Wang,J.; Hsieh,F.; Diatchenko,L.; Marusina,K.; Farmer,A.A.; Rubin,G.M.; Hong,L.; Stapleton,M.; Soares,M.B.; Bonaldo,M.F.; Casavant,T.L.; Scheetz,T.E.; Brownstein,M.J.; Usdin,T.B.; Toshiyuki,S.; Carninci,P.; Prange,C.; Raha,S.S.; Loquellano,N.A.; Peters,G.J.; Abramson,R.D.; Mullahy,S.J.; Bosak,S.A.; McEwan,P.J.; McKernan,K.J.; Malek,J.A.; Gunaratne,P.H.; Richards,S.; Worley,K.C.; Hale,S.; Garcia,A.M.; Gay,L.J.; Hulyk,S.W.; Villalon,D.K.; Muzny,D.M.; Sodergren,E.J.; Lu,X.; Gibbs,R.A.; Fahey,J.; Helton,E.; Ketteman,M.; Madan,A.; Rodrigues,S.; Sanchez,A.; Whiting,M.; Madan,A.; Young,A.C.; Shevchenko,Y.; Bouffard,G.G.; Blakesley,R.W.; Touchman,J.W.; Green,E.D.; Dickson,M.C.; Rodriguez,A.C.; Grimwood,J.; Schmutz,J.; Myers,R.M.; Butterfield,Y.S.; Krzywinski,M.I.; Skalska,U.; Smailus,D.E.; Schnerch,A.; Schein,J.E.; Jones,S.J.; Marra,M.A.
TITLE (TI): Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
JOURNAL (SO): Proc. Natl. Acad. Sci. U.S.A., 99 (26), 16899-16903 (2002)
OTHER SOURCE (OS): CA 138:67676

REFERENCE: 2 (bases 1 to 2338)
AUTHOR (AU): Strausberg,R.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (09-JAN-2003) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..2338 | /organism="Homo sapiens"<br>/mol-type="mRNA"<br>/db-xref="taxon:9606"<br>/clone="MGC:41892 IMAGE:5286243"<br>/tissue-type="Brain, hypothalamus"<br>/clone-lib="NIH-MGC-96"<br>/lab-host="DH10B"<br>/note="Vector: pBluescript" |
| gene | 1..2338 | /gene="EFNB3"<br>/note="synonyms: LERK8, EFL6, |

CDS 398..1420

/db-xref="LocusID:1949"
/db-xref="MIM:602297"
/gene="EFNB3"
/codon-start=1
/product="ephrin-B3, precursor"
/protein-id="AAH42944.1"
/db-xref="GI:27696535"
/db-xref="LocusID:1949"
/db-xref="MIM:602297"
/translation="MGPPHSGPGGVRVGALLLLG
VLGLVSGLSLEPVYWNSANKRFQA
EGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEF
YKLYLVGGAQGRRCEAPPAPNLLL
TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY
IIATSDGTREGLESLQGGVCLTRG
MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH
SLEPGKENLPGDPTSNATSRGAEG
PLPPPSMPAVAGAAGGLALLLLGVAGAGGAMCWR
RRRAKPSESRHPGPGSFGRGGSLG
LGGGGGMGPREAEPGELGIALRGGGAADPPFCPH
YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV"

SEQUENCE (SEQ):

```
     1 ggttttctcc cttagcccgc tgccctcaat cccagcgagg ctggggctcc ggctcggcgc
    61 ccccttcctc gctccctggt ccggcgcccc atgccgcccc cgcccggtcc ccggctccac
   121 cagtccccca cttaggcggg ctcacagatc ccggggtgct ggcgcgtggg ccgggggcgc
   181 gtagggcgcc tgcagacggc ccctggaagg gctctggtgg ggctgagcgc tctgccgcgg
   241 gggcgcgggc acagcaggaa gcaggtccgc gtgggcgctg ggggcatcag ctaccggggt
   301 ggtccgggct gaagagccag gcagccaagg cagccacccc gggggggtggg cgactttggg
   361 ggagttggtg ccccgccccc caggccttgg cggggtcatg gggcccccccc attctgggcc
   421 gggggggcgtg cgagtcgggg ccctgctgct gctgggggtt ttggggctgg tgtctgggct
   481 cagcctggag cctgtctact ggaactcggc gaataagagg ttccaggcag agggtggtta
   541 tgtgctgtac cctcagatcg gggaccggct agacctgctc tgccccaggg cccggcctcc
   601 tggccctcac tcctctccta attatgagtt ctacaagctg tacctggtag ggggtgctca
   661 gggccggcgc tgtgaggcac cccctgcccc aaacctcctt ctcacttgtg atcgcccaga
   721 cctggatctc cgcttcacca tcaagttcca ggagtatagc cctaatctct ggggccacga
   781 gttccgctcg caccacgatt actacatcat tgccacatcg gatgggaccc gggagggcct
   841 ggagagcctg cagggaggtg tgtgcctaac cagaggcatg aaggtgcttc tccgagtggg
   901 acaaagtccc cgaggagggg ctgtcccccg aaaacctgtg tctgaaatgc ccatggaaag
   961 agaccgaggg gcagcccaca gcctggagcc tgggaaggag aacctgccag gtgaccccac
  1021 cagcaatgca acctcccggg gtgctgaagg ccccctgccc cctcccagca tgcctgcagt
  1081 ggctggggca gcaggggggc tggcgctgct cttgctgggc gtggcagggg ctgggggtgc
  1141 catgtgttgg cggagacggc gggccaagcc ttcggagagt cgccaccctg gtcctggctc
  1201 cttcgggagg ggagggtctc tgggcctggg gggtggaggt gggatgggac ctcgggaggc
  1261 tgagcctggg gagctaggga tagctctgcg gggtggcggg gctgcagatc ccccccttctg
  1321 cccccactat gagaaggtga gtggtgacta tgggcatcct gtgtatatcg tgcaggatgg
  1381 gcccccgcag agccctccaa acatctacta caaggtatga gggctcctct cacgtggcta
  1441 tcctgaatcc agcccttctt ggggtgctcc tccagtttaa ttcctggttt gagggacacc
  1501 tctaacatct cggcccccctg tgcccccccca gcccccttcac tcctcccggc tgctgtcctc
  1561 gtctccactt ttaggattcc ttaggattcc cactgcccca cttcctgccc tcccgtttgg
  1621 ccatgggtgc ccccctctgt ctcagtgtcc ctggatcctt tttccttggg gaggggcaca
  1681 ggctcagcct cctctctgac catgacccag gcatccttgt ccccctcacc cacccagagc
  1741 taggggcggg aacagcccac cttttggttg gcaccgcctt ctttctgcct ctcactggtt
  1801 ttctcttctc tatctcttat tctttccctc tcttccgtct ctaggtctgt tcttcttccc
  1861 tagcatcctc ctccccacat ctcctttcac cctcttggct tcttatcctg tgcctctccc
  1921 atctcctggg tgggggcatc aaagccatttc tcccccttagc tttcagcccc ccttctgacc
  1981 tctcatacca accactcccc tcagtctgcc aaaaatgggg gccttatggg gaaggctctg
  2041 acactccacc ccagctcagg ccatgggcag cagggctcca ttctctggcc tggcccaggc
  2101 ctctacatac ttactccagc catttggggt ggttgggtca tgacagctac catgagaaga
  2161 agtgtcccgt tttgtccagt ggccaatagc aagatatgaa ccggtcggga catgtatgga
  2221 cttggtctga tgccgaatgg gccacttggg accggaagtg actttctcca gacaagaggt
  2281 gaccaggccc ggacagaaat ggcctgggaa gtagcagaag agaaaaaaaa aaaaaaaa
```

L7 ANSWER 148 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AX578105 GenBank (R)
GenBank ACC. NO. (GBN): AX578105
GenBank VERSION (VER): AX578105.1 GI:27647313
CAS REGISTRY NO. (RN): 495565-98-5
SEQUENCE LENGTH (SQL): 3394
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Patent
DATE (DATE): 8 Jan 2003
DEFINITION (DEF): Sequence 227 from Patent WO02081745.
SOURCE: Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo

NUCLEIC ACID COUNT (NA): 625 a 949 c 945 g 875 t

REFERENCE: 1

AUTHOR (AU): Garcia,T.; roman Roman,S.; Baron,R.; Call,K.; Theilhaber,J.; Connolly,T.; Jackson,A.; Bushnell,S.E.; Rawadi,G.

TITLE (TI): Genes involved in osteogenesis, and methods of use

JOURNAL (SO): Patent: WO 02081745-A 227 17-OCT-2002; Aventis Pharma S.A. (FR)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..3394 | /organism="Homo sapiens"<br>/db-xref="taxon:9606"<br>/note="Homo sapiens ephrin-B3 (EFNB3), mRNA" |

SEQUENCE (SEQ):

```
     1 gaattccgac ttgttttgtg gtctaacata tggtctatgc tgcagaatgg tccatgtgct
    61 gatgagaaga atgtatattc tgcagctgtt ggaagaaagg gtctgtaaat gtctgttagg
   121 tccatttggt ctataatgca gattaagtct gatgtttctt tctagatgat ctgcccaata
   181 ctgaaagtga ggcattaaaa tcccctgcct ttttttgtat taggatctgc ctctctcttt
   241 agctctaata gtgtttgttt atacatgtga gtactttggt attgggtgca tatatattta
   301 aaattgttac atccttttgc tgaattgatc ccttttttcat tatgtaatga tcttctttgt
   361 ccctttttat gttttctgac ttagtctatt atgaataagt ggcgcctgca gacggccccc
   421 ggaagggctc tggtggggct gagcgctctg ccgcgggggc gcgggcacag caggaagcag
   481 gtccgcgtgg gcgctggggg catcagctac cggggtggtc cgggctgaag agccaggcag
   541 ccaaggcagc caccccgggg ggtgggcgac tttgggggag ttggtgcccc gccccccagg
   601 ccttggcggg gtcatggggc ccccccattc tgggccgggg ggcgtgcgag tcggggccct
   661 gctgctgctg ggggttttgg ggctggtgtc tgggctcagc ctggagcctg tctactggaa
   721 ctcggcgaat aagaggttcc aggcagaggg tggttatgtg ctgtaccctc agatcgggga
   781 ccggctagac ctgctctgcc cccgggcccg gcctcctggc cctcactcct ctcctaatta
   841 tgagttctac aagctgtacc tggtaggggg tgctcagggc cggcgctgtg aggcaccccc
   901 tgccccaaac ctccttctca cttgtgatcg cccagacctg gatctccgct tcaccatcaa
   961 gttccaggag tatagcccta atctctgggg ccacgagttc cgctcgcacc acgattacta
  1021 catcattgcc acatcggatg ggacccggga gggcctggag agcctgcagg gaggtgtgtg
  1081 cctaaccaga ggcatgaagg tgcttctccg agtgggacaa agtccccgag gaggggctgt
  1141 cccccgaaaa cctgtgtctg aaatgcccat ggaaagagac cgaggggcag cccacagcct
  1201 ggagcctggg aaggagaacc tgccaggtga ccccaccagc aatgcaacct cccggggtgc
  1261 tgaaggcccc ctgccccctc ccagcatgcc tgcagtggct ggggcagcag gggggctggc
  1321 gctgctcttg ctgggcgtgg caggggctgg gggtgccatg tgttggcgga gacggcgggc
  1381 caagccttcg gagagtcgcc accctggtcc tggctccttc gggaggggag ggtctctggg
  1441 cctggggggt ggaggtggga tgggacctcg ggaggctgag cctggggagc tagggatagc
  1501 tctgcggggt ggcggggctg cagatccccc cttctgcccc cactatgaga aggtgagtgg
  1561 tgactatggg catcctgtgt atatcgtgca ggatgggccc ccccagagcc ctccaaacat
  1621 ctactacaag gtatgagggc tcctctcacg tggctatcct gaatccagcc cttcttgggg
  1681 tgctcctcca gtttaattcc tggtttgagg gacacctcta acatctcggc cccctgtgcc
  1741 cccccagccc cttcactcct cccggctgct gtcctcgtct ccacttttag gattccttag
  1801 gattcccact gccccacttc ctgccctccc gtttggccat gggtgccccc ctctgtctca
  1861 gtgtccctgg atccttttc cttggggagg ggcacaggct cagcctcctc tctgaccatg
  1921 acccaggcat ccttgtcccc ctcacccacc cagagctagg ggcgggaaca gcccaccttt
  1981 tggttggcac cgccttcttt ctgcctctca ctggttttct cttctctatc tcttattctt
  2041 tccctctctt ccgtctctag gtctgttctt cttccctagc atcctcctcc ccacatctcc
  2101 tttcaccctc ttggcttctt atcctgtgcc tctcccatct cctgggtggg ggcatcaaag
  2161 catttctccc cttagctttc agccccccctt ctgacctctc ataccaacca ctcccctcag
  2221 tctgccaaaa atgggggcct tatggggaag gctctgacac tccaccccag ctcaggccat
  2281 gggcagcagg gctccattct ctggcctggc ccaggcctct acatacttac tccagccatt
  2341 tggggtggtt gggtcatgac agctaccatg agaagaagtg tcccgttttg tccagtggcc
  2401 aatagcaaga tatgaaccgg tcgggacatg tatggacttg gtctgatgct gaatgggcca
  2461 cttgggaccg gaagtgactt gctccagaca agaggtgacc aggcccggac agaaatggcc
  2521 tgggaagtag cagaagcagt gcagcaggaa ctggaagtgc cttcatccag gacaggaagt
  2581 agcacttctg aaacaggaag tggtctggct ggaactccaa gtggcttagt ctgggggatc
  2641 aggaggtggg aggtggatgg ttcttattct gtggagaaga agggcgggaa gaacttcctt
  2701 tcaggaggaa gctggaactt actgactgta agaggttaga ggtggaccga gaaggacttt
  2761 tcccagtctt cagtggcact tcccaagatc tcccttccct tgtgctctgt gctgatttta
  2821 ggacagctaa gatgactgcc atgtgctgtg gcaggcctaa tttgtcttgt tctttccttt
  2881 ccatatccca gtataatctc tgttaatcaa caggactacc ccaagaaccc atgtgctctc
  2941 ccgagtaacc cagatggctg tcttgttcat tccatcctac atttctgact cctttcagac
  3001 tcaacacagt tcccttctta gtgaccaaaa tggtggccta ctggctggtc tagctgacag
  3061 tggtacttag caaaggccac tgtttccata gtgaccagct gatacctctt cctgccctct
  3121 agtgtgcaat tgggtgttgc ctcagtttcc tcccagctca gttttattag atcaaagctg
  3181 ttgttgggca ccaggttggc cacctcaatc accagccaag atggttgctt tgtccaccag
```

3301 tcctttctggg gaacaggaag ttgatattgc catggtggcg gggtatgccg tcacctcagt
3361 agttttactg taaaagggaa atttgaagga attc

L7 ANSWER 149 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AK048305 GenBank (R)
GenBank ACC. NO. (GBN): AK048305
GenBank VERSION (VER): AK048305.1 GI:26339255
CAS REGISTRY NO. (RN): 492920-48-6
SEQUENCE LENGTH (SQL): 3126
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): High-Throughput CDNA Sequencing
DATE (DATE): 3 Apr 2004
DEFINITION (DEF): Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130048B01 product:m- ***ephrin*** - ***B3*** mRNA, full insert sequence.
KEYWORDS (ST): HTC; CAP trapper
SOURCE: Mus musculus (house mouse)
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus

COMMENT:
cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.
Please visit our web site for further details.
URL:http://genome.gsc.riken.jp/
URL:http://fantom.gsc.riken.jp/.

REFERENCE: 1
AUTHOR (AU): Carninci,P.; Hayashizaki,Y.
TITLE (TI): High-efficiency full-length cDNA cloning
JOURNAL (SO): Meth. Enzymol., 303, 19-44 (1999)
OTHER SOURCE (OS): CA 131:318304

REFERENCE: 2
AUTHOR (AU): Carninci,P.; Shibata,Y.; Hayatsu,N.; Sugahara,Y.; Shibata,K.; Itoh,M.; Konno,H.; Okazaki,Y.; Muramatsu,M.; Hayashizaki,Y.
TITLE (TI): Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
JOURNAL (SO): Genome Res., 10 (10), 1617-1630 (2000)
OTHER SOURCE (OS): CA 134:305920

REFERENCE: 3
AUTHOR (AU): Shibata,K.; Itoh,M.; Aizawa,K.; Nagaoka,S.; Sasaki,N.; Carninci,P.; Konno,H.; Akiyama,J.; Nishi,K.; Kitsunai,T.; Tashiro,H.; Itoh,M.; Sumi,N.; Ishii,Y.; Nakamura,S.; Hazama,M.; Nishine,T.; Harada,A.; Yamamoto,R.; Matsumoto,H.; Sakaguchi,S.; Ikegami,T.; Kashiwagi,K.; Fujiwake,S.; Inoue,K.; Togawa,Y.; Izawa,M.; Ohara,E.; Watahiki,M.; Yoneda,Y.; Ishikawa,T.; Ozawa,K.; Tanaka,T.; Matsuura,S.; Kawai,J.; Okazaki,Y.; Muramatsu,M.; Inoue,Y.; Kira,A.; Hayashizaki,Y.
TITLE (TI): RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer
JOURNAL (SO): Genome Res., 10 (11), 1757-1771 (2000)

REFERENCE: 4
AUTHOR (AU): The RIKEN Genome Exploration Research Group Phase II Team; the FANTOM Consortium.
TITLE (TI): Functional annotation of a full-length mouse cDNA collection
JOURNAL (SO): Nature, 409, 685-690 (2001)
OTHER SOURCE (OS): CA 134:203311

REFERENCE: 5
AUTHOR (AU): The FANTOM Consortium; the RIKEN Genome Exploration Research Group Phase I & II Team.
TITLE (TI): Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
JOURNAL (SO): Nature, 420, 563-573 (2002)
OTHER SOURCE (OS): CA 138:131939

AUTHOR (AU): Adachi,J.; Aizawa,K.; Akimura,T.; Arakawa,T.; Bono,H.; Carninci,P.; Fukuda,S.; Furuno,M.; Hanagaki,T.; Hara,A.; Hashizume,W.; Hayashida,K.; Hayatsu,N.; Hiramoto,K.; Hiraoka,T.; Hirozane,T.; Hori,F.; Imotani,K.; Ishii,Y.; Itoh,M.; Kagawa,I.; Kasukawa,T.; Katoh,H.; Kawai,J.; Kojima,Y.; Kondo,S.; Konno,H.; Kouda,M.; Koya,S.; Kurihara,C.; Matsuyama,T.; Miyazaki,A.; Murata,M.; Nakamura,M.; Nishi,K.; Nomura,K.; Numazaki,R.; Ohno,M.; Ohsato,N.; Okazaki,Y.; Saito,R.; Saitoh,H.; Sakai,C.; Sakai,K.; Sakazume,N.; Sano,H.; Sasaki,D.; Shibata,K.; Shinagawa,A.; Shiraki,T.; Sogabe,Y.; Tagami,M.; Tagawa,A.; Takahashi,F.; Takaku-Akahira,S.; Takeda,Y.; Tanaka,T.; Tomaru,A.; Toya,T.; Yasunishi,A.; Muramatsu,M.; Hayashizaki,Y.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail:genome-res@gsc.riken.jp, URL:http://genome.gsc.riken.jp/, Tel:81-45-503-9222, Fax:81-45-503-9216)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..3126 | /organism="Mus musculus"<br>/mol-type="mRNA"<br>/strain="C57BL/6J"<br>/db-xref="FANTOM-DB:C130048B01"<br>/db-xref="taxon:10090"<br>/clone="C130048B01"<br>/tissue-type="head"<br>/clone-lib="RIKEN full-length enriched mouse cDNA library"<br>/dev-stage="16 days embryo" |
| CDS | 369..1391 | /note="unnamed protein product; m-ephrin-B3 mRNA (GB\|AF025288, evidence: BLASTN, 99%, match=1077) putative"<br>/codon-start=1<br>/protein-id="BAC33299.1"<br>/db-xref="GI:26339256"<br>/translation="MGAPHFGPGGVQVGALLLLG<br>FAGLVSGLSLEPVYWNSANKRFQA<br>EGGYVLYPQIGDRLDLLCPRARPPGPHSSPSYEF<br>YKLYLVEGAQGRRCEAPPAPNLLL<br>TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY<br>IIATSDGTREGLESLQGGVCLTRG<br>MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH<br>SAEPGRDTIPGDPSSNATSRGAEG<br>PLPPPSMPAVAGAAGGMALLLLGVAGAGGAMCWR<br>RRRAKPSESRHPGPGSFGRGGSLG<br>LGGGGGMGPREAEPGFLGIALRGGGTADPPFCPH<br>YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV" |

SEQUENCE (SEQ):

```
     1 gaatcccggc gaggctgggg ctccagctcg gtgtctcctt cttcgctccc ttgcccggcg
    61 cctcatgttg cccccgcccg gccctcggct ccccatgtcc cccacgtagc ggggcgcaca
   121 aatcccgagg tgcggcgcgt gggccgggggg cgcgtaaggc gcctgcagac ggcccctgca
   181 agggttcttg tggggctgag cgctctggag ccggggagca agcatcgcag aaaagagggt
   241 ccttgtggga gctgggggtg actagccacc caccagggtg actggggttc cacagcgtgg
   301 tagccacccc tgggcggtga gagactttgg gggagttggt gccccgcccc caggcccttg
   361 gtagggtcat gggggccccc cattttgggc caggggtgt gcaagtcggg gccctgctgc
   421 tgttaggttt tgcggggctg gtatctggac tcagcctgga gcctgtctac tggaactcgg
   481 cgaataagag gttccaggca gagggcggtt acgtgcttta tcctcagatc ggggaccggc
   541 tagatctact ttgtccccgg gctcggcctc ctggccccca ctcctctcct agttatgagt
   601 tctacaaact gtacctggta gagggtgccc agggtcggcg ttgtgaggca ccccctgccc
   661 caaaccttct tctcacatgt gaccggccag acctggacct ccgcttcacc atcaagttcc
   721 aggaatacag ccctaacctc tggggccacg agttccgatc ccaccacgat tactacataa
   781 ttgccacatc agacgggacc cgggaaggcc ttgagagctt gcaaggaggc gtgtgcctaa
   841 ccagaggcat gaaggtgctt ctgcgagtgg gacaaagtcc ccgaggagga gctgtacccc
   901 gaaaacctgt gtctgaaatg cccatggaga gagacagagg ggcagctcac agcgcggaac
```

```
   1021 gccccctgcc ccctcccagc atgcccgcag tggctggggc agcagggggg atggcgctgc
   1081 tcttgctggg cgtggcaggg gctgggggtg ccatgtgttg gcggagacgg cgggccaagc
   1141 cttcggagag tcgccaccct ggtcctggct cctttgggag gggagggtct ctgggcctgg
   1201 gtggtggagg agggatgggg cctcgggaag ctgagcctgg ggagctagga atagccctgc
   1261 ggggtggtgg gactgcagac ccccccttct gccctcacta cgagaaggtg agcggtgact
   1321 atgggcaccc tgtgtacatt gtgcaggatg ggccccccca gagccctccg aacatctatt
   1381 acaaggtatg agggctcctc ccacctggct ctcctcaatc tagccgtcca tggggtgctc
   1441 ctccagtgta attcatggta tgagggacac ctgcgccatg actttggccc cctttgccct
   1501 accagctctt tggctcctcc tggctatagc cctcatctcc aattttagga tcccttaaga
   1561 cttgactaca ccttttcctg acctccccga ctgaccctca tttgactgtg ggcactcctc
   1621 tgtttctgcc tcttagggga gggggtcac aggctcagcc tcccttaatc actacccagg
   1681 tgtcctttct ccctcaccca cccagagtgg gggtggggac agtctgtctt ttggttggca
   1741 cctctttctg cctctcacca tttttctctt ctctctattt cttattctct ctctctcctg
   1801 tgtctaggtc tgttctcttc ctcctcccta gcctcctcct tacatctcct tttaccctct
   1861 cggcttcttg tccttcctgt gcctctcacg tgtctcctgg gttggggcat caaagcatct
   1921 ctcctctttg ctcttggccc tttccaacct ttcataccaa ctgctccccc ctgtccgcca
   1981 aaaacggggg cttgcggggg gtgggggggga gattctggaa ctctaccccc ccagctccag
   2041 gcatgggcac agggcctctt tccctgcctt tctgtgtact tactccagcc atttggggtg
   2101 gttattgggc cacaactact accatgagaa gaagtgtcct gttgtggcca gtggctgata
   2161 ggaagacatg aagcagtgtg gacatgatgg actgtgtctg atgccgaatg ggcatcagat
   2221 aggaagtgac tcgttccaga caagaagtga ccaggcctgg acagaaatgg cctgggaagt
   2281 gtccgcagca ggaactggaa gtgccttcat ccagaacagg aagtcgcact tctgaaatag
   2341 gaagtggtct ggctggaatt ccaagtggct tagtctgggg aggtggcctg ggtgggggtg
   2401 ggggcatggg aagtggatgg ttcttaccct gtggagaaag gggcaggagg aactccctgc
   2461 tttaggagga agctggaact taccactgtg agaggacaga tgtggactga gagttttctt
   2521 agtgttcagt ggcacttccc aaggacccct tcccttgtgc tctgtgcagt ttttaggaca
   2581 gctaagatga ctgccacttg ctgtggcagg cccaatttgt cttgttctcc ccttactgta
   2641 ccccagtata atctctgttg atcaacagaa ctaccccaag aacccacatg ttctccccac
   2701 ctaaccagac ggctgtctgg ctgatgcctt cctcccttca agcccaacac agcgcccttg
   2761 tcagtgaaga ggtggtccat ggactggtct agctgatggc agttattagc actggttgct
   2821 gtttccatag tgacaagcct atacctcttc ccgctcttta gtgtgcagtg ggctgctgcc
   2881 tcggtgttct cccgcctcag ttttattaga tcaaagctgc ccttggccat catgttggcc
   2941 acctcaatca ccagccaaaa tggttgcttt gtccaccaga ggtcaagcca tctctctggc
   3001 gctgtagttc ccagctcctt ctagggaaca ggaagttgat attgccattg gggaggtggc
   3061 ggggtatggc cgtcacctcg atagttttat tgtaaaaggg aaatttgaac aacaacaaaa
   3121 aaactg
```

L7 ANSWER 150 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

```
LOCUS (LOC):                BC022499     GenBank (R)
GenBank ACC. NO. (GBN):     BC022499
GenBank VERSION (VER):      BC022499.1  GI:18490292
CAS REGISTRY NO. (RN):      392429-35-5
SEQUENCE LENGTH (SQL):      2673
MOLECULE TYPE (CI):         mRNA; linear
DIVISION CODE (CI):         Primates
DATE (DATE):                4 Feb 2002
DEFINITION (DEF):           Homo sapiens, Similar to   ***ephrin***     ***B3***   ,
                            clone IMAGE:4814898, mRNA, partial cds.
SOURCE:                     human.
 ORGANISM (ORGN):           Homo sapiens
                            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
                            Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini;
                            Hominidae; Homo
NUCLEIC ACID COUNT (NA): 532 a   788 c   703 g   650 t
COMMENT:
     Contact: MGC help desk
     Email: cgapbs-r@mail.nih.gov
     Tissue Procurement: Miklos Palkovits, M.D., Ph.D.
     cDNA Library Preparation: Michael J. Brownstein (NHGRI) &  Shiraki
     Toshiyuki and Piero Carninci (RIKEN)
     cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
     DNA Sequencing by: Sequencing Group at the Stanford Human Genome
     Center, Stanford University School of Medicine, Stanford, CA  94305
     Web site:       http://www-shgc.stanford.edu
     Contact:  (Dickson, Mark) mcd@paxil.stanford.edu
     Dickson, M., Schmutz, J., Grimwood, J., Rodriquez, A., and Myers,
     R. M.
     Clone distribution: MGC clone distribution information can be found
     through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
     Series: IRAK Plate: 32 Row: l Column: 19.
REFERENCE:                  1  (bases 1 to 2673)
   AUTHOR (AU):             Strausberg,R.
   TITLE (TI):              Direct Submission
   JOURNAL (SO):            Submitted (01-FEB-2002) National Institutes of Health,
```

Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..2673 | /organism="Homo sapiens"<br>/db-xref="taxon:9606"<br>/clone="IMAGE:4814898"<br>/tissue-type="Brain, hippocampus"<br>/clone-lib="NIH-MGC-95"<br>/lab-host="DH10B"<br>/note="Vector: pBluescript" |
| CDS | <1..859 | /codon-start=2<br>/product="Similar to ephrin B3"<br>/protein-id="AAH22499.1"<br>/db-xref="GI:18490293"<br>/translation="DRLDLLCPRARPPGPHSSPN<br>YEFYKLYLVGGAQGRRCEAPPAPN<br>LLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH<br>DYYIIATSDGTREGLESLQGGVCL<br>TRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRG<br>AAHSLEPGKENLPGDPTSNATSRG<br>AEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAM<br>CWRRRRAKPSESRHPGPGSFGRGG<br>SLGLGGGGGMGPREAEPGELGIALRGGGAADPPF<br>CPHYEKVSGDYGHPVYIVQDGPPQ<br>SPPNIYYKV" |

SEQUENCE (SEQ):

```
   1 ggaccggcta gacctgctct gcccccgggc ccggcctcct ggccctcact cctctcctaa
  61 ttatgagttc tacaagctgt acctggtagg gggtgctcag ggccggcgct gtgaggcacc
 121 ccctgcccca aacctccttc tcacttgtga tcgcccagac ctggatctcc gcttcaccat
 181 caagttccag gagtatagcc ctaatctctg gggccacgag ttccgctcgc accacgatta
 241 ctacatcatt gccacatcgg atgggacccg ggagggcctg gagagcctgc agggaggtgt
 301 gtgcctaacc agaggcatga aggtgcttct ccgagtggga caaagtcccc gaggaggggc
 361 tgtccccccga aaacctgtgt ctgaaatgcc catggaaaga gaccgagggg cagcccacag
 421 cctggagcct gggaaggaga acctgccagg tgaccccacc agcaatgcaa cctcccgggg
 481 tgctgaaggc cccctgcccc ctcccagcat gcctgcagtg gctggggcag caggggggct
 541 ggcgctgctc ttgctgggcg tggcaggggc tgggggtgcc atgtgttggc ggagacggcg
 601 ggccaagcct tcggagagtc gccaccctgg tcctggctcc ttcgggaggg gagggtctct
 661 gggcctgggg ggtggaggtg ggatgggacc tcgggaggct gagcctgggg agctagggat
 721 agctctgcgg ggtggcgggg ctgcagatcc ccccttctgc ccccactatg agaaggtgag
 781 tggtgactat gggcatcctg tgtatatcgt gcaggatggg cccccccaga gccctccaaa
 841 catctactac aaggtatgag ggctcctctc acgtggctat cctgaatcca gccttcttg
 901 gggtgctcct ccagtttaat tcctggtttg agggacacct ctaacatctc ggccccctgt
 961 gcccccccag ccccttcact cctcccggct gctgtcctcg tctccacttt taggattcct
1021 taggattccc actgccccac ttcctgccct cccgtttggc catgggtgcc cccctctgtc
1081 tcagtgtccc tggatccttt ttccttgggg aggggcacag gctcagcctc ctctctgacc
1141 atgacccagg catccttgtc cccctcaccc acccagagct aggggcggga acagcccacc
1201 ttttggttgg caccgccttc tttctgcctc tcactggttt tctcttctct atctcttatt
1261 ctttccctct cttccgtctc taggtctgtt cttcttccct agcatcctcc tccccacatc
1321 tcctttcacc ctcttggctt cttatcctgt gcctctccca tctcctgggt gggggcatca
1381 aagcatttct ccccttagct ttcagccccc cttctgacct ctcataccaa ccactccccc
1441 cagtctgcca aaaatggggg ccttatgggg aaggctctga cactccaccc cagctcaggc
1501 catgggcagc agggctccat tctctggcct ggcccaggcc tctacatact tactccagcc
1561 atttggggtg gttgggtcat gacagctacc atgagaagaa gtgtcccgtt ttgtccagtg
1621 gccaatagca agatatgaac cggtcgggac atgtatggac ttggtctgat gccgaatggg
1681 ccacttggga ccggaagtga cttgctccag acaagaggtg accaggccca gacagaaatg
1741 gcctgggaag tagcagaagc agtgcagcag gaactggaag tgccttcatc caggacagga
1801 agtagcactt ctgaaacagg aagtggtctg gctggaactc caagtggctt agtctggggg
1861 atcaggaggt gggaggtgga tggttcttat tctgtggaga agaagggcgg gaagaacttc
1921 ctttcaggag gaagctggaa cttactgact gtaagaggtt agaggtggac cgagaaggac
1981 ttttcccagt cttcagtggc acttcccaag atctcccttc ccttgtgctc tgtgctgatt
2041 ttaggacagc taagatgact gccatgtgct gtggcaggcc taatttgtct tgttctttcc
2101 tttccatatc ccagtataat ctctgttaat caacaggact accccaagaa cccatgtgct
2161 ctcccgagta acccagatgg ctgtcttgtt cattccatcc tacatttctg actcctttca
2221 gactcaacac agttcccttc ttagtgacca aaatggtggc ctactggctg gtctagctga
2281 cagtggtact tagcaaaggc cactgtttcc atagtgacca gctgatacct cttcctgccc
2341 tctagtgtgc aattgggtgt tgcctcagtt tcctcccagc tcagttttat tagatcaaag
2401 ctgttgttgg gcaccaggtt ggccacctca atcaccagcc aagatggttg ctttgtccac
2461 cagaggtcaa gttcaccctct ctggtgctgt agttcccagc tccttcctga tttttctaat
2521 cgctcccttct ggggaacagg aagttgatat tgccatggtg gcgggatatg ccgtcacctc
2581 agtagtttta ctgtaaaagg gaaatttgaa caacaaaaac caaaaaaaat aaaaataaaa
2641 aacttcaaaa gttgacgaaa aaaaaaaaaa aaa
```

L7 ANSWER 151 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BI313373 GenBank (R)
GenBank ACC. NO. (GBN): BI313373
GenBank VERSION (VER): BI313373.1 GI:14987700
CAS REGISTRY NO. (RN): 349277-22-1
SEQUENCE LENGTH (SQL): 456
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Expressed sequence tag
DATE (DATE): 20 Jul 2001
DEFINITION (DEF): dah92f01.y1 NICHD XGC Emb4 Xenopus laevis cDNA clone IMAGE:4957560 5' similar to TR:Q9PT69 Q9PT69 ***EPHRIN*** - ***B3*** PRECURSOR. ;, mRNA sequence.
SOURCE: African clawed frog.
ORGANISM (ORGN): Xenopus laevis
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae; Xenopodinae; Xenopus
NUCLEIC ACID COUNT (NA): 118 a 152 c 92 g 94 t
COMMENT:
Other_ESTs: dah92f01.x1
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Martha Rebbert, Steven L. Klein, Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: Xenopus clones from this library are available through the I.M.A.G.E. Consortium/LLNL at: info@image.llnl.gov
Seq primer: -40RP from Gibco
High quality sequence stop: 434.
REFERENCE: 1 (bases 1 to 456)
AUTHOR (AU): NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE (TI): National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL (SO): Unpublished (1997)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..456 | /organism="Xenopus laevis"<br>/db-xref="taxon:8355"<br>/clone="IMAGE:4957560"<br>/clone-lib="NICHD XGC Emb4"<br>/dev-stage="embryo, stage 31-32"<br>/lab-host="DH10B (phage-resistant)"<br>/note="Organ: whole embryo; Vector: pCMV-SPORT6; Site-1: NotI; Site-2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 2.1 kb. Constructed by Life Technologies. Note: This is a Xenopus Gene Collection (XGC ) library." |

SEQUENCE (SEQ):
```
   1 ggcagcagta gcccagagag ggggagagac agggaccaga caaaaccccc actctcatga
  61 gtaacatgca gccccctcc cccacttctc agcagccccc caatggtctc cagaagaccc
 121 tccaatccta aagaccccga gtctttccat gaaatatggg aaaacttctc ctgctaaact
 181 ttcccccctt cccctgaaca gcagcaaatc cagcgacaac aaaggagcaa aagaagcccc
 241 cgtcccaccc aaaaacctcc cttgcccccc gtccttttgt gcatttccca ttgaatttcc
 301 ccttgaaaca tgatgtttgg ccgggagttg gccacggctt tgtacatacc gatgctcttc
 361 acctggtggg atttctctat gatctcagcc ctcagcctgg accccattta ctggaacagc
 421 tccaacaaaa ggtttgagga cactgagggg tacgta
```

L7 ANSWER 152 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AF375227 GenBank (R)
GenBank ACC. NO. (GBN): AF375227
GenBank VERSION (VER): AF375227.1 GI:14495333
CAS REGISTRY NO. (RN): 342875-57-4
SEQUENCE LENGTH (SQL): 996
MOLECULE TYPE (CI): mRNA; linear

DATE (DATE): 20 Jun 2001
DEFINITION (DEF): Danio rerio ***ephrin*** ***B3*** mRNA, complete cds.
SOURCE: zebrafish.
ORGANISM (ORGN): Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes; Cyprinidae; Danio
NUCLEIC ACID COUNT (NA): 231 a 293 c 256 g 216 t
REFERENCE: 1 (bases 1 to 996)
AUTHOR (AU): Chan,J.; Mably,J.D.; Serluca,F.C.; Chen,J.N.; Goldstein,N.B.; Thomas,M.C.; Cleary,J.A.; Brennan,C.; Fishman,M.C.; Roberts,T.M.
TITLE (TI): Morphogenesis of prechordal plate and notochord requires intact Eph/ephrin B signaling
JOURNAL (SO): Dev. Biol., 234 (2), 470-482 (2001)
OTHER SOURCE (OS): CA 135:164797
REFERENCE: 2 (bases 1 to 996)
AUTHOR (AU): Chan,J.; Mably,J.D.; Serluca,F.C.; Chen,J.-N.; Goldstein,N.B.; Thomas,M.C.; Cleary,J.A.; Brennan,C.; Fishman,M.C.; Roberts,T.M.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (01-MAY-2001) Department of Cancer Biology, Dana-Farber Cancer Institute, 1 Jimmy Fund Way, Boston, MA 02115, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..996 | /organism="Danio rerio"<br>/db-xref="taxon:7955" |
| CDS | 1..996 | /codon-start=1<br>/product="ephrin B3"<br>/protein-id="AAK64277.1"<br>/db-xref="GI:14495334"<br>/translation="MASRGCVNGLGILLIFLVDL<br>LGITATNMEPIYWNSLNKRFSDDK<br>GYVLYPQIGDRLDLICPSSDPPGPRAPADYEYYK<br>LYLVSSREQADRCEVTGAPNLLLT<br>CDKPNSDMRFTIKFQEYSPNLWGHEFKTNHDYFI<br>IATSDGTRQGLESMRGGVCATQGM<br>KVVLKVGQSPYGLPAKSPKPDSAGRINNPNPGTG<br>NSTHPQIPPRGSGGENGPLPASNI<br>AVIAGAAGGSAFLLLVTAVICVVCYRRRHAKHSE<br>SHHPPLSLSSLTSPKRGCGGGVGG<br>GNNNGSEPSDIIIPLRTSDSAYCPHYEKVSGDYG<br>HPVYIVQEMPPQSPANIYYKV" |

SEQUENCE (SEQ):

```
   1 atggcgagtc ggggctgtgt aaatggattg ggaattctcc tgatattctt agtggattta
  61 ctcgggatca cggcgaccaa catggagccc atctactgga attccttgaa caaaaggttt
 121 agtgacgata agggttatgt cctgtaccct caaattggtg atcgtctgga tctcatttgc
 181 ccgtcttcag atccgcctgg ccctcgtgcc cctgctgatt atgagtacta taaactgtac
 241 ctggtttcgt ctcgggagca ggcagacagg tgtgaagtga ccggagcccc gaacctgctt
 301 ctcacctgcg ataaacccaa cagcgacatg cgcttcacca tcaagtttca ggagtactcg
 361 ccaaacctgt ggggccacga gtttaagacc aaccacgact acttcatcat tgctacatca
 421 gacgggacgc gtcaggggct ggagagcatg agaggaggag tttgcgctac acagggcatg
 481 aaggtggtgc tgaaagtggg acagagtcca tatggtctgc cagccaaatc tccaaaacct
 541 gactccgcgg gccgtatcaa caacccaaac ccaggtactg gaaacagcac ccatccgcaa
 601 attcccccta gaggttctgg tggtgaaaac ggcccccttc ctgcctccaa catcgcagtt
 661 atcgccggtg cggctggcgg ttcagcattc ctcctgctcg tcactgctgt gatctgcgtg
 721 gtgtgctacc gacgccgaca cgccaaacat tccgaatcgc accatcctcc cctgtccctc
 781 tcctctctga cctcacccaa acggggatgt ggcgggggcg taggggcgg caacaacaac
 841 ggctcagagc ctagcgacat catcatccca ctgcggactt ctgactccgc ctactgcccg
 901 cactacgaga aagtgagcgg ggactacggc catccggtct acatcgtaca ggagatgcct
 961 cctcagagtc ccgccaacat ctattataaa gtatga
```

L7 ANSWER 153 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AK027329 GenBank (R)
GenBank ACC. NO. (GBN): AK027329
GenBank VERSION (VER): AK027329.1 GI:14041934
CAS REGISTRY NO. (RN): 390634-29-4
SEQUENCE LENGTH (SQL): 2153
MOLECULE TYPE (CI): mRNA; linear

DATE (DATE): 30 Jan 2004
DEFINITION (DEF): Homo sapiens cDNA FLJ14423 fis, clone HEMBA1005699, moderately similar to ***EPHRIN*** - ***B3*** PRECURSOR.
KEYWORDS (ST): oligo capping; fis (full insert sequence)
SOURCE: Homo sapiens (human)
ORGANISM (ORGN): Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo
COMMENT:
NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing and clone selection: Helix Research Institute (supported by Japan Key Technology Center etc.) and Department of Virology, Institute of Medical Science, University of Tokyo.
REFERENCE: 1
AUTHOR (AU): Ota,T.; Suzuki,Y.; Nishikawa,T.; Otsuki,T.; Sugiyama,T.; Irie,R.; Wakamatsu,A.; Hayashi,K.; Sato,H.; Nagai,K.; Kimura,K.; Makita,H.; Sekine,M.; Obayashi,M.; Nishi,T.; Shibahara,T.; Tanaka,T.; Ishii,S.; Yamamoto,J.; Saito,K.; Kawai,Y.; Isono,Y.; Nakamura,Y.; Nagahari,K.; Murakami,K.; Yasuda,T.; Iwayanagi,T.; Wagatsuma,M.; Shiratori,A.; Sudo,H.; Hosoiri,T.; Kaku,Y.; Kodaira,H.; Kondo,H.; Sugawara,M.; Takahashi,M.; Kanda,K.; Yokoi,T.; Furuya,T.; Kikkawa,E.; Omura,Y.; Abe,K.; Kamihara,K.; Katsuta,N.; Sato,K.; Tanikawa,M.; Yamazaki,M.; Ninomiya,K.; Ishibashi,T.; Yamashita,H.; Murakawa,K.; Fujimori,K.; Tanai,H.; Kimata,M.; Watanabe,M.; Hiraoka,S.; Chiba,Y.; Ishida,S.; Ono,Y.; Takiguchi,S.; Watanabe,S.; Yosida,M.; Hotuta,T.; Kusano,J.; Kanehori,K.; Takahashi-Fujii,A.; Hara,H.; Tanase,T.; Nomura,Y.; Togiya,S.; Komai,F.; Hara,R.; Takeuchi,K.; Arita,M.; Imose,N.; Musashino,K.; Yuuki,H.; Oshima,A.; Sasaki,N.; Aotsuka,S.; Yoshikawa,Y.; Matsunawa,H.; Ichihara,T.; Shiohata,N.; Sano,S.; Moriya,S.; Momiyama,H.; Satoh,N.; Takami,S.; Terashima,Y.; Suzuki,O.; Nakagawa,S.; Senoh,A.; Mizoguchi,H.; Goto,Y.; Shimizu,F.; Wakebe,H.; Hishigaki,H.; Watanabe,T.; Sugiyama,A.; Takemoto,M.; Kawakami,B.; Yamazaki,M.; Watanabe,K.; Kumagai,A.; Itakura,S.; Fukuzumi,Y.; Fujimori,Y.; Komiyama,M.; Tashiro,H.; Tanigami,A.; Fujiwara,T.; Ono,T.; Yamada,K.; Fujii,Y.; Ozaki,K.; Hirao,M.; Ohmori,Y.; Kawabata,A.; Hikiji,T.; Kobatake,N.; Inagaki,H.; Ikema,Y.; Okamoto,S.; Okitani,R.; Kawakami,T.; Noguchi,S.; Itoh,T.; Shigeta,K.; Senba,T.; Matsumura,K.; Nakajima,Y.; Mizuno,T.; Morinaga,M.; Sasaki,M.; Togashi,T.; Oyama,M.; Hata,H.; Watanabe,M.; Komatsu,T.; Mizushima-Sugano,J.; Satoh,T.; Shirai,Y.; Takahashi,Y.; Nakagawa,K.; Okumura,K.; Nagase,T.; Nomura,N.; Kikuchi,H.; Masuho,Y.; Yamashita,R.; Nakai,K.; Yada,T.; Nakamura,Y.; Ohara,O.; Isogai,T.; Sugano,S.
TITLE (TI): Complete sequencing and characterization of 21,243 full-length human cDNAs
JOURNAL (SO): Nat. Genet., 36 (1), 40-45 (2004)
OTHER SOURCE (OS): CA 140:158332
REFERENCE: 2
AUTHOR (AU): Isogai,T.; Ota,T.; Hayashi,K.; Sugiyama,T.; Otsuki,T.; Suzuki,Y.; Nishikawa,T.; Nagai,K.; Sugano,S.; Shiratori,A.; Sudo,H.; Wagatsuma,M.; Hosoiri,T.; Kaku,Y.; Kodaira,H.; Kondo,H.; Sugawara,M.; Takahashi,M.; Chiba,Y.; Ishida,S.; Murakawa,K.; Ono,Y.; Takiguchi,S.; Watanabe,S.; Kimura,K.; Murakami,K.; Ishii,S.; Kawai,Y.; Saito,K.; Yamamoto,J.; Wakamatsu,A.; Nakamura,Y.; Nagahari,K.; Masuho,Y.; Ninomiya,K.; Iwayanagi,T.
TITLE (TI): NEDO human cDNA sequencing project
JOURNAL (SO): Unpublished
REFERENCE: 3 (bases 1 to 2153)
AUTHOR (AU): Isogai,T.; Otsuki,T.
TITLE (TI): Direct Submission

Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..2153 | /organism="Homo sapiens"<br>/mol-type="mRNA"<br>/db-xref="taxon:9606"<br>/clone="HEMBA1005699"<br>/tissue-type="whole embryo, mainly head"<br>/clone-lib="HEMBA1"<br>/dev-stage="embryo, 10 weeks"<br>/note="cloning vector: pME18SFL3" |

SEQUENCE (SEQ):

```
   1 aatcccagcg aggctggggc tccggctcgg cgccccttc ctcgctccct ggtccggcgc
  61 cccatgccgc ccccgccccgg tccccggctc ccccagtccc ccacttaggc gggctcacag
 121 atcccggggt gctggcgcgt gggccgggggg cgcgtagggc gcctgcagac ggcccctgga
 181 agggctctgg tggggctgag cgctctgccg cgggggcgcg ggcacagcag gaagcaggtc
 241 cgcgtgggcg ctgggggcat cagctaccgg ggtggtccgg gctgaagagc caggcagcca
 301 aggcagccac cccggggggt gggcgacttt gggggagggt ctctgggcct gggggggtgga
 361 ggtgggatgg gacctcggga ggctgagcct ggggagctag ggatagctct gcgggggtggc
 421 ggggctgcag atccccccctt ctgcccccac tatgagaagg tgagtggtga ctatgggcat
 481 cctgtgtata tcgtgcagga tgggcccccc cagagccctc caaacatcta ctacaaggta
 541 tgagggctcc tctcacgtgg ctatcctgaa tccagccctt cttggggtgc tcctccagtt
 601 taattcctgg tttgagggac acctctaaca tctcggcccc ctgtgccccc ccagcccctt
 661 cactcctccc ggctgctgtc ctcgtctcca cttttaggat tccttaggat tcccactgcc
 721 ccacttcctg ccctcccgtt tggccatggg tgccccctc tgtctcagtg tccctggatc
 781 ctttttcctt ggggaggggc acaggctcag cctcctctct gaccatgacc caggcatcct
 841 tgtcccctc acccacccag agctaggggc gggaacagcc caccttttgg ttggcaccgc
 901 cttctttctg cctctcactg gttttctctt ctctatctct tattctttcc ctctcttccg
 961 tctctaggtc tgttcttctt ccctagcatc ctcctcccca catctccttt caccctcttg
1021 gcttcttatc ctgtgcctct cccatctcct gggtgggggc atcaaagcat ttctcccctt
1081 agctttcagc ccccttctg acctctcata ccaaccactc ccctcagtct gccaaaaatg
1141 ggggccttat ggggaaggct ctgacactcc accccagctc aggccatggg cagcagggct
1201 ccattctctg gcctggccca ggcctctaca tacttactcc agccatttgg ggtggttggg
1261 tcatgacagc taccatgaga agaagtgtcc cgttttgtcc agtggccaat agcaagatat
1321 gaaccggtcg ggacatgtat ggacttggtc tgatgctgaa tgggccactt gggaccggaa
1381 gtgacttgct ccagacaaga ggtgaccagg cccggacaga aatggcctgg gaagtagcag
1441 aagcagtgca gcaggaactg gaagtgcctt catccaggac aggaagtagc acttctgaaa
1501 caggaagtgg tctggctgga actccaagtg gcttagtctg ggggatcagg aggtgggagg
1561 tggatggttc ttattctgtg gagaagaagg gcgggaagaa cttcctttca ggaggaagct
1621 ggaacttact gactgtaaga ggttagaggt ggaccgagaa ggacttttcc cagtcttcag
1681 tggcacttcc caagatctcc cttcccttgt gctctgtgct gattttagga cagctaagat
1741 gactgccatg tgctgtggca ggcctaattt gtcttgttct ttcctttcca tatcccagta
1801 taatctctgt taatcaacag gactacccca agaacccatg tgctctcccg agtaacccag
1861 atggctgtct tgttcattcc atcctacatt tccgactcct ttcagactca acacagtttt
1921 attagatcaa agctgttgtt gggcaccagg ttggccacct caatcaccag ccaagatggt
1981 tgctttgtcc accagaggtc aagttcacct ctctggtgct gtagttccca gctccttcct
2041 gatttttcta atcgctcctt ctggggaaca ggaagttgat attgccatgg tggcggggta
2101 tgccgtcacc tcagtagttt tactgtaaaa gggaaatttg aacaacaaaa acc
```

L7 ANSWER 154 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

| | |
|---|---|
| LOCUS (LOC): | BG348825 GenBank (R) |
| GenBank ACC. NO. (GBN): | BG348825 |
| GenBank VERSION (VER): | BG348825.1 GI:13169251 |
| CAS REGISTRY NO. (RN): | 325600-11-1 |
| SEQUENCE LENGTH (SQL): | 556 |
| MOLECULE TYPE (CI): | mRNA; linear |
| DIVISION CODE (CI): | Expressed sequence tag |
| DATE (DATE): | 28 Feb 2001 |
| DEFINITION (DEF): | dad19b07.x1 Wellcome CRC pCS107 tropicalis St10-12 Silurana tropicalis cDNA clone IMAGE:4439773 3' similar to TR:Q9PT69 Q9PT69 ***EPHRIN*** - ***B3*** PRECURSOR. ;, mRNA sequence. |
| SOURCE: | western clawed frog. |
| ORGANISM (ORGN): | Silurana tropicalis<br>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae; Xenopodinae; Silurana |
| NUCLEIC ACID COUNT (NA): | 137 a 129 c 124 g 166 t |

Other ESTs: dad19b07.y1
Contact: Sandy Clifton, Ph.D.
WashU Xenopus EST project, 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Library constructed by A. Zorn and J. Mason (Wellcome/CRC Institute ). DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: Xenopus clones from this library are available through the I.M.A.G.E. Consortium/LLNL at: info@image.llnl.gov
Seq primer: -40UP from Gibco
High quality sequence stop: 471.

REFERENCE: 1 (bases 1 to 556)
AUTHOR (AU): Clifton,S.; Johnson,S.L.; Blumberg,B.; Song,J.; Hillier,L.; Pape,D., Martin,J. ; Wylie,T.; Underwood,K.; Theising,B.; Bowers,Y.; Person,B.M; Gibbons,M.; Harvey,N.; Ritter,E.; Jackson,Y.; McCann,R.; Waterston,R.; Wilson,R.
TITLE (TI): WashU Xenopus EST project, 1999
JOURNAL (SO): Unpublished (1999)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..556 | /organism="Silurana tropicalis"<br>/db-xref="taxon:8364"<br>/clone="IMAGE:4439773"<br>/clone-lib="Wellcome CRC pCS107 tropicalis St10-12"<br>/tissue-type="whole embryo, stages 10-12"<br>/lab-host="DH10B (phage-resistant)"<br>/note="Vector: pCS107; Site-1: NotI; Site-2: EcoRI; cDNAs were oligo-dT primed and directionally cloned. Average insert size 1.5 kb, range 0.5-4 kb. Library constructed by A. Zorn and J. Mason (Wellcome/CRC Institute). " |

SEQUENCE (SEQ):

```
     1 ttttttttct tgcataacat tgttatccca tggttccttc taaccttgtg cgcccagaac
    61 attccttctc tgtatatttg tctctataca tgtgggtagg tgctgccata ctgtttccaa
   121 taggccctgt attataaatc ttaacttatt gttcatattg tacagcgctg cggaacatgt
   181 tggcgcttaa taaataaatg ttaataataa taacctgact gctatcagtc ctttcaggct
   241 atattccagc agatcagccc ctcactatcc ccgtcccacc tcacccccat accattgtcc
   301 ctagtgatgg aatctcatta tttcagcaat gggacgtacc tccgaaattt ggaatgtcag
   361 ggtttggcac agatggtgaa atcccagaat cctttcctgc agatgagggt ctgcgaggag
   421 gaggcgcccc attaggatct gtgtggagac aggaatggaa taggtgactg tggagatgca
   481 gaaaggggat ctcaccatca gcataggaag gggttcctta ctgtaagggc agtcaggtta
   541 tggggttccc taccca
```

L7 ANSWER 155 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BB125170 GenBank (R)
GenBank ACC. NO. (GBN): BB125170
GenBank VERSION (VER): BB125170.1 GI:8779494
CAS REGISTRY NO. (RN): 275955-70-9
SEQUENCE LENGTH (SQL): 301
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Expressed sequence tag
DATE (DATE): 28 Jun 2000
DEFINITION (DEF): BB125170 RIKEN full-length enriched, 16 days neonate cerebellum Mus musculus cDNA clone 9630003J17 3' similar to NM 001406 Homo sapiens ***ephrin*** - ***B3*** (EFNB3) mRNA, mRNA sequence.
SOURCE: house mouse.
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus

COMMENT:
Contact: Yoshihide Hayashizaki
Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center(GSC), Yokohama Institute
The Institute of Physical and Chemical Research (RIKEN)
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
Tel: 81-45-503-9222
Fax: 81-45-503-9216
Email: genome-res@gsc.riken.go.jp,
URL:http://genome.gsc.riken.go.jp/
Carninci,P., Nishiyama,Y., Westover,A., Itoh,M., Nagaoka,S., Sasaki ,N., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.
Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U.S.A. 95 (2), 520-524 (1998)
Itoh,M., Kitsunai,T., Akiyama,J., Shibata,K., Izawa,M., Kawai,J., Tomaru,Y., Carninci,P., Shibata,Y., Ozawa,Y., Muramatsu,M., Okazaki ,Y. and Hayashizaki,Y.
Automated filtration-based high-throughput plasmid preparation system. Genome Res. 9 (5), 463-470 (1999)
Carninci,P. and Hayashizaki,Y.
High-efficiency full-length cDNA cloning. Methods Enzymol. 303, 19-44 (1999)
Please visit our web site (http://genome.rtc.riken.go.jp) for further details.

REFERENCE: 1 (bases 1 to 301)
AUTHOR (AU): Konno,H.; Aizawa,K.; Akahira,S.; Akiyama,J.; Arakawa,T.; Carninci,P. ; Endo,T.; Fukuda,S.; Fukunishi,Y.; Hara,A.; Hayatsu,N.; Hirozane,T.; Hori,F.; Ishii,Y.; Ishikawa,J.; Ishikawa,T.; Itoh,M.; Izawa,M.; Kadota,K.; Kagawa,I.; Kai,C.; Kawai,J.; Kikuchi,N.; Kiyosawa,H.; Kojima,Y.; Kondo,S.; Koya,S.; Kurihara,C.; Kusakabe,M., Matsuyama,T. ; Miki,R.; Mizuno,Y.; Nakamura,M.; Oda,H.; Okazaki,Y., Ono,T.y; Owa,C.; Saito,H.; Sakai,C.; Sato,K.; Shibata,K.; Shibata,Y.,; Shigemoto,Y.; Shinagawa,A.; Shiraki,T.; Sogabe,Y.; Sugahara,Y., Suzuki,H.,; Suzuki,H.; Tagawa,A.; Takahashi,F.; Tominaga,N.; Toya,T.a; Tsunoda,Y.; Watahiki,A.; Watanabe,S.; Yamamura,T.; Yamanaka,I., Yano,R.H; Yasunishi,A.; Yokota,T.; Yoshida,K.; Yoshiki,A.; Yoshino,M..; Muramatsu,M.; Hayashizaki,Y.
TITLE (TI): RIKEN Mouse ESTs (Konno,H., et al.)
JOURNAL (SO): Unpublished (2000)

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..301 | /organism="Mus musculus"<br>/db-xref="taxon:10090"<br>/clone="9630003J17"<br>/clone-lib="RIKEN full-length enriched, 16 days neonate cerebellum"<br>/tissue-type="cerebellum"<br>/dev-stage="16 days neonate"<br>/lab-host="DH10B"<br>/note="Site-1: SalI; Site-2: BamHI; cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5' GAGAGAGAGAAGGATCCAAGAGCTCTTTTTTTTT TTTTTTTVN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by |

round of normalization to Rot = 20.0 and subtraction to Rot = 370.0. Second strand cDNA was prepared with the primer adapter of sequence [5' GAGAGAGAGATTCTCGAGTTAATTAAATTAATCC CCCCCCCCCCC 3']. cDNA was cleaved with XhoI and BamHI. Vector: a modified pBluescript KS(+) after bulk excision from Lambda FLC I."

SEQUENCE (SEQ):

```
     1 tccaatatga aaaccatcac ttcttcccct ttatactctg catgacctga tccctcgatc
    61 ttctccctcc tcagtttaaa aatattaaag ctgcccttgc ccatcatttt ggctacctca
   121 atcaccagcc aaaatggttc ctttgtccac cagaattcaa tctatttttc cggcactcta
   181 gttcccagct ccttttaggg aacaggaagt tgatattgcc ataggggagg agtcggggta
   241 tggccgttac ttcgatagtt tcattgttaa agggaaattt gaaaaacaac aaaaaaattg
   301 g
```

L7 ANSWER 156 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): XLA236866 GenBank (R)
GenBank ACC. NO. (GBN): AJ236866
GenBank VERSION (VER): AJ236866.1 GI:6689567
CAS REGISTRY NO. (RN): 252840-76-9
SEQUENCE LENGTH (SQL): 1145
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Other vertebrates
DATE (DATE): 17 Apr 2000
DEFINITION (DEF): Xenopus laevis mRNA for ***ephrin*** - ***B3*** .
SOURCE: African clawed frog.
ORGANISM (ORGN): Xenopus laevis
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae; Xenopodinae; Xenopus
NUCLEIC ACID COUNT (NA): 258 a 302 c 299 g 286 t
REFERENCE: 1 (bases 1 to 1145)
AUTHOR (AU): Helbling,P.M.; Saulnier,D.M.; Robinson,V.; Christiansen,J.H.; Wilkinson,D.G.; Brandli,A.W.
TITLE (TI): Comparative analysis of embryonic gene expression defines potential interaction sites for Xenopus EphB4 receptors with ephrin-B ligands
JOURNAL (SO): Dev. Dyn., 216 (4-5), 361-373 (1999)
OTHER SOURCE (OS): CA 132:178235
REFERENCE: 2 (bases 1 to 1145)
AUTHOR (AU): Brandli,A.W.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (25-FEB-1999) Brandli A.W., Institute of Cell Biology, Swiss Federal Institute of Technology, ETH Honggerberg, Zurich, CH-8093, SWITZERLAND

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..1145 | /organism="Xenopus laevis"<br>/db-xref="taxon:8355"<br>/clone="PAU.10"<br>/tissue-type="embryonic head"<br>/dev-stage="embryonic stage 28-30" |
| sig-peptide | 16..90 | |
| CDS | 16..999 | /function="Eph receptor family ligand"<br>/codon-start=1<br>/product="ephrin-B3"<br>/protein-id="CAB65511.1"<br>/db-xref="GI:6689568"<br>/translation="MFSRECALYIRMLFTLWDFC<br>SISALSLDPIYWNSSNKRFEDTEG<br>YVLYPQIGDRLDLLCPRSEPQGPFSSSPYEYYKL<br>YLVGTKEEMSSCSILRTPNLLLTC<br>DRPSQDLRFTIKFQEFSPNLWGHEFQSQRDYYII<br>ATSDGTMDGIETLQGGVCETKGMK<br>VTLKVGQSPNGATPPRRPSSAGKDSGISPSVPNP<br>DIPNVGETSGNATKTGENGPLPIS<br>HVPLVAGAAGGAALLLLVFGVVGWVCHRRRQAKH |

HEPSDIIMPLRPSEAGAFCPHYEKVSGDYGHPVY
IVQDMASQSPANIYYKV"

SEQUENCE (SEQ):

```
     1 tgccctttaa tcagcatgtt ttcccgggaa tgtgctttgt acataaggat gttattcacc
    61 ttgtgggatt tctgctccat ctcagcgctg agcctggacc ccatttactg gaacagctca
   121 aacaaaaggt ttgaggacac tgaggggtac gtgctctatc cccagattgg agaccggctg
   181 gacctgttgt gccccccgttc tgagccccag ggccccttct cctcgtcccc atatgaatac
   241 tacaagttgt acctggtggg caccaaggaa gagatgtcct cctgctccat cctgagaact
   301 cccaacctcc tcctgacctg tgaccgaccc tcgcaggact tgcgcttcac catcaagttt
   361 caggaattca gccccaatct gtggggacac gagttccagt ctcagcggga ttattacatt
   421 attgccacct cggatgggac gatggatggg atagagaccc ttcagggagg agtgtgtgag
   481 accaaaggca tgaaggtcac cttaaaggtt gggcagagtc ctaatggggc gactcctcct
   541 cgcagaccct catctgcagg aaaggattct gggatttcac catccgtgcc aaaccctgac
   601 attccaaatg ttggagaaac atctggcaat gcaaccaaga ccggggaaaa tggtcctctg
   661 cccatctccc atgttcctct agtagctggt gctgcgggtg gggctgcact tctgctgctg
   721 gtctttggag tagtgggatg ggtctgtcat aggcgacgtc aggccaaaca cagcgacacc
   781 cggcacccac ctctctctct aggatccatc acctccccaa aaagaggagg taacaacaac
   841 ggccatgagc ccagtgacat catcatgccc cttcgaccgt ccgaagcggg tgccttttgc
   901 cctcactatg agaaagtcag tggggactat ggacaccctg tttatatcgt tcaggacatg
   961 gccagccaga gccctgccaa catctactac aaagtataaa acaactgcca gcatttttg
  1021 tccttgtagc tttttgtttt tgggcggggc taactgtagg atgtttgtgg ggtgggttgc
  1081 aggatgtctt ggaatgaagg tgggaatgtg ttcattgcaa tgttggtatt tggagggtaa
  1141 gtctt
```

L7 ANSWER 157 OF 159 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): AF025288 GenBank (R)
GenBank ACC. NO. (GBN): AF025288
GenBank VERSION (VER): AF025288.1 GI:2558959
CAS REGISTRY NO. (RN): 199149-58-1
SEQUENCE LENGTH (SQL): 1079
MOLECULE TYPE (CI): mRNA; linear
DIVISION CODE (CI): Rodents
DATE (DATE): 5 Feb 1998
DEFINITION (DEF): Mus musculus m- ***ephrin*** - ***B3*** mRNA, complete cds.
SOURCE: house mouse.
ORGANISM (ORGN): Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus
NUCLEIC ACID COUNT (NA): 194 a 316 c 361 g 208 t
REFERENCE: 1 (bases 1 to 1079)
AUTHOR (AU): Brambilla,R.; Bruckner,K.; Orioli,D.; Bergemann,A.D.; Klein,R.
TITLE (TI): Similarities and differences in the way transmembrane-type ligands interact with the Elk subclass of Eph receptors
JOURNAL (SO): Mol. Cell. Neurosci., 8 (2-3), 199-209 (1996)
OTHER SOURCE (OS): CA 126:5125
REFERENCE: 2 (bases 1 to 1079)
AUTHOR (AU): Bergemann,A.D.; Zhang,L.; Chiang,M.K.; Brambilla,R.; Klein,R.; Flanagan,J.G.
TITLE (TI): ***Ephrin*** - ***B3*** , a ligand for the receptor EphB3, expressed at the midline of the developing neural tube
JOURNAL (SO): Oncogene, 16 (4), 471-480 (1998)
OTHER SOURCE (OS): CA 128:240109
REFERENCE: 3 (bases 1 to 1079)
AUTHOR (AU): Bergemann,A.D.; Zhang,L.; Chiang,M.-K.; Brambilla,R.; Klein,R.; Flanagan,J.G.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (15-SEP-1997) Pathology, Mount Sinai, One Gustave L. Levy, New York, NY 10029-6574, USA

FEATURES (FEAT):

| Feature Key | Location | Qualifier |
|---|---|---|
| source | 1..1079 | /organism="Mus musculus"<br>/db-xref="taxon:10090"<br>/tissue-type="brain"<br>/dev-stage="newborn" |
| CDS | 43..1065 | /note="ligand of EphB class receptor tyrosine kinases; |

/codon-start=1
/product="m-ephrin-B3"
/protein-id="AAC53537.1"
/db-xref="GI:2558960"
/translation="MGAPHFGPGGVQVGALLLLG
FAGLVSGLSLEPVYWNSANKRFQA
EGGYVLYPQIGDRLDLLCPRARPPGPHSSPSYEF
YKLYLVEGAQGRRCEAPPAPNLLL
TCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYY
IIATSDGTREGLESLQGGVCLTRG
MKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH
SAEPGRDTIPGDPSSNATSRGAEG
PLPPPSMPAVAGAAGGMALLLLGVAGAGGAMCWR
RRRAKPSESRHPGPGSFGRGGSLG
LGGGGGMGPREAEPGELGIALRGGGTADPPFCPH
YEKVSGDYGHPVYIVQDGPPQSPP NIYYKV"

SEQUENCE (SEQ):

```
      1 tttgggggag ttggtgcccc gcccccaggc cttggtaggg tcatgggggc cccccatttt
     61 gggccagggg gtgtgcaagt cggggccctg ctgctgttag gttttgcggg gctggtatct
    121 ggactcagcc tggagcctgt ctactggaac tcggcgaata agaggttcca ggcagagggc
    181 ggttacgtgc tttatcctca gatcggggac cggctagatc tactttgtcc ccgggctcgg
    241 cctcctggcc cccactcctc tcctagttat gagttctaca aactgtacct ggtagagggt
    301 gcccagggtc ggcgttgtga ggcacccccc gccccaaacc ttcttctcac atgtgaccgg
    361 ccagacctgg acctccgctt caccatcaag ttccaggaat acagccctaa cctctggggc
    421 cacgagttcc gatcccacca cgattactac ataattgcca catcagacgg gacccgggaa
    481 ggccttgaga gcttgcaagg aggcgtgtgc ctaaccagag gcatgaaggt gcttctgcga
    541 gtgggacaaa gtccccgagg aggagctgta ccccgaaaac ctgtgtctga aatgcccatg
    601 gagagagaca gaggggcagc tcacagcgcg gaacctggga gggacaccat accaggtgac
    661 cccagcagca atgcaacctc ccggggtgct gaaggccccc tgccccctcc cagcatgccc
    721 gcagtggctg gggcagcagg ggggatggcg ctgctcttgc tgggcgtggc aggggctggg
    781 ggtgccatgt gttggcggag acggcgggcc aagccttcgg agagtcgcca ccctggtcct
    841 ggctcctttg ggaggggagg gtctctgggc ctgggtggtg gaggagggat ggggcctcgg
    901 gaagctgagc ctggggagct aggaatagcc ctgcggggtg gtgggactgc agacccccccc
    961 ttctgccctc actacgagaa ggtgagcggt gactatgggc accctgtgta cattgtgcag
   1021 gatgggcccc cccagagccc tccgaacatc tattacaagg tatgagggct cctccctcc
```

L7 ANSWER 158 OF 159 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2003:152522 TOXCENTER
DN DART-TER-3000624
TI Effects of pre- and postnatal methylmercury exposure on expression of EPHS and ephrins in the mouse.
AU Wilson D T; Reuhl K R; Zhou R
CS Toxicology, Rutgers University, Piscataway, NJ.
NC ES 05022
ES 07148
ES 11256
SO Toxicologist 2003 Mar;72(S-1):67. Toxicologist,
ISSN: 0731-9193.
DT Abstract; (MEETING ABSTRACT)
FS DART
LA English
ED Entered STN: 20030708
Last Updated on STN: 20030708

L7 ANSWER 159 OF 159 CONFSCI COPYRIGHT 2004 CSA on STN
AN 2004:15585 CONFSCI
DN 04-015585
TI ***Ephrin*** - ***B3*** controls proliferation in the adult subventricular zone
AU Ricard, J.; Salinas, J.A.; Liebl, D.J.
SO University of Miami, School of Medicine; URL: www.med.miami.edu.
Meeting Info.: 000 7201: 2004 Miami Nature Biotechnology Winter Symposium (0007201). Miami Beach, FL (USA). 31 Jan-4 Feb 2004. University of Miami.
DT Conference
FS DCCP
LA English
STN INTERNATIONAL LOGOFF AT 12:32:44 ON 21 OCT 2004